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And indeed there will be time
For the yellow smoke that slides along the street,
Rubbing its back upon the window-panes;
There will be time, there will be time
To prepare a face to meet the faces that you meet;
There will be time to murder and create,
And time for all the works and days of hands
That lift and drop a question on your plate;
Time for you and time for me,
And time yet for a hundred indecisions
And for a hundred visions and revisions
Before the taking of a toast and tea.
In the room the women come and go
Talking of Michelangelo.
And indeed there will be time
To wonder, “Do I dare?” and, “Do I dare?”
Time to turn back and descend the stair,
With a bald spot in the middle of my hair
(They will say: “How his hair is growing thin!”)
My morning coat, my collar mounting firmly to the chin,
My necktie rich and modest, but asserted by a simple pin
(They will say: “But how his arms and legs are thin!)
Do I dare
Disturb the universe?
In a minute there is time
For decisions and revisions which a minute will reverse.
The love song of J. Alfred Prufrock
By T.S. Eliot | 1888-1965
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“Urinary tract infections have plagued mankind  
long before bacteria were recognized”1 
Different hypotheses have been described to explain the typical symptoms of an in-
fection of the urinary tract such as dysuria and frequency.1 One such hypothesis is the 
well-known disharmony of the four humors or body fluids of Hippocrates; black bile, 
yellow bile, phlegm and blood.1 Complementary to the different hypotheses to explain 
urinary tract infection (UTI) symptoms, numerous interventions to reduce the burden of 
UTI have been used, ranging from herbs to animal urine (cow, sheep or goat).1 
Compared to UTI, bacteriuria (the presence of bacteria in urine) is a more modern diag-
nosis since the existence and clinical relevance of bacteria was only discovered between 
the 17th and 19th century.1 The discovery of bacteria was succeeded by the discovery of 
a targeted treatment for the presence of bacteria, antibiotics currently a common used 
intervention to treat bacteriuria and related infections.1 
Nowadays bacteriuria is divided into asymptomatic bacteriuria (ASB) and bacteriuria 
with specific symptoms, also called UTI.2-3 ASB is defined as significant bacteriuria (≥105 
colony forming units (cfu)/mL) without the complaints of a UTI.3,4  A UTI is further divi-
ded into a lower or upper UTI. A lower UTI only involves the bladder and patients are 
frequently presenting with frequency, urgency and/or a burning sensation while urina-
ting. In case of an upper UTI the kidneys are involved as well, which results in loin pain 
and/or systemic symptoms including fever.2,4
ASB and UTI are among the most commonly diagnosed medical conditions in women, 
especially in women with diabetes mellitus (DM) and in pregnant women.2,3,5,6
Studies in women with DM compared to women without DM found a two to threefold 
increase in prevalence of ASB (26% versus 6%) and a slight increased risk of UTIs.6-10 
Moreover women with DM and a UTI are more susceptible to severe and rare complica-
tions of UTI such as xanthogranulomatous pyelonephritis.8,10 
The prevalence of ASB in pregnant women has been reported between 2% and 10%.5,11-
13 A limited number of, mostly outdated, studies showed that in 30% to 50% pregnant 
women developed pyelonephritis during pregnancy when ASB is left untreated.13,14 
Data providing insight in the incidence of UTI in pregnant women is limited. The repor-
ted incidence of culture confirmed UTI is low and varies between 1.3 and 2.3%.15,16 
But we know from a recent study that a UTI is the most frequent reason for pregnant 
women to visit a general practitioner in the Netherlands.17
The prevalence of DM, including gestational diabetes mellitus (GDM) is increasing 
worldwide.6,18 Women with DM are considered immunocompromised and are therefore 
possibly more prone to develop infections of which the urinary tract is one of the most 
prevalent sites of infection.6,7 
ONEDIABETES MELLITUS | PREGNANT WOMEN
Pregnancy related dilatation of the urine collecting system (bladder, ureters and kidneys) 
and the decreased peristalsis of the ureter facilitate bacterial colonisation which may 
result in ASB and/or UTI during pregnancy.19-21 
More importantly, as has been shown in some old studies that ASB and/or UTI during 
pregnancy may be a serious complication and might be associated with adverse preg-
nancy outcomes for both mother and child including preterm birth and small-for-gesta-
tional-age babies.13,14 There is some evidence that prostaglandins activated by bacterial 
and host signals as result of the infection, play a role inducing preterm labour. However, 
the exact causal mechanisms remain unknown.13,22
Summarizing in both women with DM and in pregnant women ASB and UTI are asso-
ciated with adverse events for both the women and the infant. In spite of this, essential 
evidence to underpin several important decisions in Dutch clinical guidelines is missing. 
This can result in suboptimal care.  
For this thesis we attempted to provide some of the lacking evidence focussing on tre-
atment of UTI in women with DM, reliable urine sample collection in pregnant women, 
prevention of recurrent UTI in pregnant women the prevalence of ASB and incidence 
of UTI in pregnant women with and without DM and finally the need for screening for 
ASB in pregnant women with and without DM. 
Women with diabetes mellitus
Treatment of UTI in non-pregnant women with DM
Even though a UTI in women with DM is considered to be associated with the risk of 
severe complications there are no randomised control trials addressing the optimal an-
timicrobial treatment strategy for women with DM and a UTI.2, 23-26 Therefore, merely 
based on expert opinion, women with diabetes are treated longer with antibiotics. 
Prospective studies supporting current clinical practice including recurrence rates of UTI 
in women DM are lacking. 
Pregnant women
Collecting a urine sample in pregnant women
Urine is essentially sterile but during collection it might become contaminated with 
flora and epithelial cells from both the vagina and the urethra.27 Especially in pregnant 
women practical factors such as weight gain and vaginal discharge may complicate 
collection of an uncontaminated sample.28 One way to reduce contamination is to col-
lect a midstream sample without the first portion that may contain epithelial cells and 
microorganisms originated from the urethra and vagina.28 However to further reduce 
contamination current Dutch general practitioner and obstetric guidelines recommend 




sample in the morning or a midstream sample after cleaning of the vagina (clean-
catch urine sample).2,24 At present evidence for use of these more elaborate collection 
methods in pregnant women is limited and a study comparing the described methods 
desirable.
Interventions for preventing recurrent UTI in pregnant women
Up to 30% of women experience at least one recurrence within one year after the initial 
UTI.29-32 In pregnant women a recurrence rate up to 23% within the same pregnancy 
has been reported.33 As UTI are associated with obstetric complications, prevention of 
a UTI recurrence may prevent adverse pregnancy outcome. Since only a limited number 
of antibiotics are regarded safe to use during pregnancy and antibiotic resistance rates 
are increasing it is commendable to also consider non-pharmacological interventions 
for the prevention of recurrent UTI in pregnant women.34 Again evidence is limited 
and Dutch obstetric guidelines were only able to make a tentative recommendation for 
the use cranberries to prevent recurrent UTI mainly based on trials performed in non-
pregnant women.3 An overview of existing trials comparing both pharmacological and 
non-pharmacological interventions for preventing RUTI in pregnant women is essential. 
Screening for ASB in pregnant women 
Most developed countries screening (and treating) programmes for ASB during preg-
nancy in place directed to prevent pyelonephritis and/or preterm birth. In contrast to 
international guidelines, current Dutch guidelines do not recommend routine screening 
for ASB in pregnancy.3,11 No studies assessing maternal and neonatal outcomes af-
ter screening for ASB have been published and the association between ASB, pyelo-
nephritis and preterm birth is uncertain.3 Therefore, Dutch guidelines emphasize that 
more research in the Netherlands is needed starting with up-to-date numbers of the 
prevalence of ASB and incidence of UTI in pregnant women.3 
Pregnant women with diabetes mellitus
Screening for ASB in pregnant women with and without DM
DM including gestational DM is thought to be a risk factor for both ASB and UTI in 
pregnant women.35-37 However, recent data on the prevalence of ASB and UTI are lac-
king in pregnant women with DM in developed countries. To further reinforce evidence 
based decisions on ASB screening and treating policies identifying high-risk groups such 
as pregnant women with DM or GDM is desirable.
ONEOUTLINE OF THIS THESIS
Conclusions
The described existing gaps in evidence, which is essential to inform clinical practice, 
provided the foundation for this thesis. The overarching aim of the thesis is therefore, to 
provide the vital evidence for guideline committees, to base their recommendations on 
diagnosis and treatment on ASB and UTI on, especially focussing on these two patient 
groups of women with DM and pregnant women.  
Outline of this thesis 
In Chapter 2 the literature concerning ASB and UTI in women with DM and pregnant 
women, two special patient groups, is reviewed to provide up-to-date background in-
formation. 
Chapter 3 and 4 explore and compare the prescribed antibiotic treatment for UTI and 
associated recurrence rates in women with and without DM using Dutch pharmacy 
dispensing data. 
Chapter 5 concerns ‘the most reliable way to Collect Urine in Pregnant women’ (CUP) 
study that focuses on urine-sampling methods in pregnant women to assess bacteriu-
ria. The study compares contamination rates of three urine-sampling methods to inform 
clinical practice; morning, midstream and clean-catch samples.
The optimal pharmacological (antibiotics) and non-pharmacological intervention(s) for 
preventing recurrent urinary tract infections during pregnancy are discussed in Chapter 
6 in a Cochrane review. 
Chapter 7 encompasses the protocol for a cohort study with an imbedded randomised 
control trial in the Netherlands aiming to provide evidence for the benefit and cost-
effectiveness of an ASB screening and treating programme in pregnant women. 
In Chapter 8 and 9 the results of the two ‘PRegancy ASB & UTI’ PRABUTI-studies are 
presented. The aim of both PRABUTI studies is to compare prevalence of ASB and in-
cidence of UTI between pregnant women with DM and without DM. The first study 
(Chapter 8) is a retrospective study using patient records performed in Adelaide, Aus-
tralia where screening and treating of ASB during pregnancy is standard practice. The 
second study (Chapter 9) is a prospective study performed in the Netherlands where 
screening and treating of ASB is not standard practice. For this study pregnant women 
with and without DM were screened for ASB. Comparing both studies provide more 
insight in the effectiveness of ASB screening (and treating) programme to prevent ad-
verse pregnancy outcomes.
Finally in Chapter 10 we will highlight the major findings and discuss if screening of 
ASB during pregnancy is worthwhile to prevent serious pregnancy complications like 
preterm birth applying the criteria of Wilson and Jungner.38 This chapter includes a 
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Asymptomatic bacteriuria (ASB) and urinary tract infections (UTIs) in women with di-
abetes mellitus and during pregnancy are common and can have far-reaching conse-
quences for the woman and neonate. This review describes epidemiology, risk factors, 
complications and treatment of UTI and ASB according to recent developments in these 
two groups.
RECENT FINDINGS
Most articles addressing the epidemiology and risk factors of ASB and UTI in diabetic 
and pregnant women confirmed existing knowledge. New insights were obtained in 
the association between sodium-glucose cotransporter-2 (SGLT2) inhibitors, as medica-
tion for diabetes mellitus type 2, and a small increased risk for UTI due to glucosuria and 
the possible negative effects of UTI, including urosepsis,on bladder and kidney function 
in diabetic women. Predominantly, potential long-term effects of antibiotic treatment 
of ASB or UTI during pregnancy on the neonate have received attention, including an-
tibiotic resistance and epilepsy.
SUMMARY
SGLT2 inhibitors were associated with a small increased risk for UTI, UTI in diabetic 
women may lead to bladder and kidney dysfunction, and antibiotic treatment of ASB 
and UTI during pregnancy was associated with long-term effects on the neonate. Up-
to-date research on the effectiveness and long-term effects of ASB screening and treat-
ment policies, including group B Streptococcus bacteriuria in pregnancy, is warranted 
to inform clinical practice.
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Key points
•	 Due to the increased urine glucose excretion, the newly developed sodium–glucose 
cotransporter-2 inhibitors for the treatment of diabetes mellitus type 2 are associa-
ted with a very small increased risk of urinary tract infections (UTIs).
•	 Diabetes mellitus with complications is an independent predictor of major abnor-
malities (for instance hydronephrosis or urolithiasis) on imaging in adult patients 
with community-acquired urosepsis.
•	 Group B Streptococcus (GBS) bacteriuria is more common in pregnant women and 
associated with adverse pregnancy complications such as chorioamnionitis, but tre-
atment implications for clinical practice are not clear.
•	 Recently, more attention has been drawn to the effects of antibiotic treatment of 
ASB or UTI during pregnancy, which may have long-term consequences for the 
neonate such as epilepsy and antibiotic resistance. More research is needed to 
further explore and confirm these findings.
•	 The outdated evidence of the effects of ASB in combination with the possible ne-
gative effects of antibiotic use to treat ASB during pregnancy warrants up-to-date 
research about the ASB screening and treatment policies during pregnancy.
TWOINTRODUCTION
Introduction
Asymptomatic bacteriuria (ASB) and urinary tract infection (UTI) are among the most 
common diagnoses worldwide. Particularly in special patient groups such as women 
with diabetes mellitus and pregnant women, complications can have far-reaching con-
sequences such as pyelonephritis or adverse effects for the neonate. Moreover, UTIs 
may present differently in diabetic and pregnant women owing to disparities in un-
derlying pathogenesis or causative uropathogens. This review provides an overview of 
the most recent clinical studies of interest (published from 2012 till now) concerning 
epidemiology, risk factors, consequences and treatment of UTI and ASB in diabetic and 
pregnant women.
Asymptomatic bacteriuria and urinary tract infection in women 
with diabetes mellitus 
Women with diabetes mellitus are considered susceptible to both UTI and some of its 
rare but severe consequences.
Epidemiology
No recent studies have been published on the prevalence of ASB in women with dia-
betes mellitus. The prevalence of ASB is known to be higher in women with diabetes 
mellitus than in those without diabetes mellitus.1 
A study using general practice data from the years 1990-2007 in the United Kingdom 
confirmed previously described increased adjusted hazard ratio of UTI of 1.53 (95% 
confidence interval (CI) 1.45-1.60) in diabetic compared with nondiabetic women. The 
UTI incidence rate was 72.8/1000 person-years (95% CI 70.6-75.0) in women with dia-
betes. The incidence was higher in women with previously diagnosed diabetes mellitus 
than in women who were recently (within 6 months) diagnosed (91.9/1000 person-
years, 95% CI 84.3-99.4 vs. 70.5/1000 person-years, 95% CI 68.2-72.8).2 
Confounders such as age or increased regular check-ups resulting in more diagnostic 
investigations may be the basis for the increased infection rates found in patients with 
diabetes. A study analysing healthcare-associated infections in Turkey found that UTI 
was the most common infection in patients with diabetes mellitus (37.2% of all infecti-
ons), which was significantly higher than in patients without diabetes mellitus (29.8%). 
However, after adjusting for age and sex, no difference in UTI incidence between pa-
tients with and without diabetes mellitus was present.3 
Risk factors for diabetes mellitus
Prevalence of ASB and incidence of UTI differ within women with diabetes mellitus. 
These differences can possibly be attributed to additional risk factors of the patient such 
as the existence of comorbidities or medication use.
27
28
TWO ASB & UTI IN SPECIAL PATIENT GROUPS: PREGNANCY AND DM
Al-Rubeaan et al. studied 1000 Saudi diabetic patients to assess prevalence and risk 
factors for UTI.4 Risk factors found to be associated with UTI were female sex (relative 
risk (RR) 6.10, 95% CI 4.34-8.57), hypertension (RR 1.20, 95% CI 1.06-1.36), insulin 
therapy (RR 1.41, 95% CI 1.26-1.58), BMI greater than 30 kg/m2 (RR 1.72, 95% CI 
1.53-1.94) and nephropathy (microalbuminuria) (RR 1.42, 95% CI 1.04-1.94).
In addition, a study (n = 3152) using pooled safety data of 12 trials reported that tre-
atment of type 2 diabetes with a recently developed sodium-glucose cotransporter-2 
(SGLT2) inhibitor, dapagliflozin, was accompanied by a very small increased risk (SGLT2, 
2.5mg 3.6%, 5mg 5.7% or 10mg 4.3% vs. placebo, 3.7%) of UTI compared with 
placebo. SGLT2 inhibitors are a new class of oral diabetes medication. These agents 
induce renal glucosuria by selectively targeting the renal SGLT2 transporter in patients 
with type 2 diabetes mellitus.5 A smaller (n = 551) randomized controlled trial compa-
ring the SGLT2 canagliflozin with placebo or sitagliptin found a slightly increased risk of 
ASB and UTI 12 weeks after start with the medication, but this did not reach statistical 
significance (ASB, 7.7 vs. 6.3%, odds ratio (OR) 1.23, 95% CI 0.45-3.98; UTI, 5.0 vs. 
3.8%, OR 1.31, 95% CI 0.45-4.68).6 
Complications
Serious and well known consequences in patients with diabetes mellitus involve pyelo-
nephritis, including emphysematous pyelonephritis, bacteraemia and urosepsis. Tsu et 
al. confirmed in a retrospective study that most (66.7%) patients with emphysematous 
pyelonephritis suffered from diabetes.7 High tissue glucose levels, creating a favourable 
environment for the growth and multiplication of microorganisms, might be one of the 
aspects in the pathogenesis of this severe kind of pyelonephritis. A case report descri-
bed bilateral emphysematous pyelonephritis caused by Escherichia coli in combination 
with a splenic abscess in a 66-year-old woman with untreated diabetes.8 
A number of recently published studies focused on the association between UTI and 
bladder or kidney function. Chiu et al. showed that UTI in diabetic patients with late-
stage chronic kidney disease was associated with reversible superimposed acute kidney 
injury.9 In addition, recurrent UTI was found to be associated with impaired voiding 
function and diabetic bladder dysfunction in women with type 2 diabetes mellitus.10 
Diabetes mellitus with complications was an independent predictor of major abnor-
malities (for instance hydronephrosis or urolithiasis) on ultrasonography or computed 
tomography (CT) scan in adult patients with community-acquired urosepsis.11 In addi-
tion, a study of 271 E. coli random urine and bloodstream isolates performed in Taiwan 
by Wang et al. demonstrated that poorer glycaemic control and more virulent E. coli 
isolates were more often associated with the presence of urosepsis in diabetic patients 
(80% women) than the presence of only ASB or UTI in this patient group.12
Treatment
Guidelines recommend not to treat ASB in diabetic patients.13 Despite the fact that 
UTI in patients with diabetes mellitus is associated with more, severe and uncommon 
complications, trials addressing the optimal treatment of UTI are missing. Some stu-
TWOEPIDEMIOLOGY
dies report on difference in recurrence rates after treatment with different antibiotics, 
which may provide some guidance when treating UTI in patients with diabetes mellitus. 
Wang et al. reported similar antimicrobial resistance patterns of E. coli isolates between 
patients with and without diabetes.12 Only resistance for second and third-generation 
cephalosporins was higher in patients with diabetes mellitus (24-25% vs. 12-14%).
Asymptomatic bacteriuria and urinary tract infection in pregnant 
women
Pregnant women are a vulnerable group when it comes to UTIs, not only because of the 
differences in pathophysiology or the limited treatment options but also because of the 
possible impact of the infection and treatment on both the mother and the neonate.
Epidemiology
Several studies were published on prevalence of ASB in pregnancy. In general, the stu-
dies were of poor quality: small sample size, prevalence of ASB diagnosed at different 
gestational ages or the definition of ASB as not clearly defined.
In a prospective cohort study performed in India, 371 pregnant women were screened 
for ASB before 20 weeks’ and 274 women between 32 and 34 weeks’ gestation. The 
prevalence of ASB was 17% in early pregnancy and 16% in the third trimester. Even 
though all pregnant women with ASB received antimicrobial treatment, an increased in-
cidence of preterm labour (RR 3.27, 95% CI 1.38-7.72) and neonatal weight below the 
10th percentile (RR 3.79, 95% CI 1.80-7.97) was found in women with ASB in the third 
trimester compared with women without ASB. No differences were found between 
women with and women without ASB in early pregnancy.14 
Another study performed in Nigeria showed a 40% prevalence of ASB (50 of 124 
women) in pregnant women between 9 and 24 weeks’ gestation. Surprisingly, Stap-
hylococcus aureus (72%) and Proteus spp. (14%) and not E. coli (4%) were the most 
common pathogens.15 In other studies, S. aureus is only found in around 5% of the 
cases.16 These findings suggest that contamination with skin flora instead of real bacte-
riuria was present in the majority of patients. Unfortunately, the authors do not provide 
a definition of ‘significant’ growth or ‘positive culture’ in the methods.15 
Studies focusing on the occurrence of UTI during pregnancy published recently used 
mainly population-based data. Bruce et al. analysed data of 37 741 pregnancies of pa-
tients registered at a health maintenance organization in Georgia and found UTI to be 
one of the five most common conditions during pregnancy (12%).17 The incidence of 
UTI during pregnancy studied in 4501 Jordan women was even higher (20.2%).18 In the 
Netherlands, UTI is the most frequent reason for a general practitioner (GP) visit during 
pregnancy. UTI diagnosis was more common in pregnant than in nonpregnant women 
(14 vs. 6 per 100 women).19 
Concluding, both ASB and UTI are common during pregnancy; however, the found 
prevalence and incidence rates were widespread, possibly due to a combination of dif-
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Risk factors
During pregnancy, physiologic and physical changes such as decreased peristalsis of the 
urinary tract facilitate the growth of bacteria, which may result in ASB or UTI.20 
A secondary analysis of an observational study with 4490 pregnant women showed 
that a BMI of 35 kg/m2 or higher was associated with an increased risk for UTI in 
pregnancy (10.2-18.3% vs. 6.2-7.6%).21 Another interesting finding was that pregnant 
women living with a cat or a dog not only had an increased E. coli colonization of the 
vaginal flora but also a higher incidence of self-reported UTI (with cat 32%, with dog 
27%, without a cat or a dog 21%), indicating possible transmission of uropathogens 
between pets and pregnant women.22 
Uropathogens
E. coli predominantly causes ASB and UTI; however, other causative uropathogens such 
as group B Streptococcus (GBS) are more often identified in pregnant women.16 
Currently, GBS bacteriuria in pregnancy receives more attention because GBS bacte-
riuria indicates more heavy colonization than vaginal GBS colonization. This theory is 
endorsed by the findings of Kessous et al., who demonstrated that GBS bacteriuria is 
associated with higher rates of obstetric complications including intrapartum fever and 
chorioamnionitis compared with women with vaginal GBS colonization or no coloniza-
tion.23 Finally, the authors found that pregnant women with GBS bacteriuria more often 
suffered from diabetes mellitus.23 Unfortunately, the implications for clinical practice 
are not clear. A recent Cochrane review on intrapartum antibiotics for known maternal 
GBS colonization concluded that there is still not enough valid information from the 
existing three small, dated and biased trials to inform clinical practice.24 However, a re-
cent guideline developed by the Society of Obstetricians and Gynaecologists of Canada 
based on articles published before 2011 recommended providing intrapartum antibio-
tics when a woman is known to have GBS bacteriuria of any colony count, to prevent 
early-onset neonatal GBS disease.25 
Complications
It is important to realize that UTIs during pregnancy may affect not only the mother but 
also the neonate. Jolley et al. described hospitalization rates for pyelonephritis during 
pregnancyusing US data from the Nationwide Inpatient Sample 2006. Cases of pye-
lonephritis were selected using ICD-9 codes, identifying 28 923 women with pyelo-
nephritis (0.6% of all pregnant women).26 Concomitant diagnoses in women with pye-
lonephritis were septicaemia (1.95%), acute respiratory failure (0.77%), preterm labour 
or premature rupture of membranes (PROM) (3.77%), anaemia (22.4%) or diabetes 
mellitus (3.7%). Some pregnant women with pyelonephritis died during their hospital 
admission, underscoring the danger of this condition; however, no actual number was 
provided.26 
TWOTREATMENT
A retrospective study from Jamaica found an incidence of 0.7% (102 in 14 651 delive-
ries) of confirmed pyelonephritis cases in pregnant women. Most cases (58.8%) were 
diagnosed in the second trimester. In only 59 of the 102 cases was a positive urine 
culture present; in other cases, the urine culture negative, contaminated or missing.27 In 
a retrospective cohort study, no differences were found in maternal morbidity (defined 
as days of admission) between pyelonephritis diagnosis antepartum and up to 6 weeks 
postpartum.28
Recent studies have focused particularly on consequences of maternal UTI on the neo-
nate. Collier et al. found that a combination of ASB, UTI and pyelonephritis during 
pregnancy in mothers with and without asthma was related to increased asthma in 
offspring until six years of age (adjusted OR 1.60, 95% CI 1.12-2.29).29 This has already 
been described in other studies. For this recent study, 1428 pregnant women with 
and without asthma were interviewed and maternal medical records were checked. No 
other maternal infections were associated with childhood asthma.29 
A case-control study comparing the association between antenatal maternal UTI and 
neonatal UTI showed that neonates admitted for the management of a UTI more often 
had a mother with a history of UTI than neonates admitted for jaundice (30.0% vs. 
6.8%, OR 5.9, 95% CI 1.9-18.3, P = 0.001). A possible explanation for this association 
is sharing of genetic make-up and/or uropathogens in one household. A limitation of 
this study is the risk of recall bias, as the mothers retrospectively reported the occur-
rence of maternal UTI and the authors did not give a clear definition of UTI.30 
A review published last year by Cunnington et al. identified five studies describing the 
association between UTI and preterm delivery.31 Only one study showed that the risk 
of preterm birth was nearly doubled in pregnant women with compared with those 
without a UTI (RR 1.35, 95% CI 1.32-1.38).31 Three other studies showed a modest 
increase with point estimates between 1.03 and 1.09 and one study did not show any 
difference (RR 0.99, 95% CI 0.91-1.08).31 Incidence of UTI recorded in 911 medical files 
of French Caribbean women during pregnancy was increased in women who delivered 
preterm (<37 weeks) compared with women who delivered term (hazard ratio 1.9, 
95% CI 1.3–2.8).32
A large, retrospective, population-based study analysing 219 612 singleton pregnancies 
found an incidence of acute antepartum pyelonephritis of 0.07% and demonstrated 
that antepartum pyelonephritis was an independent risk factor for preterm delivery (OR 
2.6, 95% CI 1.7-3.9, P < 0.001).33 
Treatment of asymptomatic bacteriuria and urinary tract infection in pregnancy
Guidelines still advise screening and treating ASB in pregnancy, although the evidence 
might be outdated. As far as we know, no studies concerning optimal treatment of 
ASB in pregnancy were published recently. Concerning the treatment of ASB or UTI, it 
has to be noted that treatment during pregnancy can be difficult, as certain antibiotics 
cannot be used. Currently, a cohort study with an embedded randomized controlled 
trial is being performed to address this issue in a modern population in the Netherlands, 
where screening and treating of ASB is not part of standard clinical practice.34
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Pregnant women often experience recurrent UTI. A Cochrane review on preventing 
recurrent UTI in pregnant women, with as primary outcomes recurrent UTI before birth 
(variously defined) and preterm birth (before 37 weeks), included only one small trial 
comparing a daily dose of nitrofurantoin and close surveillance with close surveillance 
alone. No differences were found between the two interventions on the primary out-
comes and only a significant reduction in ASB was seen in women who received close 
surveillance and nitrofurantoin. This review highlighted that more trials are necessary to 
assess the optimal intervention to prevent recurrent UTI in pregnant women.35 
The authors of another Cochrane review addressed the effectiveness of cranberries to 
prevent UTIs in pregnant women and concluded that cranberries are not effective (1.04, 
95% CI 0.93-1.17). This was based on the results of two studies, both reporting a high 
number of withdrawals possibly because of the large quantities consumed of cranberry 
juice, which can result into nausea especially during pregnancy.36 
Addressing the choice of the right antimicrobial agent was done in a Spanish retrospec-
tive observational study. The investigators analysed 50 isolated microorganisms of 93 
pregnant women with pyelonephritis and found that 10% of the cases were not pro-
perly treated with an antibiotic that matched the causative pathogen and its resistance 
pattern. In 46.2% of women with a diagnosis of pyelonephritis, no microorganisms 
were found, possibly as empirical treatment was commenced before a urine culture 
was performed.37 
Consequences of antibiotic treatment during pregnancy
After the publication (2008) of the 7-year follow-up of the ORCALE II trial, which sho-
wed an increased risk of cerebral palsy in neonates whose mothers received antibiotics 
during pregnancy, more studies focused on possible adverse effects of maternal antibi-
otic use during pregnancy.38 
Wright et al. found that early-onset sepsis caused by antibiotic-resistant microorganisms 
in neonates was associated with maternal antibiotic use during pregnancy and delivery, 
including antibiotics for bacteriuria (6% of prescriptions).39 Main indications for antibi-
otic prescriptions were preterm PROM and chorioamnionitis.39
Short-term follow-up data of maternal nitrofurantoin use in a population-based cohort 
showed no increased risk of major malformations (a OR 0.79, 95% CI 0.55-1.13), and 
only a small increased risk of neonatal jaundice when dispensed in the last 30 days be-
fore delivery (a OR 1.31, 95% CI 1.02-1.70).40 However, in a long-term Danish follow-
up study, 447 629 singleton pregnancies were followed to 9.9 years to investigate the 
relationship between maternal antibiotics use (mainly for UTI) and epilepsy. The investi-
gators found a slightly increased risk of epilepsy in children whose mothers received an-
tibiotic prescriptions (i.e. nitrofurantoin) during pregnancy; this was most pronounced 
among mothers with multiple prescriptions (hazard ratio 1.3, 95% CI 1.0-1.8). More 
research is needed to investigate confounding and the direct drug effect.41
TWOCONCLUSION
Conclusion
The recently published articles concerning epidemiology and risk factors of ASB and 
UTI in diabetic and pregnant women mainly confirmed existing knowledge. Adverse 
effects of treatment of diabetes mellitus and bacteriuria itself were emerging topics. 
The newly developed type 2 diabetes mellitus agents, SGLT2 inhibitors, were found 
to be associated with a small increased risk for UTI due to increased glucosuria. In ad-
dition, antibiotic treatment of ASB or UTI during pregnancy was related to short-term 
and long-term consequences in the neonate. In the light of the possible adverse effects 
of antibiotics, more studies exploring the possibilities for non-antibiotic interventions 
to prevent or treat ASB and UTI are needed. Moreover, evidence regarding optimal tre-
atment of UTI in diabetic patients is still lacking. Also, up-to-date studies investigating 
whether screening and treatment of ASB is still useful (including GBS bacteriuria during 
pregnancy) are necessary to inform clinical practice.
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Women with diabetes have a high incidence and complication rate of urinary tract in-
fections (UTIs). Our aims were to compare current treatment strategies with respect to 
recurrence rates in women with diabetes with those without diabetes.
RESEARCH DESIGN AND METHODS
We used a Dutch registration database containing pharmacy dispensing data. A total of 
10,366 women with diabetes (17.5% premenopausal) (aged ≤55 years) and 200,258 
women without diabetes (68% premenopausal) who received a first course of trime-
thoprim, nitrofurantoin, fosfomycin, or norfloxacin between January 1999 and Janu-
ary 2006 were included. We compared short (≤5 days) with long (>5 days) prescripti-
ons and norfloxacin with trimethoprim, nitrofurantoin, and fosfomycin. A recurrence 
was defined as a second prescription for one of the above-mentioned agents or a first 
with amoxicillin (clavulanic acid), fluoroquinolones, or trimethoprim/sulfamethoxazole 
between 6 and 30 days after inclusion.
RESULTS
Premenopausal women with diabetes more often received a long (26.5 vs. 19.2%; P 
< 0.001) treatment with norfloxacin (10.7 vs. 6.2%; P < 0.001) but still had a higher 
recurrence rate (16.1 vs. 12.2%; P = 0.003) compared with those without diabetes. 
Similarly, postmenopausal women with diabetes more often received a longer (32.8 
vs. 28.8%; P < 0.001) treatment with norfloxacin (15.2 vs. 12.7%; P < 0.001) but had 
a higher recurrence rate (19.1 vs. 16.4%; P < 0.001) compared with those without 
diabetes.
CONCLUSIONS
Despite the fact that patients with diabetes more often received longer and more po-
tent initial treatment than patients without diabetes, pre- and postmenopausal women 
with diabetes more often had recurrences of their UTIs.
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Introduction
Diabetes is an increasingly important endocrine disease. Incidence of infections is in-
creased in diabetic (type 1 and type 2) patients compared with control subjects.1,2 and 
the urinary tract is the most prevalent site of these infections.3 Furthermore, diabetic 
patients with a urinary tract infection (UTI) more often develop severe and rare com-
plications, such as emphysematous cystitis and papillary necrosis.4,5 Studies addressing 
differences in UTI recurrence rates between diabetic patients and control subjects show 
contradictory results for uncomplicated lower and upper UTIs.2,6-8 Currently, there are 
no controlled clinical trials investigating the optimal antimicrobial treatment strategy in 
diabetic patients with UTIs. Current recommendations rely on the opinion of experts.5,9 
It is generally recommended to treat UTIs in diabetic patients with antibiotics with high 
tissue penetration for 7–14 days. Importantly, we lack data on the clinical practice of 
how diabetic patients with a UTI are actually treated, to assess recurrence rates.
The aims of this study are to describe the treatments (duration and agents) for uncom-
plicated UTIs in women with and without diabetes in the Netherlands and to analyze 
recurrence rates of these UTIs within 30 days after the last treatment.
Research design and methods
Database
Data were obtained from the PHARMO Record Linkage System. The PHARMO Institute 
is an independent scientific research organization dedicated to studying drug use and 
outcomes in daily practice in the Netherlands. The PHARMO Record Linkage System 
includes, among other databases, the drug dispensing records from community phar-
macies linked to hospital discharge records of more than 2 million community-dwelling 
inhabitants of 40 demographically well-defined Dutch regions. For all residents, the 
computerized drug dispensing histories contain data concerning the dispensed drug, 
prescriber specialty, dispensing date, dispensed amount, prescribed dose regimens, and 
the legend duration of use (prescription length). All drugs are coded according to the 
Anatomical Therapeutic Chemical Classification. The hospital records include detailed 
information concerning the primary and secondary diagnoses, procedures, and dates of 
hospital admission and discharge. All diagnoses are coded according to the ICD-9-CM 
(available at http://www.pharmo.nl/). Data between 1 January 1999 and 31 December 
2005 were used.
Inclusion criteria
Data of all women aged >12 years, receiving at least one prescription of trimethoprim, 
norfloxacin, nitrofurantoin, or fosfomycin in the period after the first of January 1999 
and first of January 2006 with follow-up data of at least 30 days, were extracted.6
THREEINTRODUCTION
Following the Dutch guidelines, trimethoprim/sulfamethoxazole, amoxicillin, and fluor-
quinolones other than norfloxacin are rarely prescribed for uncomplicated UTIs because 
of the high resistance rates (available at http://www.swab.nl) in the Netherlands or due 
to the advice to preserve these antibiotics for complicated UTIs.
Exclusion criteria
To limit the study population to women with uncomplicated UTIs, we wanted to exclu-
de all women with possible recurrent UTIs because of secondary diseases or underlying 
abnormalities. Therefore, all factors that belong to the definition of complicated UTIs 
were considered exclusion criteria10:
•	 Pregnancy (delivery during the follow-up period or folic acid prescription in the 
preceding year and during the follow-up).
•	 Patients with known anatomical abnormalities, for example, indwelling urinary ca-
theter or hospitalization for a urethral stricture in the follow-up period.
•	 The use of the following medication in the preceding year and during the follow-
up: antiretroviral treatment for HIV; immune suppressive drugs; chemotherapy; and 
medication for renal insufficiency, such as calcium binding agents.
•	 Patients receiving a first prescription with duration of >30 days.
•	 Patients with a second prescription within 5 days after their first prescription, indi-
cating acute side effects or loss of recipe or medication.
•	 Patients receiving in the preceding year trimethoprim, norfloxacin, nitrofurantoin, 
or fosfomycin, indicating prophylaxis for recurrent UTIs.
Outcome parameters
The primary outcome was the prescription for a second antibiotic course or a hospitali-
zation admission for a UTI during the follow-up period.
Definitions
The cohort entry date was defined as the day that the patient received her first pres-
cription trimethoprim, norfloxacin, nitrofurantoin, or fosfomycin. The history period 
was defined as 1 year before study inclusion. The follow-up period was defined as the 
duration of the first prescription plus 30 days after the cohort entry date. Patients with 
diabetes were defined by prescription of one or more glucose-lowering medications 
(tablets or insulin) in the history or in the follow-up period.
Premenopausal women were defined as aged ≤55 years at the dispensing date of their 
first prescription. Postmenopausal women were women aged >55 years at the moment 
of the dispensing date of their first prescription. This is a conservative definition of 
postmenopausal women, since the worldwide mean age of menopause is 49.2 years.
A “new” diagnosis of UTI (inclusion criteria for this study) was defined as a patient with 
no prescription for trimethoprim, norfloxacin, nitrofurantoin, or fosfomycin in the his-
tory (1 year) and a first prescription for trimethoprim, norfloxacin, nitrofurantoin, or fos-
fomycin in the period from 1 January 1999 to 31 December 2005. The first prescription 
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is always one of the following antibiotics: trimethoprim, norfloxacin, nitrofurantoin, or 
fosfomycin. A recurrent UTI was defined as a prescription for trimethoprim, norfloxa-
cin, nitrofurantoin, or fosfomycin or amoxicillin, fluoroquinolones, amoxicillin/clavulanic 
acid, or trimethoprim/sulfamethoxazole in the follow-up period (5 days after the first 
prescription until 30 days after the end of the first prescription) or hospitalization admis-
sion with the diagnosis of a UTI. These recurrences could be relapses (second infection 
with the same organism) or reinfections (second infection with a different organism). 
Hospital admissions were included as cases diagnosed according to the ICD-9 system 
with either a kidney infection (590), cystitis (595), urethritis (not sexually transmitted) 
(597), urethral syndrome (597), or other disorders of urethra and urinary tract (599).
Some of the above-mentioned antibiotics for a recurrent UTI could also be used for 
other diseases than UTIs. To exclude antibiotics prescriptions for other infections than a 
UTI, all analyses were repeated with the use of comedication, defined as medication gi-
ven at the same moment as the antibiotic for a recurrent UTI from one of the following 
anatomical therapeutic chemical groups: A (gastrointestinal), D (skin), R (respiratory), 
and S (ear or eye). Similarly, analyses were repeated with prescriptions from other spe-
cialties than general practitioners excluded.
Aggressive treatment for a UTI was defined as a treatment with an antibiotic that has 
high tissue penetration (in kidney and prostate). For the first prescription agents only, 
norfloxacin has this potency.
Statistical analyses and ethics
Data were analyzed using SPSS software for Windows, version 14.0. Medication use 
and recurrence rate were compared between women with and without diabetes. Ana-
lyses were done with a  Chi-squared test. We corrected for age by comparing different 
age strata. A P value <0.05 was considered to be statistically significant.
Ethical approval was not necessary because all data were anonymized before entering 
the PHARMO database. Researchers only have information on sex and age of the pa-
tient. All other identifying information is deleted after the linkage with the hospital 




Initially, the database consisted of 246,306 women who were aged ≥12 years and re-
ceived a prescription for trimethoprim, norfloxacin, nitrofurantoin, or fosfomycin in the 




•	 Women ≥12 years
•	 With at least one prescription of  
trimthoprim, norfloxacin, nitrofurantoin 
or fosfomycin
•	 Study period is from the first of January 
1999 until the first of January 2006
•	 Only prescriptions < 31 days
Patients
N = 246,306
Excluded N = 21,808 (9.2% with DM)
•	 Patients with one of the following pres-
criptions during the preceding year and 
the follow-up period (9.3% with DM):
 - Antiretroviral treatment for human 
immunodeficiency infection (HIV) 
 - Immune suppresive drugs e.g. 
prednisone 
 - Chemotherapy 
 - Folic acid (pregnancy) 
 - Patients with a catheter
•	 Patients who had a delivery in the 
follow-up period (0.9% with DM)
•	 Patients with known anatomical 
abnormalities (urethral stricture) (9.1% 
with DM)
Excluded N = 15,539 (7.6% with DM)
•	 Patients receiving in the preceding year: 
trimethoprim, norfloxacin, nitrofuran-
toin or fosfomycin, indicating recurrent 
UTI
Some patients are excluded because of two 
or more reasons
Total patients excluded
N = 35,682 (8.4% with DM)
Total patients
N = 210,624
Figure 1. Numbers of included and excluded women in the total study group.
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Exclusion criteria
A total of 21,808 women were excluded for different reasons (Figure 1), and another 
15,539 women were excluded because they had a UTI in the year before the cohort 
entry date. Finally, the study included 210,624 women: 10,366 women with diabetes 
(17.5% premenopausal women aged ≤55 years) and 200,258 women without diabetes 
(68% premenopausal).
Premenopausal women
Baseline characteristics of the premenopausal women are shown in Table 1. Percentage 
of prescriptions with norfloxacin were significantly higher and the treatment duration 
was significantly longer in premenopausal women with diabetes compared with those 
without. The recurrence rate (Table 2) was significantly higher in premenopausal wo-
men with diabetes: 16.1% in women with diabetes and 12.2% in women without 
diabetes (P = 0.002). There was no significant difference between hospitalization of 
women with and without diabetes (0.1 vs. 0.1%, P = 0.790). In both analyses, the re-
sults were similar in age strata.
Postmenopausal women
Baseline characteristics of the postmenopausal women are shown in Table 1. Percen-
tage prescriptions with norfloxacin were significantly higher and the treatment duration 
was significantly longer in postmenopausal patients with diabetes compared with those 
Table 1. Treatment of UTIs in pre- and postmenopausal women with and without diabetes
Premenopausal women Postmenopausal women
With DM Without DM p-value With DM Without DM p-value
N 1,817 136,195 8,549 64,063
Age (median (25e;75e)) 47 (38;52) 34 (23;44) 75 (67;81) 70 (62;79)
Insulin (%) 892 (49.1) 0 2,830 (33.1) 0
Oral antidiabetics (%) 1,163 (64.0) 0 6,841 (80.0) 0
Trimethoprim (%) 773 (42.5) 63,094 (46.3) 0.001 3,499 (40.9) 27,573 (43.0) <0.001
Nitrofurantoin (%) 847 (46.6) 64,357 (47.3) 0.588 3,737 (43.7) 28,239 (44.1) 0.520
Fosfomycin (%) 2 (0.1) 245 (0.2) 0.484 15 (0.2) 136 (0.2) 0.483
Norfloxacin (%) 195 (10.7) 8,499 (6.2) <0.001 1,298 (15.2) 8,115 (12.7) <0.001
Treatment ≤5 days 1,336 (73.5) 110,024 (80.8) <0.001 5,748 (67.2) 45,617 (71.2) <0.001
Treatment >5 days 481 (26.5) 26,171 (19.2) <0.001 2,801 (32.8) 18,446 (28.8) <0.001
Data are n (%) or median (25th to 75th percentile).
THREERESULTS
without. The recurrence rate (Table 2) was significantly higher in postmenopausal wo-
men with diabetes: 19.1% in women with and 16.4% in women without diabetes (P 
< 0.001). There was a significant difference in hospitalization frequency between post-
menopausal women with and without diabetes (0.3 vs. 0.2%, P = 0.003). A total of 23 
the postmenopausal women with diabetes and 83 without diabetes were hospitalized 
because they had an infection of the kidneys or other disorder of the urinary tract. In 
both analyses, the results were similar in age strata.
Secondary analyses
Therapeutic courses given to diabetic (DM+ group) or nondiabetic (DM− group) pre- or 
postmenopausal women were consistent with the Dutch guidelines (see CONCLUSI-
ONS) in 71% (premenopausal DM+ women), 79.8% (premenopausal DM− women), 
51.8% (postmenopausal DM+ women), and 55.4% (postmenopausal DM− women) 
of the cases. 
General practitioners prescribed 92.0–96.1% of the antimicrobials in all patient groups. 
When all analyses were repeated with only the prescriptions by the general practitio-
ners, similar results were found. The same was true when all analyses were repeated 
after excluding patients who were using comedication at the time of the antibiotic 
prescription.
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Table 2. Recurrence rates and treatment of a recurrent UTI in pre- and postmenopausal women with and 
without diabetes
Premenopausal women Postmenopausal women
With DM Without DM p-value With DM Without DM p-value
N 1,817 136,195 8,549 64,063
2nd prescription (%) 292 (16.1) 16,586 (12.2) 0.002 1,636 (19.1) 10,498 (16.4) <0.001
Hospitalization (%) 2 (0.1) 124 (0.1) 0.790 25 (0.3) 97 (0.2) 0.003
Trimethoprima (%) 53 (18.2) 3,176 (19.1) 0.667 306 (18.7) 1,871 (17.8) 0.387
Nitrofurantoina (%) 82 (28.1) 5,848 (35.3) 0.011 476 (29.1) 3,153 (30.0) 0.440
Fosfomycina (%) 0 37 (0.2) 0.419 1 (0.1) 24 (0.2) 0.165
Norfloxacina (%) 54 (18.5) 2,449 (14.8) 0.076 351 (21.5) 2,252 (21.5) 0.998
Amoxicillina (%) 28 (9.6) 1,603 (9.7) 0.965 112 (6.8) 664 (6.3) 0.423
Amoxicillin/clavulanic 
acida (%)
26 (8.9) 1,192 (7.2) 0.261 129 (7.9%) 716 (6.8) 0.116
TMP/SMXa (%) 22 (7.5) 1,183 (7.1) 0.792 97 (5.9) 784 (7.5) 0.026
Ciprofloxacina (%) 17 (5.8) 783 (4.7) 0.380 120 (7.3) 774 (7.4) 0.957
Fluoroquinolonesa,b (%) 10 (3.4) 315 (1.9) 0.060 44 (2.7) 260 (2.5) 0.608
Data are n (%). a Percentages from second prescription. b Without norfloxacin and ciprofloxacin.
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Conclusions
In this study, we found that both pre- and postmenopausal women with diabetes re-
ceive longer and more potent antimicrobial treatment for uncomplicated UTIs com-
pared with pre- and postmenopausal women without diabetes. However, despite this 
more aggressive treatment, both pre- and postmenopausal women with diabetes had 
more recurrences of their UTIs than women without diabetes. Besides that, hospitaliza-
tion for complications of the UTI was significantly more often seen in postmenopausal 
women with diabetes.
The choice for a more potent antibiotic was not to treat a recurrent UTI, since all pa-
tients with a UTI in the previous 12 months were excluded. The percentages of women 
with a recurrent UTI were comparable with the results found by Lawrenson et al., who 
demonstrated that overall 14% of 75,045 newly treated patients with a UTI (0.7% of 
all patients had diabetes) received a second antibiotic within 28 days.7
The longer prescription period for diabetic patients with an uncomplicated UTI with 
norfloxacin is not in accordance with the national Dutch guideline in use in the study 
period. The recommendation in the national Dutch guideline 1999 in use during the 
study period for an uncomplicated UTI was a 3-day oral antimicrobial regimen with 
either 100 mg nitrofurantoin three times daily or 300 mg trimethoprim once daily for 
patients with and without diabetes.11 There were no differences in antimicrobial resis-
tance percentages of causative uropathogens, isolated in the same period as the data 
of the present study, between women with and without diabetes.12 Treating physicians 
may have been chosen for longer treatment duration and a more aggresive antibiotic 
due to the higher risk of complications of UTIs.
Postmenopausal women with diabetes were significantly more often admitted to the 
hospital than women without diabetes. These results are comparable with those from a 
Canadian study that demonstrated that patients with diabetes more often had a hospi-
talization or physician claims for an infectious disease than patients without diabetes.1 
However, in contrast to the mortality rate outside the hospital, the mortality rate inside 
the hospital is not higher in patients with diabetes.1,3 Therefore, it seems possible that 
physicians refer patients with diabetes faster and treat them more aggressively in the 
hospital compared with patients without diabetes.
To our knowledge, this is the first study of its kind with this amount of (more than 
200,000) patients. In addition, in contrast to most earlier studies in which the recur-
rence rate of UTIs were described, we also compared the different treatment strategies 
between women with and without diabetes and analyzed pre- and postmenopausal 
women separately.2,6,7 The risk factors for UTIs are partly different in pre- and postme-
nopausal women, and therefore they should not be regarded as identical entities.13,14 
Furthermore, it is only possible to interpret the recurrence rates when the initial treat-
ment strategies of the two groups are known.
THREECONCLUSION
This study has several limitations. In the first place, it is retrospective and we do not 
have records on what the reasons of the treating physician were when prescribing a 
specific antimicrobial agent or a longer treatment duration. It can be possible that di-
abetic patients more often had symptoms of a UTI with tissue invasion (pyelonephritis 
or urosepsis).15,16 We have shown before that only 0.5% of diabetic patients with a 
UTI had clinical symptoms of a pyelonephritis compared with 0.2% in control sub-
jects. Others have demonstrated that the risk ratio for pyelonephritis in patients with 
compared with those without diabetes ranges from 1.86 to 4.4.17-19 These numbers 
make clear that even when more women with diabetes had clinical symptoms of a 
pyelonephritis and therefore were treated with norfloxacin during a longer period, this 
cannot totally explain the demonstrated differences. It therefore seems likely that the 
physician took diabetes status into account when prescribing antibiotic therapy. Based 
on drug-dispensing data, we may have missed diabetic women treated with diet and 
exercise only. On the other hand, we know that many patients with diabetes are not 
diagnosed, so any definition of diabetes in this type of database research has imperfec-
tions.20 Furthermore, it is not possible to distinguish between type 1 and type 2 diabetes 
because patients in both groups could receive a treatment with insulin. This division is, 
for this study, not that important because in an earlier study we showed a comparable 
incidence of UTI in patients with type 1 and type 2 diabetes.21 Unfortunately, because 
we did not have urine culture results, we were not able to distinguish between a relapse 
and a reinfection, which could have influenced the subsequent treatment decision.
Furthermore, because follow-up was only 30 days, it is possible that pregnant women 
might have been misclassified (delivery after >30 days). Another limitation is that the 
level of sexual activity was unknown despite the fact that this is an important risk factor 
for UTI in premenopausal women. However, we do not expect that a higher percentage 
of pregnant women (and therefore women with a complicated UTI) were included in 
the diabetic women group or that diabetic women had a higher frequency of sexual 
intercourse. Moreover, pregnant women with a UTI are mostly treated with amoxicillin/
clavulanic acid or a cephalosporin in the Netherlands and therefore would not have 
been included in this study at all. Therefore, it is unlikely that this possible misclassifica-
tion or lack of information on risk factors would have influenced our results.
Furthermore, no differences were found after analyzing only the prescriptions of the 
general practitioners. Another limitation is that women with a recurrence could have 
underlying anatomical abnormalities like bladder neuropathy. Therefore, we excluded 
all women who had a UTI in the previous year to minimize this group.
In conclusion, we showed that both pre- and postmenopausal women with diabetes 
and a UTI receive a more aggressive and longer treatment but still have more recurren-
ces of their UTIs than women without diabetes. Whether therapy with a longer duration 
or an antibiotic with high tissue penetration contributes to lower recurrence rates needs 
further investigation. Therefore, a prospective randomized control trial with different 
treatment strategies must determine which treatment strategy is optimal in diabetic 
women with a UTI.
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Postmenopausal women with diabetes mellitus (DM) have an increased incidence of 
urinary tract infections (UTI) compared to women without DM. The aim of this study is 
to compare recurrence rates of UTI in postmenopausal women with DM after treatment 
with nitrofurantoin, the agent of first choice following the Dutch guidelines, with two 
other common prescribed antibiotics trimethoprim and norfloxacin. 
METHODS
We used a PHARMO database with pharmacy dispensing data. A total of 8534 post-
menopausal (>55 years) women with DM who received a first course of nitrofurantoin, 
trimethoprim or norfloxacin were included. The UTI recurrence rates after treatment 
with these three different antimicrobial agents were compared. Recurrence was defined 
as a second prescription for nitrofurantoin, trimethoprim or norfloxacin or a first with 
fosfomycin, amoxicillin, fluoroquinolones, or trimethoprim/sulfamethoxazole between 
6 and 30 days after inclusion. 
RESULTS
Postmenopausal women with DM had significantly more UTI recurrences when they 
were treated with nitrofurantoin (22.7%) compared to trimethoprim (17.7%) or nor-
floxacin (14.2%) irrespective of the treatment duration. There was a trend that longer 
treatment duration was associated with higher recurrence rates. 
CONCLUSIONS
Postmenopausal women with DM had more UTI recurrences when they are treated with 
nitrofurantoin, agent of first choice, compared to trimethoprim or norfloxacin.
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Introduction
Postmenopausal women with diabetes mellitus (DM) have an increased incidence and 
complication rate of urinary tract infections (UTI) compared to women without DM.1-3 
As far as we are aware, no randomized trials comparing different antibiotic treatments 
for UTI in women with DM are present. Because of the possible severity of UTI in pa-
tients with DM international guidelines recommend prolonged treatment with specific 
antimicrobial agents in these patients. However, most recommendations rely on expert’s 
opinions.4
The aim of this study is to compare recurrence rates of UTI in postmenopausal women 
with DM after treatment with nitrofurantoin, the agent of first choice following the 
Dutch guidelines with trimethoprim and norfloxacin which are also frequently used.
Methods
We used a PHARMO database with pharmacy dispensing data. A total of 8534 post-
menopausal (>55 years) women with DM who received a first course of nitrofurantoin, 
trimethoprim or norfloxacin during the study period from the first of January 1999 
until the first of January 2006 were included. All women with recurrent UTI because of 
known secondary or underlying abnormalities were excluded.
The UTI recurrence rates after treatment with these different antimicrobial agents were 
compared. Recurrence, the primary outcome, was defined as a secondacin or a first with 
fosfomycin, amoxicillin, fluoroquinolones, or trimethoprim/sulfamethoxazole between 
6 and 30 days after inclusion. Furthermore we compared recurrence rates between dif-
ferent treatment duration groups using chi-squared test. The extended methods have 
been described elsewhere.5
Results
Postmenopausal women with DM had significantly more UTI recurrences when they 
were treated with nitrofurantoin (22.7%) compared to trimethoprim (17.7%) or nor-
floxacin (14.2%) irrespective of the treatment duration. There was a trend that longer 
treatment duration with the same antimicrobial agent was associated with higher recur-
rence rates. For the majority of women nitrofurantoin or trimethoprim was prescribed 
4 to 5 days and norfloxacin 6 to 7 days (Table 1 and Figure 1).
FOURCONCLUSIONS
Figure 1. The recurrence rates by antibiotic type and by duration in postmenopausal women with diabetes
* P <0.05 between recurrences rates nitrofurantoin and trimethoprim. 
** P <0.05 between recurrences rates nitrofurantoin and norfloxacin.
Conclusions
In this study we found that postmenopausal women with DM had more UTI recurrences 
when they were treated with nitrofurantoin, the first choice agent, compared to trime-
thoprim or norfloxacin, irrespective of the treatment duration.
Our results differ from Lawrenson et al., who demonstrated no significant difference in 
recurrence rates between nitrofurantoin, trimethoprim or norfloxacin in premenopausal 
women aged 15-44 years with and without DM.6 These differences can be explained 
by the study population of the present study that consisted of only postmenopausal 
women with DM. In addition it has been described before that trimethoprim and nor-
floxacin may reach therapeutic tissue concentrations in contrast to nitrofurantoin.7
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Table 1. Postmenopausal women with diabetes
Characteristics
N 8,534
Age (median (25e;75e)) 75 (67;81)
Use of insulin 2,826 (33.1%)
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Treatment duration was not a primary outcome. Unexpectedly, we found that prolon-
ged treatment with the same antimicrobial agent was associated with increasing recur-
rence rates. We assume that physicians prescribe a treatment with a longer duration 
for patients who clinically have a more severe UTI. Therefore, we cannot conclude that 
prolonged treatment is causally associated with higher recurrence rates.
These longer treatment durations were not in agreement with the recommendations 
in the national Dutch guideline 1999 in use during the study period. In this guideline it 
was recommended to treat lower UTI in women with and without diabetes in the same 
manner, namely with a 3-day oral antimicrobial regimen with either nitrofurantoin 100 
mg BID or trimethoprim once daily.
To our knowledge, this is one of the few studies that give us some insight in the tre-
atment that is possibly required for UTI in postmenopausal women with DM, a special 
patient group which certainly needs more attention taking the increased incidence of 
UTI and associated complications in account.1-3
The strength of this study is the large dataset with more than 8000 patients of an un-
selected population with a complete follow-up.
There are some limitations. Most important, clinical characteristics of the study popula-
tion, like the severity of symptoms, were not available. Therefore, it was not possible to 
differentiate between complicated and uncomplicated, and upper and lower UTI. These 
could partly explain the lower recurrence rate in patients treated with norfloxacin, or 
the increased prolonged treatment. Combined with the observational design of the 
study causal conclusions cannot be made.
In conclusion, we showed that postmenopausal women with diabetes and a UTI had 
more UTI recurrences when they were treated with nitrofurantoin (agent of first choice) 
compared to trimethoprim or norfloxacin irespective of the treatment duration. We 
want to be modest to make conclusions, because cofounding by indication our might 
have influenced these results. However, the results of this study emphasize that the op-
timal treatment of UTI in postmenopausal women with DM is not known. Randomized 
controlled trials with different treatment strategies are warranted to answer the questi-
on what the optimal treatment strategy is for UTI in postmenopausal women with DM.
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To estimate and compare contamination rates of three different urine-sampling me-
thods in pregnant women to assess bacteriuria.
METHODS
In this cross-sectional study, 113 pregnant women collected three different midstream 
urine samples consecutively: morning (first void); midstream (void without further in-
structions); and clean-catch sample (void after cleaning). The following end points were 
considered contaminants: epithelial cells, Gram-positive rods or mixed bacteria in the 
Gram stain, and mixed growth or skin flora in the urine culture. Intraindividual varia-
bility in contaminants was quantified with Fleiss-Cohen’s weighted [kappa] statistic. 
Differences between samples were assessed using generalized estimating equations.
RESULTS
Mainly low numbers of Gram-positive rods were more likely to be present in Gram 
stains of midstream samples compared with clean-catch samples (77.7% compared 
with 66.7%, P=.022). Morning samples showed more mixed growth compared with 
midstream samples (6.2% compared with 0.9%, P=.050). No consistency in quantity 
of contaminants was found in midstream samples compared with morning and clean-
catch samples. No differences were found between the other end points in all three 
urine samples (P>.05). The study could detect an odds ratios of 2.0 for differences in 
urine-sampling methods with 80% power and 5% significance for most end points.
CONCLUSIONS
In pregnant women, the contamination rate of midstream samples is comparable with 
the contamination rates of morning and clean-catch samples. The quantity of conta-
minants varied among the three samples collected by one woman. These results show 
that more complex, unpractical, and time-consuming morning and clean-catch samples 




FIVE CUP STUDY: URINE SAMPLING METHODS IN PREGNANT WOMEN
Introduction
Urine is supposed to be sterile but may become contaminated during micturition with 
flora and epithelial cells from both the vagina and urethra.1,2 Contamination of a urine 
sample can contribute to under- or overdiagnosis of bacteriuria.
It is important to adequately diagnose bacteriuria in pregnant women given the pos-
sible complications of asymptomatic bacteriuria and urinary tract infections for both 
mother and fetus.3,4 However, collection of uncontaminated voided urine samples is 
difficult and sometimes not feasible in pregnant women because of practical factors like 
weight gain and increased vaginal discharge.
Present guidelines underscore the need to collect a midstream urine sample because 
the first portion of urine may contain epithelial cells and microorganisms originated 
from the urethra or vagina, which may cause contamination.5 More elaborate sam-
pling methods such as midstream clean-catch urine sample and collection of the first 
concentrated urine sample in the morning have been introduced to further minimize 
contamination and optimize diagnosis of bacteriuria. However, a clean-catch sample is 
time-consuming and frequently performed incorrectly. Collection of a morning sample 
is not practicable because the patient may visit the physician during the daytime. Con-
taminated urine samples may lead to unnecessary treatment, need for second sample, 
and additional costs.
The question remains whether these more laborious urine-sampling methods outweigh 
the extra effort. In this present study, we compared contamination rates detected with 
Gram stain and urine culture of two more complex urine-sampling methods (morning 
and clean-catch samples) with midstream sample without instructions (reference test) 
in pregnant women.
Patients and methods
We conducted a cross-sectional study from April 2010 to April 2011. A convenience 
sample of 113 women was selected, because the study could not be adequately po-
wered by lack of information on urine contamination levels and correlation between 
contamination levels of urine samples taken from the same women during pregnancy. 
For discordant proportions of more than 0.4, our sample size would be adequate to 
detect odds ratios (ORs) of 2.5 or more for testing correlated proportions (McNemar) 
with 80% power and a (two-sided) significance level of .05. A post hoc power analysis 
would be conducted to determine the minimal detectable OR in our study.
All pregnant women (18 years or older) with an uncomplicated singleton pregnancy 
attending the obstetrics clinic Vida in Amsterdam, the Netherlands, for routine pre-
natal visits with a pregnancy duration of at least 22 weeks of gestation were eligible.6 
After women gave informed consent, they were asked to collect three urine samples 
consecutively within 24 hours using three different sampling methods the day of the 
next prenatal visit. Oral and written sampling instructions were provided. Women were 
excluded for the following reasons: urine samples were not analyzed within 48 hours or 
the sampling method was not adequately coded. Dates of birth and pregnancy duration 
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were collected from the medical records. The study was approved by the medical ethical 
committee of the Academic Medical Center in Amsterdam.
Three methods of urine sampling were compared in all pregnant women: (1) midstream 
urine sample (midstream): midstream urine sample without further instructions (refe-
rence urine sample). To collect a midstream urine sample, women were instructed to 
discharge their first and to collect their second urine portion; (2) morning midstream 
urine sample (morning): midstream urine of the first concentrated urine sample in the 
morning; and (3) midstream clean-catch urine sample (clean-catch): midstream urine 
of the urine sample voided after local disinfection of the meatus and adjacent mucosa 
with cotton balls with water while spreading the labia during urinating.
The urine samples were always collected in the same order: morning, midstream, and 
clean-catch sample. This order would probably provide the best unbiased estimates of 
contamination rates for each urine-sampling method.
The coded urine samples were refrigerated and sent to the laboratory of the Academic 
Medical Center and tested by a combination of leukocyte esterase and nitrite dipstick 
test, a Gram stain (semiquantitative test), and a urine culture following standard opera-
ting procedures. The sampling method was blinded.
Manual interpretation of the complete Gram-stained slide was done with a magnifica-
tion 12.5x100 and read semiquantitatively per item as none (score 0: 0 cells or orga-
nisms per Gram stain), sporadic (score 1: 1 to 10 cells or organisms per Gram stain), few 
(score 2: one to two cells or organism per high-power field), moderate (score 3: 2 to 10 
organisms or 2 to 5 cells per high-power field), many (score 4: 10-50 organisms or 5-10 
cells per high-power field), or much (score 5: more than 50 organisms or more than 
10 cells per high-power field). The following items were scored: epithelial cells, Gram-
positive rods (including lactobacilli), Gram-positive cocci, Gram-negative rods, and leu-
kocytes. The assumption is that Gram-positive rods represent nonuropathogens and 
Gram-positive cocci and Gram-negative rods may indicate uropathogens. The variable 
mixed bacteria are defined as the presence of two or more different bacteria species 
detected with the Gram stain.
The urine culture was examined daily for growth and finally interpreted as follows: 
negative: defined as no growth or the growth of only skin flora; undefined: in practice 
some culture results need to be interpreted in combination with the background of the 
patient, namely mixed growth: growth of at least two organisms or more (mostly nonu-
ropathogens). In most cases, specific identification of these organisms was not made7,8; 
low colony count: growth less than 104 colony-forming units (CFU) per milliliter of one 
uropathogen; positive: defined as the presence of one uropathogen with a growth 
of at least 104 CFU/mL or more. Common uropathogens are Escherichia coli, Proteus 
mirabilis, Klebsiella pneumoniae, Enterococcus species, and Pseudomonas aeruginosa. 
Organisms that are normally found on the skin and external genitalia including lactoba-
cilli, corynebacteria, and coagulase-negative staphylococci were considered nonuropa-
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thogens and contaminants and therefore the identification of these microorganisms did 
not define a positive culture8-10; the leukocyte esterase dipstick was negative or 1+, 2+, 
or 3+ (all positive). The nitrite dipstick was read negative or positive.
The following items were considered as contaminants1,7-12: Gram stain: epithelial cells, 
Gram-positive rods (including lactobacilli), mixed bacteria (more than one type); urine 
culture: growth of skin flora, mixed growth. Because urine is supposed to be sterile, all 
amounts were gauged as contamination. Attempting to distinguish between clinically 
relevant and irrelevant contamination, different cutoff points were defined. For the 
Gram stain, the semiquantitative score many (score 4 out of 5) or much (score 5 out 
of 5) and for urine cultures growth 104 CFU/mL or greater (score 4 or 5 out of 5) was 
considered relevant.
Another way to evaluate the influence of contamination is to assess the need for a 
second urine sample. When no interpretation can be made of the original culture as a 
result of overgrowth of contaminants, the Gram stain can help to distinguish between 
the possible presence of an infection or simply contamination by differentiating infec-
tion parameters (ie, leukocytes) and contaminants (ie, epithelial cells).2 For this study, 
we considered that the presence of leukocytes in combination with quantitatively more 
epithelial cells in the Gram stain warrants a second sample.
Intraindividual consistency and variability in quantities of present contaminants can be 
assessed because all three different urine samples were collected by one woman wit-
hin a couple of hours, mostly the same day. The midstream sample was used as the 
reference test and was compared with either morning or clean-catch samples using 
Fleiss-Cohen’s weighted [kappa] statistic.13 We used the following interpretation for 
the [kappa] values: less than 0.00 poor agreement; 0.00-0.20 slight agreement; 0.21-
0.40 fair agreement; 0.41-0.60 moderate agreement; 0.61-0.80 substantial agreement; 
0.81-0.90 almost perfect agreement.14
To estimate and to test an effect of morning and clean-catch samples on urine conta-
mination with respect to the more practical midstream sample, generalized estimating 
equations were applied on the ordinal test results.15 This type of analysis takes into 
account the possible correlation between multiple results from participants. The cor-
relation between urine samples was assumed to be the same for any pair of urine sam-
ples (ie, exchangeable correlation matrix). The probability on an ordinal outcome was 
modelled with the cumulative logit function (similar to logistic regression), which would 
result in ORs for morning and clean-catch samples with respect to midstream samples. 
Furthermore, confidence intervals on the ORs were determined using the empirical or 
sandwich variance estimator to provide an estimate of the standard error on the OR that 
is valid for possible misspecifications of the correlation matrix. Finally, an overall effect 
of any difference between the urine samples was determined first with a test statistic 
called the generalized score test. A p value of <0.05 was considered significant. Models 




Table 1 shows the participants’ characteristics. During the study period, 118 pregnant 
women were enrolled. Five women were excluded for either incomplete or inadequate 
coded urine samples. The ages (n=113) ranged from 19.8 to 42.5 years with a mean of 
30.4 years. The gestational age ranged from 23.0 to 39.4 weeks with a mean of 32.0 
weeks.
In total 336 urine samples were collected: 112 midstream, 113 morning, and 111 clean-
catch urine samples; 110 women collected three and three women only two urine 
samples.
No consistency in quantity of contaminants was found between midstream samples 
and morning and clean-catch samples. The weighted [kappa] statistic for epithelial cells 
was established at 0.19 (-0.00 to 0.38) and 0.10 (-0.10 to 0.29) for the morning and 
clean-catch samples compared with midstream samples, respectively. This indicates a 
slight agreement or consistency between samples of the same women during pregnan-
cy. For Gram-positive rods, these weighted [kappa] statistics were given by 0.19 (0.00-
0.38) and 0.35 (0.18-0.52), respectively, presenting a slight or possibly fair consistency. 
For skin flora they were determined at 0.44 (0.28-0.59) and 0.48 (0.31-0.65), which 
indicates moderate agreement.
Table 2 shows the Gram stain results. The presence of epithelial cells in the urine sam-
ples were determined at 58.9% (midstream), 50.4% (morning), and 56.8% (clean-
catch). The generalized score test on the ordinal test outcomes did not demonstrate a 
difference among the urine samples (P=.201). Only 2.1% of all urine samples contained 
relevant contaminating numbers of epithelial cells (score 4 or 5 out of 5).
Gram-positive rods were present in 72.0% of all urines samples, but they seem more 
present in midstream samples (midstream 77.7%; morning 71.7%; clean-catch 66.7%) 
compared with clean-catch samples. Indeed, the generalized score test applied to the 
ordinal test outcomes gave a P value equal to .022 (midstream compared with morning: 
0.68, 95% confidence interval [CI] 0.45-1.04; midstream compared with clean-catch: 
OR 0.60, 95% CI 0.42-0.86). After interpretation of the absolute numbers, this diffe-
rence was mainly the result of variation in low numbers of Gram-positive rods.
No differences were seen in the presence of mixed bacteria (P=.272). These percentages 
were 25.9% (midstream); 34.5% (morning); and 27.9% (clean-catch). See Tables 2 and 
3 for further details of other bacteria and leukocytes.
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Table 1. Demographic characteristics of pregnant women
Characteristics N=113
Age at day of collection (y) 30.4 (19.8;42.5)
Gestational age at day of collection (wk) 32.0 (23.0;39.4)
Figures are mean (range).
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a Numbers (0-5) in parentheses indicate the semiquantitative scores. b “Few” (score 2 out of 5) is not used 
with epithelial cells. c “>1 type of bacteria” represents the outcome mixed bacteria.
FIVERESULTS
In total 14 (4.2%) positive cultures were found in six (5.3%) pregnant women. E coli 
was found in all three urine samples of four women (104 CFU/mL or greater). In one 
woman P mirabilis (104 CFU/mL) was only found in the morning sample and in another 
woman P aeruginosa (104-105 CFU/mL) was only found in the midstream sample. In 12 
of the 14 positive urine samples, also growth of skin flora was found. In total 18 urine 
cultures were interpreted as undefined. Low colony count bacteriuria was found in 
seven urine samples. Mixed growth was found in 11 (3.3%) urine samples (midstream 
0.9%; morning 6.2%; clean-catch 2.7%), mainly in morning samples. The generalized 
score test on the ordinal test results showed a significant difference (0.050). The pre-
sence of skin flora (midstream 87.5%; morning 90.3%; clean-catch 86.5%) was high 
but comparable in all three sampling techniques (P=.565). The presence of an irrelevant 
quantity of skin flora (83.9% less than score 4 of 5) in all cultures was ubiquitous. For 
further details, see Tables 3 and 4.
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Table 3. Generalized score test resultsa
Variable Effecta P-valueb
































Data are odds ratio (95% confidence interval) unless otherwise specified. a An odds ratio (OR) above 1 indi-
cates that the midstream sample has a lower probability of contamination than the other sample. Of all end 
points, the first OR concerns the comparison between midstream and morning samples and the second OR 
concerns the comparison between midstream and clean-catch samples. For example, the OR for midstream 
compared with morning samples for epithelial cells in the Gram stain is 0.71 and the OR for midstream com-
pared with clean-catch is 1.00. b P value is calculated with the generalized estimated equations-test. <.05 was 
considered significant.
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In 285 urine samples, a nitrite and leukocyte dipstick test was performed. A positive leu-
kocyte test was present in 143 of the 285 urine samples (50.2%) and a positive nitrite 
test in 14 (4.9%) samples. Only in 23 of 143 (16.1%) samples with a positive leukocyte 
test were leukocytes also seen in the Gram stain. Only three samples, all collected by 
one woman, of 14 positive nitrite tests were correlated with a positive culture.
Using the ratio of epithelial cells and leukocytes, a second sample was warranted in 
11 (3.3%) of 336 samples because more epithelial cells then leukocytes were present. 
These equivocal results were seen in all sampling methods (midstream four; morning 
four; clean-catch three).
Based on the standard errors for the estimated effects of morning and clean-catch sam-
ples with respect to midstream samples, a minimal detectable OR was determined for 
each outcome in Table 3. For mixed growth and leukocytes, an OR of minimally 14.0 
and 3.3 could be detected, respectively, with 80% power. For all other variables, this 
OR was less than or equal to 2.0.
Discussion
In this study, we demonstrated comparable contamination rates among midstream, 
morning, and clean-catch samples. Only midstream samples showed significantly more 
Gram-positive rods, although mainly in low numbers, compared with clean-catch sam-
ples; however, morning samples showed more mixed growth compared with mids-
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CFU, colony-forming unit. a “mixed growth” represents growth of at least 2 organisms or more. 
b “Low colony count” represents the presence of one uropathogen with a growth of less than 104 CFU/mL.
c “Positive” represents the presence of one uropathogen with a growth of 104 CFU/mL or greater.
FIVEDISCUSSION
tream samples. The overall prevalence of clinically irrelevant quantities of contamination 
was high in all three samples. These results show that midstream samples are equivocal 
to morning and clean-catch samples to assess bacteriuria in pregnant women.
The strength of this study is that all three different samples were collected consecutively 
by one pregnant woman within a few hours, which enabled us to investigate intraindi-
vidual consistency in quantity of contaminants. More insight is given in the composition 
of urine samples with or without cleaning by presenting the uncensored data instead 
of using a composite outcome.
A limitation of this study is that although instructions were given to the pregnant wo-
men, we did not verify whether cleansing or midstream collection was accurately perfor-
med. However, this reflects clinical practice.9 Furthermore, the study was not powered 
for differences between samples as a result of lack of information on the frequencies of 
the ordinal outcomes and the correlation between these outcomes from samples of the 
same women. The sample size was too small to detect differences in collection methods 
for leukocytes and mixed growth but not for the other variables because ORs below 2.0 
could have been detected with 80% power and 5% significance. This suggests that the 
study was appropriately powered for nearly all end points.
Earlier studies concluded that perineal cleaning has no role in reducing contamination 
in either pregnant or nonpregnant women.8,9,12,16 Morning urine samples and Gram 
stain results were not investigated in studies conducted in pregnant women. In addi-
tion in the study of Holliday et al, the samples were not collected consecutively by one 
woman and Schlager et al only looked at bacterial contamination and not at other end 
points such as epithelial contamination.9,12 We also analyzed our data as ordinal outco-
mes, which makes our results less dependent on differences in threshold values used to 
determine contamination.
Gram-positive rods were more often seen in midstream samples compared with clean-
catch samples. Because it mainly concerned low quantities, we conclude that the in-
fluence on the culture results is negligible. In six (5.3%) pregnant women, we found 
positive cultures. In two women, only one in three samples showed significant bacteri-
uria. This discrepancy in culture results has been described earlier.9 In the present study, 
the results of 18 urine cultures were undefined, meaning mixed growth or a low colony 
count was found. After earlier research, both mixed growth and low colony count 
can indicate “true” bacteriuria and therefore may need extra evaluation in combina-
tion with symptoms, especially in high-risk patients.2,7 In healthy pregnant women, it 
probably suggests contamination. In this study, morning samples showed significantly 
more mixed growth compared with midstream samples. The increased concentration 
of morning urine may explain this difference. In accordance with earlier research, both 
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Nearly all our samples could be considered as contaminated. Nonetheless, the defini-
tion of contamination is arbitrary and the influence of contamination on culture results 
varies between patient groups. A more uniform and clinically useful definition of con-
tamination is needed. We propose to distinguish between relevant and irrelevant con-
tamination based on the need for a second sample because the original sample is not 
interpretable as a result of contamination. This implicates that in our population, in less 
than 4%, a second sample was warranted independently of the sampling method. We 
recognize that the need for a second sample is a subjective parameter.
The found contamination rate can be an overestimation because laboratory technicians 
may be focused on scoring contamination or an underestimation because women who 
participated in this study were possibly more eager to collect urine samples properly.
In general, broad intraindividual variability was found in quantities of contaminants 
among the three urine samples. This further emphasizes the irrelevance which sampling 
method is used.
In conclusion, the overall contamination was high with all three urine-sampling me-
thods; nonetheless, the need for a second sample was low. On the basis of these re-
sults, we recommend the use of the easy and practical midstream sample to assess 
bacteriuria in pregnant women because the morning and clean-catch samples do not 
outweigh their associated extra time and costs. 
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Recurrent urinary tract infections (RUTI) are common in women who are pregnant and 
may cause serious adverse pregnancy outcomes for both mother and child including 
preterm birth and small-for-gestational-age babies. Interventions used to prevent RUTI 
in women who are pregnant can be pharmacological (antibiotics) or non pharmacologi-
cal (cranberry products, acupuncture, probiotics and behavioural modifications). So far 
little is known about the best way to prevent RUTI in pregnant women.
OBJECTIVES
To assess the effects of interventions for preventing recurrent urinary tract infections 
in pregnant women. The primary maternal outcomes were RUTI before birth (variously 
defined) and preterm birth (before 37 weeks). The primary infant outcomes were small-
for gestational age and total mortality.
SEARCH METHODS
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (8 June 
2012) and reference lists of retrieved articles.
SELECTION CRITERIA
Published, unpublished and ongoing randomised controlled trials (RCTs), quasi-RCTs, 
clustered-randomised trials and abstracts of any intervention (pharmacological and 
non-pharmacological) for preventing RUTI during pregnancy (compared with another 
intervention, placebo or with usual care).
DATA COLLECTION AND ANALYSIS
Two review authors independently evaluated the one identified trial for inclusion and 
assessed trial quality. Two review authors extracted data. Data were checked for ac-
curacy.
MAIN RESULTS
The review included one trial involving 200 women. The trial compared a daily dose of 
nitrofurantoin and close surveillance (regular clinic visit, urine cultures and antibiotics 
when a positive culture was found) with close surveillance only. No significant differen-
ces were found for the primary outcomes: recurrent pyelonephritis (risk ratio (RR) 0.89, 
95% confidence interval (CI) 0.31 to 2.53, one study, 167 women), recurrent urinary 
tract infection before birth (RR 0.30, 95% CI 0.06 to 1.38; one study 167 women) and 
79
80
SIX INTERVENTIONS FOR PREVENTING RECURRENT UTI DURING PREGNANCY
preterm birth (before 37 weeks) (RR 1.18, 95% CI 0.42 to 3.35; one study 147 women). 
The incidence of asymptomatic bacteriuria (ASB) (at least 103 colonies per mL) (secon-
dary outcome), only reported in women with a clinic attendance rate of more than 90% 
(RR 0.55, 95% CI 0.34 to 0.89; one study, 102 women), was significantly reduced in 
women who received nitrofurantoin and close surveillance.
AUTHORS’ CONCLUSIONS
A daily dose of nitrofurantoin and close surveillance has not been shown to prevent 
RUTI compared with close surveillance alone. A significant reduction of ASB was found 
in women with a high clinic attendance rate and who received nitrofurantoin and close 
surveillance. There was limited reporting of both primary and secondary outcomes for 
both women and infants. No conclusions can be drawn regarding the optimal interven-
tion to prevent RUTI in women who are pregnant. Randomised controlled trials com-
paring different pharmacological and non-pharmacological interventions are necessary 
to investigate potentially effective interventions to prevent RUTI in women who are 
pregnant.
PLAIN LANGUAGE SUMMARY
Recurrent urinary tract infections (RUTI) are common in women generally and par-
ticularly in pregnant women. A urinary tract infection (UTI) is an infection of the 
urinary tract (bladder, kidneys) due to the presence of bacteria in the urine (bac-
teriuria). During pregnancy UTI may be a serious complication that is associated 
with adverse pregnancy outcomes for both mother and child including preterm 
birth and small-for-gestational-age babies. Therefore, it is important to define the 
optimal intervention for preventing RUTI during pregnancy to improve pregnancy 
outcomes. Interventions used to prevent RUTI in pregnant women can be pharma-
cological (antibiotics) or non-pharmacological (cranberry products, acupuncture, 
probiotics and behavioural modifications). So far little is known about the best way 
to prevent RUTI in pregnant women.
This review identified one study involving 200 pregnant women who received ni-
trofurantoin (antibiotics) and close surveillance (regular clinic visit, urine cultures 
and antibiotics when a positive culture was found) or close surveillance alone. 
Suppressive therapy with daily dose of nitrofurantoin and close surveillance was 
not shown to prevent RUTI compared with close surveillance alone. A significant 
reduction of asymptomatic bacteriuria (presence of bacteria in the urine without 
the symptoms of a UTI) was found in women with a high clinic attendance rate 
who received nitrofurantoin and close surveillance. Due to lack of evidence no 
conclusions can be drawn. Future randomised controlled trials comparing different 
pharmacological and non-pharmacological interventions are necessary to assess 
the optimal intervention to prevent RUTI in women who are pregnant. Such trials 
should report on a comprehensive range of outcomes for both women and infants.
SIXBACKGROUND
Background
Description of the condition 
Recurrent urinary tract infections (RUTI) are a common healthcare problem in women 
generally and particularly in pregnant women. Up to 30% of women who are not 
pregnant experience at least one recurrence within a year after the initial infection.1-4 A 
urinary tract infection  (UTI) is an infection of the urinary tract which can be divided in 
lower and upper UTI based on the location of the infection. A lower UTI is an infection 
of the bladder and results in a combination of significant bacteriuria and symptoms 
such as dysuria (painful urination) and frequency. In practice the diagnosis of UTI is 
often based on clinical symptoms alone. An upper UTI or pyelonephritis is an infection 
of the kidney accompanied by symptoms such as fever and renal tenderness. Asympto-
matic bacteriuria (ASB) is significant bacteriuria without symptoms of a UTI.5,6
A UTI during pregnancy may be a serious complication as it is associated with adverse 
pregnancy outcomes for both mother and child.7-13 Important complications include 
preterm birth and small-for-gestational-age babies, although an association between 
UTI and preterm birth and small-for-gestational-age babies has not been clearly esta-
blished.8,9,14-17 Associations seen between UTI and adverse pregnancy outcomes in older 
studies (before the 1970s) may no longer be as evident with the advent of more antibi-
otic prescriptions.8,10 While causal mechanisms remain unknown, there is evidence sup-
porting the important role that prostaglandins, stimulated by bacterial and host signals 
following an infection, play in inducing preterm labour.18,19
The exact incidence of symptomatic UTI in women who are pregnant is unknown.20 Two 
studies report an incidence between 1% to 2.3% during pregnancy for their particular 
population.15,21 Pyelonephritis (infection of the kidney) occurs in 2% of pregnancies, 
with a recurrence rate up to 23% within the same pregnancy or soon after the birth.22,23 
Some international guidelines recommend screening and treating ASB in women who 
are pregnant to prevent UTI and possible adverse pregnancy outcomes.24 This policy is 
followed by many countries and might have had an impact on the recently described 
incidences of both UTI and RUTI during pregnancy.
Varying definitions of RUTI exist, especially in pregnant women. In non-pregnant wo-
men RUTI is frequently defined as three episodes of UTI in the previous 12 months, or 
two episodes in the last six months.25-27 For this review we used the following criteria for 
RUTI: pregnant women with a history of one or more UTI before or during pregnancy. 
We decided to include women with only one UTI as well because one UTI during preg-
nancy can be a reason to start prophylaxis during pregnancy both in practice and for 
research trials. Most UTI recurrences occur in the first three months following the initial 
infection.1 In studies on RUTI in pregnant women, one episode of UTI during pregnancy 
is often an indication to start prophylaxis to prevent RUTI.28,29 
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Uropathogens, generally originating in the rectal flora, may cause a UTI when they as-
cend to the bladder after they colonise the urethra and the periurethral area. The patho-
genesis of a UTI in women who are suffering from RUTI is considered comparable with 
a single infection in women without a history of RUTI.30,31 In RUTI, uropathogens pos-
sibly recolonise the bladder after treatment because they are not eliminated from the 
rectal flora.2 E. coli is the most common UTI uropathogen.6,31 Especially in the presence 
of structural abnormalities of the urinary tract, the following organisms are associated 
with RUTI: Proteus, Pseudomonas, Klebsiella and by Enterobacter spp. and enterococci 
and staphylococci.6 
There are four patterns of response of bacteriuria to therapy: cure, bacteriologic per-
sistence, bacteriologic relapse or reinfection. Bacteriologic persistence is persistence of 
bacteriuria with the same microorganism after 48 hours of treatment.6 Relapse is an 
infection with the same microorganism that caused initial infection and usually occurs 
within one to two weeks after the cessation of treatment. A relapse indicates that the 
infecting organism has persisted in the urinary tract. Reinfection is an infection after ste-
rilisation of the urine. Most of the time there is a change in bacterial species. Reinfection 
can be defined as a ‘true’ recurrence. Both persistence and relapse may be related to 
inadequate treatment.6,30 Although relapse and reinfection are two distinct outcomes, 
they both can be grouped under the wider outcome of recurrence.
During pregnancy up to 90% of the women develop dilatation of the collecting system 
(ureters and renal pelvis) and decreased peristalsis of the ureters and bladder, which 
may facilitate bacterial colonisation and ascending infection due to urinary stasis.23,32,33 
The main risk factors for RUTI in premenopausal women are the age at first UTI (less 
than 15 years of age indicates a greater risk of RUTI), a family history of UTI in their 
mother, frequency of sexual intercourse, the use of spermicides and new sexual part-
ners.2,4,34,35 In women who are pregnant, a high parity is a risk factor for UTI.36,37
Description of the intervention
Interventions used to prevent RUTI in pregnant women can be pharmacological or non-
pharmacological. Pharmacological interventions consist of antibiotics that may be pres-
cribed in different ways to prevent RUTI, continuous prophylaxis, post-coital prophylaxis 
and patient initiated therapy based on symptoms of a UTI. The non-pharmacological 
interventions include cranberries (juice or tablets), probiotics, acupuncture and behavi-
oural modifications such as frequent and complete voiding, voiding after sexual inter-
course, liberal fluid intake, and wiping techniques. Other potential interventions, such 
as vaccines and bacterial interference where one bacterial strain prevents colonisation 
with another strain and topical application of carbohydrates, are still under develop-
ment.25 
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How the intervention might work
Various antibiotic regimens, used as a continuous or as post-coital prophylaxis, reduce 
the number of RUTI in women who are not pregnant.29,30,38 The effect of post-coital 
prophylaxis is related to frequency of sexual intercourse and mostly results in less anti-
biotic use in comparison with daily prophylaxis.2,30 Antibiotics may cause adverse effects 
such gastrointestinal symptoms and vaginal and oral candidiasis.25,38 Furthermore, not 
all antibiotics used as prophylaxis for RUTI in non-pregnant women may be safe during 
pregnancy. Because of this, women who are pregnant often prefer not to use antibio-
tics during their pregnancy. In addition, the number of drug-resistant bacteria is incre-
asing, which may influence the potential prophylactic effect of different antibiotics in 
the future. Different antibiotics such as nitrofurantoin, amoxicillin and fosfomycin have 
been used to treat primary UTI in women who are pregnant.13 Antibiotic effect depends 
on the concentration of the antimicrobial agent achieved in the urine in conjunction 
with the sensitivity of the organism(s) to that antibiotic.6 
Cranberry products (mainly juice) have been used as an intervention to prevent RUTI for 
decades. It has been shown in vitro that cranberries prevent bacteria adhering to the 
uro-epithelial cells in the bladder.39,40 Without adhesion the bacteria are unable to cause 
a UTI.39,40 In some of the published studies on cranberries in non-pregnant women, 
there have been significant withdrawals or losses to follow-up.39 Nausea and vomiting 
due to physiologic changes in pregnancy can further decrease adherence.41 A recent 
trial in non-pregnant premenopausal women showed that antibiotics (trimethoprim-
sulfamethoxazole) once daily is more effective in preventing RUTI than cranberry capsu-
les twice daily, at the expense of emerging antibiotic resistance.42 
Two small randomised controlled trials (with unclear risk of selection bias) have compa-
red acupuncture with no treatment to prevent RUTI in women who are not pregnant. 
Both showed significant results in preventing RUTI.43,44
It is suggested that some Lactobacillus species prevent uropathogen colonisation of the 
vagina, a necessary step in ascending infection of the bladder. Studies show that certain 
Lactobacillus species can be given orally or vaginally and reduce RUTI through colonisa-
tion of the vagina and reducing vaginal coliform counts.45,46 In postmenopausal women 
the use of lactobacilli capsules twice daily seems nearly as effective in preventing RUTI 
as the use of antibiotics once daily, without increase of antibiotic resistance.47 
Although behavioural modifications are unlikely to be harmful in women who are not 
pregnant, little information is available that these interventions actually work. Sexually 
active women who use spermicide while suffering from RUTI are recommended to use 
an alternative form of contraception.25 Spermicide use increases the risk of colonisation 
of the vaginal and periurethral area with uropathogens and increases the adherence 
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Why it is important to do this review
There are two Cochrane reviews on prevention of UTI, both in women who were not 
pregnant.38,39 The selection criteria in Jepson et al. would have covered studies of wo-
men who were pregnant, but none of their eligible studies included pregnant women.39 
The results described in the Cochrane review ‘Antibiotics for preventing recurrent urina-
ry tract infections in non-pregnant women’ show that continuous antibiotic prophylaxis 
for six to 12 months reduced the rate of UTI during prophylaxis when compared with 
placebo. However, women who used antibiotic prophylaxis had more adverse effects.38 
The results described in the Cochrane review ‘Cranberries for preventing urinary tract 
infections’ demonstrate that cranberry juice may decrease the number of symptomatic 
UTIs over a 12-month period, particularly for women with RUTI. Furthermore, they 
conclude that cranberry juice may not be acceptable over long periods of time because 
there were large numbers of dropouts.39 A Cochrane protocol on ‘Probiotics for preven-
ting urinary tract infections in adults and children’ will include studies in women who 
are pregnant.48 
Preterm birth, one of the possible serious complications of a UTI during pregnancy, is 
the main cause of neonatal mortality and morbidity worldwide. The costs of preterm 
birth are enormous. These costs are mainly associated with intensive care for the neona-
tes.49-51 Prevention of RUTI and UTI will improve maternal and infant health and reduce 
the risk of preterm birth.
Different approaches have been proposed for prevention of RUTI in women who are not 
pregnant and include the use of low-dose antibiotic prophylaxis daily or post-coitally in 
sexually active women and non-pharmacological therapies such as voiding after sexual 
intercourse or ingestion of cranberry juice.38 Little is known about the best way to pre-
vent RUTI in pregnant women, especially as not all approaches used in non-pregnant 
women are applicable. Therefore, it is important to define the optimal interventions for 
preventing RUTI during pregnancy to improve pregnancy outcomes.
Objectives
To assess the effects of interventions for preventing recurrent urinary tract infections in 
pregnant women.
Methods
Criteria for considering studies for this review
Types of studies
We planned to include all published, unpublished and ongoing randomised controlled 
trials (RCTs), quasi-RCTs and clustered-randomised trials of interventions aimed at pre-
venting recurrent urinary tract infections (RUTI) during pregnancy. In future updates we 
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will also include abstracts where sufficient information is available. Abstracts containing 
limited information will be classified as ‘awaiting assessment’ until further information 
can be obtained.
Types of participants
Pregnant women with a history of one or more urinary tract infections (UTI) before or 
during pregnancy.
Types of interventions
Any intervention (pharmacological and non-pharmacological) for preventing recurrent 
urinary tract infection (RUTI) during pregnancy (compared with another intervention, 
placebo or with usual care).
Types of outcome measures
Primary outcomes
Maternal
•	 RUTI before birth (variously defined)
•	 Preterm birth (less than 37 weeks)
Infant
•	 Small-for-gestational age




•	 Proportion of pregnant women who experienced at least one UTI, identified using 
clinical criteria (dysuria)
•	 Proportion of pregnant women who experienced at least one UTI, using microbio-
logical criteria
•	 Number of UTI per woman during index pregnancy, identified using clinical criteria 
(e.g. dysuria, fever)
•	 Number of UTI per woman during index pregnancy, using microbiological criteria
•	 Number of pregnant women who were admitted antenatally because of a UTI




•	 Antenatal pyrexia requiring the use of antibiotics
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•	 Asymptomatic bacteriuria (ASB) (variously defined)
•	 Prelabour rupture of the membranes
•	 Eclampsia/pre-eclampsia (variously defined)
•	 Induction of labour
•	 Mode of birth (normal vaginal birth, operative vaginal birth, caesarean section)
•	 Intrapartum fever requiring the use of antibiotics
•	 Postpartum infection requiring the use of antibiotics
•	 Postpartum haemorrhage
•	 Chorioamnionitis (variously defined)
•	 Postpartum fever requiring the use of antibiotics
•	 Adverse effects of interventions (nausea, vomiting, diarrhoea)
•	 Proportion of women who had severe adverse effects (defined as those requiring 
withdrawal of treatment)
•	 Women’s satisfaction with treatment
Infants
•	 Stillbirths (variously defined)
•	 Death of liveborn infants prior to hospital discharge
•	 Gestational age at birth
•	 Preterm birth less than 34 weeks’ gestation
•	 Birthweight
•	 Birth centile (below 10th centile)
•	 Small-for-gestational age
•	 Five-minute Apgar score less than seven
•	 Chronic lung disease (variously defined)
•	 Intraventricular haemorrhage (variously defined)
•	 Periventricular leukomalacia
•	 Necrotising enterocolitis (variously defined)
•	 Respiratory distress syndrome (variously defined)
•	 Hyperbilirubinaemia requiring treatment
•	 Neonatal convulsions
•	 Early neonatal infection requiring antibiotics (less than 48 hours)
•	 Hypoxic ischaemic encephalopathy
•	 Neonatal encephalopathy
•	 Composite of severe neonatal morbidity (variously defined)
Use of resources, e.g. and/or costs utilisation
•	 Antenatal admission of the mother
•	 Days of antenatal admission of the mother
•	 Admission to a neonatal intensive care unit
•	 Days of admission to a neonatal intensive care unit
•	 Admission to nursery care
•	 Costs of interventions
•	 Additional visits to clinicians
•	 Costs to women and families for extra care
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Search methods for identification of studies
Electronic searches
We contacted the Trials Search Co-ordinator to search the Cochrane Pregnancy and 
Childbirth Group’s Trials Register (8 June 2012). 
The Cochrane Pregnancy and Childbirth Group’s Trials Register is maintained by the 
Trials Search Co-ordinator and contains trials identified from:
1. monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of EMBASE;
4. handsearches of 30 journals and the proceedings of major conferences;
5. weekly current awareness alerts for a further 44 journals plus monthly BioMed 
Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and EMBASE, the list of hand-
searched journals and conference proceedings, and the list of journals reviewed via the 
current awareness service can be found in the ‘Specialized Register’ section within the 
editorial information about the Cochrane Pregnancy and Childbirth group.
Trials identified through the searching activities described above are each assigned to 
a review topic (or topics). The Trials Search Co-ordinator searches the register for each 
review using the topic list rather than keywords. 
Searching other resources
In addition, we searched the reference lists of retrieved articles We did not apply any 
language restrictions to the search and in future updates, we will attempt to obtain 
translations of papers when necessary.
Data collection and analysis
Selection of studies
Two review authors independently assessed for inclusion the potential study we iden-
tified as a result of the search strategy. We resolved any disagreement through discus-
sion.
Data extraction and management
We designed a form to extract data. For the one eligible study, two review authors ex-
tracted the data using the agreed form. We resolved discrepancies through discussion. 
We entered data into Review Manager software and checked for accuracy.52 When in-
formation regarding any of the above was unclear, we attempted to contact the authors 
of the original reports to provide further details. There was no blinding of authorship.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for the one included study using 
the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventi-
ons.53 We resolved any disagreement by discussion or by involving a third assessor.
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1. Random sequence generation (checking for possible selection bias)
We described for the one included study the method used to generate the allo-
cation sequence in sufficient detail to allow an assessment of whether it should 
produce comparable groups.
We assessed the method as:
•	 low risk of bias (any truly random process, e.g. random number table; compu-
ter random number generator);
•	 high risk of bias (any non-random process, e.g. odd or even date of birth; hos-
pital or clinic record number);
•	 unclear risk of bias.
2. Allocation concealment (checking for possible selection bias)
We described for the one included study the method used to conceal allocation 
to interventions prior to assignment and assessed whether intervention allocation 
could have been foreseen in advance of, or during recruitment, or changed after 
assignment.
We assessed the methods as:
•	 low risk of bias (e.g. telephone or central randomisation; consecutively numbe-
red sealed opaque envelopes);
•	 high risk of bias (open random allocation; unsealed or non-opaque envelopes, 
alternation; date of birth);
•	 unclear risk of bias.  
3.1 Blinding of participants and personnel (checking for possible performance 
bias)
We described for the included study the methods used, if any, to blind study partici-
pants and personnel from knowledge of which intervention a participant received. 
We consider that studies are at low risk of bias if they are blinded, or if we judge 
that the lack of blinding would be unlikely to affect results. We assessed blinding 
separately for different outcomes or classes of outcomes.
We assessed the methods as:
•	 low, high or unclear risk of bias for participants;
•	 low, high or unclear risk of bias for personnel.
3.2 Blinding of outcome assessment (checking for possible detection bias)
We described for the one included study the methods used, if any, to blind out-
come assessors from knowledge of which intervention a participant received. We 
assessed blinding separately for different outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
•	 low, high or unclear risk of bias.
4. Incomplete outcome data (checking for possible attrition bias due to the 
amount, nature and handling of incomplete outcome data)
We described for the included study, and for each outcome or class of outcomes, 
the completeness of data including attrition and exclusions from the analysis. We 
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stated whether attrition and exclusions were reported and the numbers included 
in the analysis at each stage (compared with the total randomised participants), 
reasons for attrition or exclusion where reported, and whether missing data were 
balanced across groups or were related to outcomes. We planned that where suf-
ficient information was reported, or supplied by the trial authors, we would re-
include missing data in the analyses which we undertook.
We assessed methods as:
•	 low risk of bias (e.g. no missing outcome data; missing outcome data balanced 
across groups);
•	 high risk of bias (e.g. numbers or reasons for missing data imbalanced across 
groups; ‘as treated’ analysis done with substantial departure of intervention 
received from that assigned at randomisation);
•	 unclear risk of bias.
6. Selective reporting (checking for reporting bias)
We described for how we investigated the possibility of selective outcome repor-
ting bias and what we found.
We assessed the methods as:
•	 low risk of bias (where it was clear that all of the study’s pre-specified outcomes 
and all expected outcomes of interest to the review had been reported);
•	 high risk of bias (where not all the study’s pre-specified outcomes had been 
reported; one or more reported primary outcomes were not prespecified; out-
comes of interest were reported incompletely and so could not be used; study 
failed to include results of a key outcome that would have been expected to 
have been reported);
•	 unclear risk of bias.
6. Other bias (checking for bias due to problems not covered by (1) to (5) 
above)
We described for any important concerns we had about other possible sources of 
bias. We assessed whether the study was free of other problems that could put it 
at risk of bias:
•	 low risk of other bias;
•	 high risk of other bias;
•	 unclear whether there is risk of other bias.
7. Overall risk of bias
We made explicit judgements about whether the included study was at a high risk 
of bias, according to the criteria given in the Handbook.53 With reference to (1) to 
(6) above, we assessed the likely magnitude and direction of the bias and whether 
we consider it was likely to impact on the findings. In future updates if more trials 
are included, we will explore the impact of the level of bias through undertaking 
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Measures of treatment effect
Dichotomous data
For dichotomous data, we have presented results as summary risk ratio with 95% con-
fidence intervals. 
Continuous data
For continuous data, we used the mean difference with 95% confidence intervals.
Unit of analysis issues
Cluster-randomised trials
In future updates of this review, if we identify any cluster-randomised trials for inclusion, 
we will include them in the analyses along with individually-randomised trials. We will 
adjust their sample sizes using the methods described in the Handbook using an esti-
mate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), 
from a similar trial or from a study of a similar population. If we use ICCs from other 
sources, we will report this and conduct sensitivity analyses to investigate the effect 
of variation in the ICC. If we identify both cluster-randomised trials and individually-
randomised trials, we plan to synthesise the relevant information. We will consider it 
reasonable to combine the results from both if there is little heterogeneity between the 
study designs and the interaction between the effect of intervention and the choice of 
randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit and perform a sen-
sitivity analysis to investigate the effects of the randomisation unit.
Dealing with missing data
For the included study, we noted levels of attrition. In future updates of the review if 
additional trials are included, we will explore the impact of including studies with high 
levels of missing data in the overall assessment of treatment effect by using sensitivity 
analysis.
For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat 
basis, i.e. we attempted to include all participants randomised to each group in the 
analyses, and all participants were analysed in the group to which they were allocated, 
regardless of whether or not they received the allocated intervention. The denominator 
for each outcome was be the number randomised minus any participants whose out-
comes were known to be missing.
Assessment of heterogeneity
In future updates if additional trials are included, we will assess statistical heterogeneity 
in each meta-analysis using the T², I² and Chi² statistics. We will regard heterogeneity as 
substantial if the I² is greater than 30% and either T² is greater than zero, or there is a 
low P value (less than 0.10) in the Chi² test for heterogeneity. 
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Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-analysis, we will investi-
gate reporting biases (such as publication bias) using funnel plots. We will assess funnel 
plot asymmetry visually, and use formal tests for funnel plot asymmetry. For continuous 
outcomes we will use the test proposed by Egger 1997 and for dichotomous outcomes 
we will use the test proposed by Harbord 2006.54,55 If asymmetry is detected in any of 
these tests or is suggested by a visual assessment, we will perform exploratory analyses 
to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager software.52 In the future, 
we plan to use fixed-effect meta-analysis for combining data where it is reasonable to 
assume that studies are estimating the same underlying treatment effect: i.e. where 
trials are examining the same intervention, and the trials’ populations and methods are 
judged sufficiently similar. If there is clinical heterogeneity sufficient to expect that the 
underlying treatment effects differ between trials, or if substantial statistical heterogen-
eity is detected, we will use random-effects meta-analysis to produce an overall summa-
ry if an average treatment effect across trials is considered clinically meaningful. We will 
treat the random-effects summary as the average range of possible treatment effects 
and we will discuss the clinical implications of treatment effects differing between trials. 
If the average treatment effect is not clinically meaningful, we will not combine trials.
If we use random-effects analyses, we will present the results as the average treatment 
effect with its 95% confidence interval, and the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
If in future updates we identify substantial heterogeneity, we will investigate it using 
subgroup analyses and sensitivity analyses. We will consider whether an overall sum-
mary is meaningful, and if it is, use random-effects analysis to produce it.
We planned to carry out the following subgroup analyses.
1. Type of bacteriuria: asymptomatic bacteriuria (ASB) (without symptoms) versus UTI 
(with symptoms) versus pyelonephritis (requiring hospitalisation). We wish to test 
whether results differ when UTI is variously defined, according to the severity of the 
condition and the presence of symptoms.
2. Definition of RUTI: history of RUTI before pregnancy versus no history of RUTI be-
fore pregnancy. We wish to test whether results differ when women already have 
a history of RUTI before their pregnancy.
3. Gestational age at which the intervention was started before 20 weeks versus equal 
to or greater than 20 weeks. We wish to test whether the effects of the interven-
tions are different according to the stage of pregnancy in which they were started.
4. Types of interventions: pharmacological versus non-pharmacological. We wish to 
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However, we were not able to conduct subgroup analyses as we were only able to in-
clude a single study. In the future, we will use only the primary outcomes in subgroup 
analysis.
Maternal
•	 (Recurrent) UTI before birth (variously defined)
•	 Preterm birth (less than 37 weeks)
Infants
•	 Small-for-gestational age
•	 Total infant mortality (including stillbirth and death prior to discharge)
In future updates, we plan to assess subgroup differences by interaction tests available 
within RevMan.52 We will report the results of subgroup analyses quoting the X2 statistic 
and p-value, and the interaction test I² value.
Results
Description of studies
See: Characteristics of included studies.
Results of the search
The search of the Cochrane Pregnancy and Childbirth Group’s Trials Register retrieved 
two reports relating to one trial eligible for consideration. This trial (involving 200 wo-
men) was included in the review (Lenke 1983).56,57
Included studies
Only one trial, performed in Los Angeles, USA with 200 pregnant women was identified 
that met the inclusion criteria (Lenke 1983).56,57 In this study nitrofurantoin 50 mg three 
times daily and close surveillance (regular clinic visit, urine cultures and antibiotics when 
a positive culture was found) was compared with close surveillance only to prevent re-
current urinary tract infections (RUTI) in women who were pregnant and were admitted 
for pyelonephritis earlier during the index pregnancy. Close surveillance consisted of a 
visit every two weeks to a special clinic and after 36 weeks a weekly visit until birth. At 
each visit a clean-catch, mid voided urine was obtained for a routine culture and nitrite 
testing. When necessary, treatment was provided.
Risk of bias in included studies
Allocation
In the one included study (Lenke 1983), a random number table was used to generate 
the sequence.56,57 The method of treatment allocation was unclear.
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Blinding
No placebos were used and the care providers and the participants were not blinded. 
The ‘Risk of bias’ assessment was considered low for the culture results and delivery 
outcomes.
Incomplete outcome data
There were 18 post-randomisation losses to follow-up in the nitrofurantoin and close 
surveillance group and 15 in close surveillance only group. No data about post rando-
misation data exclusions were reported. The outcome birthweight of infants was not 
available for 11 (13.4%) women in the nitrofurantoin group and close surveillance and 
for nine (10.6%) in the close surveillance only group. The outcomes of birthweight 
<2500 (g), preterm birth (before 37 weeks) and five-minute Apgar score less than seven 
were not available in nine (11.0%) of the women who received nitrofurantoin and close 
surveillance and 11 (12.9%) of the women who received close surveillance only.
Selective reporting
No data were reported on the following primary outcomes: total infant mortality and 
small-for-gestational-age babies. Furthermore, only a small number of secondary outco-
mes were reported. No obvious risk of other potential sources of bias for the included 
studies was apparent. A summary is shown at Figure 1; Figure 2.
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Figure 2. ‘Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as percen-
tages across all included studies.
Effects of interventions
This review included one trial (Lenke 1983) involving 200 women.56,57
Primary outcomes
Lenke 1983 found no differences in women who developed recurrent pyelonephritis 
(upper UTI) (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.31 to 2.53 in 167 wo-
men) Analysis 1.1 or recurrent urinary tract infection (RUTI) (RR 0.30, 95% CI 0.06 to 
1.38 in 167 women) Analysis 1.2 before birth and preterm birth (before 37 weeks) (RR 
1.18, 95% CI 0.42 to 3.35 in 147 women) Analysis 1.3 between nitrofurantoin and 
close surveillance and close surveillance only.56,57 Data on total mortality and small-for-
gestational-age babies were not reported.
Secondary outcomes
The only secondary outcomes reported were birthweight less than 2500 (g) (RR 2.03, 
95% CI 0.53 to 7.80 in 147 women) Analysis 1.4, birthweight (mean difference (MD) 
-113 g, 95% CI -327.20 to 101.20 in 147 women) Analysis 1.5, five-minute Apgar sco-
re less than seven (RR 2.03, 95% CI 0.19 to 21.87 in 147 women) Analysis 1.6 and mis-
carriages (RR 3.11, 95% CI 0.33 to 29.29 in 167 women) Analysis 1.7. There were no 
significant differences between the two comparison groups for any of these outcomes.
In women who received nitrofurantoin and close surveillance the incidence of ASB de-
fined as positive cultures with at least 103 colonies per mL is only reported in women 
with more than 90% clinic attendance rate (RR 0.55, 95% CI 0.34 to 0.89 in 102 wo-
men) Analysis 1.8 and showed a significant reduction of asymptomatic positive cultures 
for women in the nitrofurantoin and close surveillance versus close surveillance alone. 
No symptomatic recurrences were seen in women with more than 90% clinic atten-




Summary of main results
In this review we found no significant differences between a combination of suppressive 
therapy with a daily dose of nitrofurantoin and close surveillance and close surveillance 
alone in preventing RUTI. Only sub-analyses in women with more than 90% follow-up 
show a decreased incidence of asymptomatic bacteriuria (ASB) in women who received 
nitrofurantoin and close surveillance compared with close surveillance only. Since only 
one study was included no other interventions to prevent RUTI in pregnant women 
were assessed.
Overall completeness and applicability of evidence
The evidence for interventions preventing RUTI in pregnant women is very incomplete. 
This review included only one relatively old (1983) trial involving 200 pregnant wo-
men with limited reporting of primary and secondary outcomes for both women and 
infants.56,57 Due to lack of randomised controlled trials (RCTs), no conclusions can be 
drawn regarding the optimal intervention to prevent RUTI in women who are pregnant.
Quality of the evidence
The included trial had moderate to high risk of bias.
Agreements and disagreements with other studies or reviews
Following the results of this review suppressive therapy with a daily dose of nitrofuran-
toin and close surveillance has not been shown to prevent RUTI compared with close 
surveillance alone. These results are not consistent with a Cochrane review on antibio-
tics to prevent urinary tract infection (UTI) in women who are not pregnant which sho-
wed that continuous antibiotic prophylaxis for six to 12 months reduced the rate of UTI 
during prophylaxis when compared with placebo.38 In this review the authors did not 
compare antibiotics with non-pharmacological interventions such as close surveillance. 
Moreover, more adverse effects were seen in the antibiotic group including vaginal 
itching and nausea. These side effects are not desirable in pregnant women since both 
are already more frequent during pregnancy.
Little is known about the effect of close surveillance on preventing RUTI. Lenke 1983 re-
ported that all of the symptomatic recurrences occurred in patients who either had poor 
clinic attendance and subsequent lack of follow-up urine cultures or were not treated 
when gram-negative organisms (mainly uropathogens) were found in their urine.56,57 
These results explain that close surveillance itself already may have an effect on preven-
ting RUTI in pregnant women.
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Authors’ conclusions
Implications for practice
This review found that daily dose of nitrofurantoin and close surveillance was not more 
likely to prevent RUTI compared with close surveillance alone. However, a significant 
reduction in asymptomatic bacteriuria was found in women with a clinic attendance 
rate of more than 90% and who received nitrofurantoin and close surveillance. It is 
important to note that the results of this review were based on only one small trial with 
limited reporting of primary and secondary outcomes in both mother and child. Due to 
the lack of RCTs no conclusions can be drawn.
Implications for research
The Cochrane review on preventing RUTI in non-pregnant women advises researchers 
to establish a definition for RUTI so RCTs can be compared easily.39 It is equally impor-
tant to have a standard definition for RUTI in women who are pregnant. Since preg-
nancy is a limited period during which a UTI may be associated with increased risks for 
both mother and baby, the definition for RUTI should be adapted for pregnant women. 
A possible definition of RUTI in pregnant women may be: at least one UTI during the 
current pregnancy or either three UTI in the 12 months or two in six months before 
onset of pregnancy.
Further large trials (with sufficient power) comparing different pharmacological and 
non-pharmacological interventions are needed to assess the optimal intervention to 
prevent RUTI in women who are pregnant. Such trials should report on a broad range 
outcomes for both women and infants. Given the significant differences found in the 
greater than 90% follow-up group, future trials should further asses the effects of close 
surveillance on preventing RUTI in pregnant women. 
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Characteristics of included studies (ordered by study ID)
Lenke 1983
Methods RCT
Participants Number of pregnant women randomised: 200
Inclusion criteria
•	 Pregnant
•	 Admitted for pyelonephritis: CVA tenderness and in addition 2 
of the following 3 criteria (1) temperature of ≥ 101oF, (2) pyuria 
(≥ 5 white blood cells per high power field) or (3) bacteriuria 
(presence of any motile rods per high power field)
Exclusion criteria
•	 Prior history of pyelonephritis during the index pregnancy
•	 Patients who delivered during the acute phase of pyelonephritis
Setting: Los Angeles, USA.
Period: October 1979 - May 1981.
Definitions
•	 Recurrent UTI: significant dysuria or frequency in absence of 
fever or CVA tenderness
•	 Recurrent pyelonephritis: CVA tenderness and in addition 2 of 
the following 3 criteria (1) temperature of ≥ 101oF, (2) pyuria 
(≥ 5 white blood cells per high power field) or (3) bacteriuria 
(presence of any motile rods per high power field)
•	 Positive culture: gram negative organisms (≥103 colonies per 
mL) with growth of no more than 1 other organism
•	 Negative culture: no growth or <103 Gram negative organisms 
per mL
•	 Contaminated culture: gram negative organisms present ≥103 
per mL) with concomitant growth of at least 2 other organisms
Interventions Intervention group (n = 100): Nitrofurantoin 50 mg orally, 3 times 
daily, for the remainder of the pregnancy plus close surveillance.
Control group (n = 100): close surveillance only.
ALL WOMEN
Follow-up (close surveillance): all patients were followed in the 
special clinic every 2 weeks until the 36 weeks when they were seen 
weekly until delivery. At each visit a clean-catch, mid voided urine 
was obtained for a routine culture and nitrite testing. When culture 
results were positive patients were attempted to reach to schedule a 
return appointment within 1 week.
Treatment: irrespective of group, patients received a short course of 
antibiotics in clinic under 3 circumstances:
•	 if the patient’s last culture (on suppression in the treated group) 
was positive; if the nitrite test was positive;
•	 if the patient developed clinical symptoms of a UTI
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•	 Clinic attendance > 90%
•	 Asymptomatic bacteriuria (ASB) in > 90% attendance group
Infants
•	 Premature birth (< 37 weeks)
•	 Birthweight (g)
•	 Birthweight ≤ 2500 (g)
•	 5 minute Apgar score < 7
•	 1 minute Apgar score < 7
•	 Placental weight (g)
•	 Head circumference (cm)
•	 Body length (cm)
•	 Post mature (> 42 weeks)
Notes •	 Funding: supported in part by Ariel Kaare Rosholt Weathers-
Lowin Medical Research Foundation and National Institute of 
Health grant HD07086-05
•	 Table shows birthweight ≥ 2500 (g). We think this should be 
<2500 (g) and have entered it accordingly.
SIXADDENDUM
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection bias)
Low risk "Random number tables"
Allocation concealment 
(selection bias)
Unclear risk Not reported
Blinding of participants and 
personnel (performance bias) 
All outcomes
Unclear risk Participant: no blinding
Clinician: no blinding
Describe:
“the control group received no 
pills”
“the doctors responsible for  
patient care were aware of 
whether the patient was in  
the treated or control group”
Blinding of outcome assessment 
(detection bias) 
All outcomes
Unclear risk Low for culture results
Low for pregnancy outcomes
Incomplete outcome data 
(attrition bias) 
All outcomes
Unclear risk Lost to follow-up:
•	 18/100 nitrofurantoin and 
close surveillance group;





High risk Overall very few pregnancy out-
comes were measured. “Obser-
vation period ended at the time 
of delivery, as logistics prevented 
longer follow-up”
Other bias Low risk No major baseline differences
CVA: costovertebral angle, mL: millilitre, RCT: randomised controlled trials, UTI: urinary tract infection
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Comparison 1. Nitrofurantoin and close surveillance versus close surveillance alone








1. Recurrent pyelonephritis 1 167
Risk Ratio 
(M-H, Fixed, 95% CI)
0.89 [0.31, 2.53]
2. Developing UTI (cystitis) 1 167
Risk Ratio 
(M-H, Fixed, 95% CI)
0.30 [0.06, 1.38]
3. Preterm birth (< 37 weeks) 1 147
Risk Ratio 
(M-H, Fixed, 95% CI)
1.18 [0.42, 3.35]
4. Birthweight < 2500 (g) 1 147
Risk Ratio 
(M-H, Fixed, 95% CI)
2.03 [0.53, 7.80] 
5. Birthweight (g) 1 147
Mean Difference 
(IV, Fixed, 95% CI)
-113.0 [-327.20, 101.20]
6. 5-minute Apgar score <7 1 147
Risk Ratio 
(M-H, Fixed, 95% CI)
2.03 [0.19, 21.87]
7. Miscarriages 1 167
Risk Ratio 
(M-H, Fixed, 95% CI)
3.11 [0.33, 29.29]
8. Asymptomatic bacteriuria 




(M-H, Fixed, 95% CI)
0.55 [0.34, 0.89] 
Analysis 1.1. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome 
1 Recurrent pyelonephritis.
Analysis 1.2. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome 
2 Developing UTI (cystitis).
SIXADDENDUM
Analysis 1.3. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome 
3 Preterm birth (< 37 weeks).
Analysis 1.4. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome 
4 Birthweight < 2500 (g).
Analysis 1.5. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome 
5 Birthweight (g).
Analysis 1.6. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome 
6 Five-minute Apgar score < seven.
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Analysis 1.7. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome 
7 Miscarriages.
Analysis 1.8. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome 
8 Asymptomatic bacteriuria in women with 90% clinical attendance.
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The prevalence of asymptomatic bacteriuria (ASB) in pregnancy is 2-10% and is associ-
ated with both maternal and neonatal adverse outcomes as pyelonephritis and preterm 
delivery. Antibiotic treatment is reported to decrease these adverse outcomes although 
the existing evidence is of poor quality. 
METHODS | DESIGN
We plan a combined screen and treat study in women with a singleton pregnancy. 
We will screen women between 16 and 22 weeks of gestation for ASB using the urine 
dipslide technique. The dipslide is considered positive when colony concentration ≥105 
colony forming units (CFU)/mL of a single microorganism or two different colonies but 
one ≥105 CFU/mL is found, or when Group B Streptococcus bacteriuria is found in any 
colony concentration. Women with a positive dipslide will be randomly allocated to 
receive nitrofurantoin or placebo 100 mg twice a day for 5 consecutive days (double 
blind). Primary outcomes of this trial are maternal pyelonephritis and/or preterm deli-
very before 34 weeks. Secondary outcomes are neonatal and maternal morbidity, neo-
natal weight, time to delivery, preterm delivery rate before 32 and 37 weeks, days of 
admission in neonatal intensive care unit, maternal admission days and costs. 
DISCUSSION
This trial will provide evidence for the benefit and cost-effectiveness of dipslide screening 
for ASB among low risk women at 16–22 weeks of pregnancy and subsequent nitrofu-
rantoin treatment. 
TRIAL REGISTRATION
Dutch trial registry: NTR-3068
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Background
Asymptomatic bacteriuria (ASB) is the presence of significant bacteriuria without the 
symptoms of a urinary tract infection (UTI). ASB occurs in 2-10% of pregnant women.1 
ASB during pregnancy can lead to serious complications for both mother and child. 
The incidence of ASB is similar in both pregnant and non-pregnant women.2 Pregnant 
women with ASB, however, develop pyelonephritis more often, probably due to the 
anatomic and physiologic changes that occur during pregnancy, which may facilitate 
bacterial growth and ascending of bacteria to the kidneys.3 If left untreated, 20% to 
40% of pregnant women with ASB will develop pyelonephritis.2,4,5 
Other possible adverse effects, such as preterm delivery and delivering a low birth 
weight infant are less well established. Preterm delivery is the main cause of neonatal 
mortality and morbidity worldwide. The causal mechanisms remain unknown. One of 
the hypotheses is that endotoxins released by bacteria cause uterine contractions lea-
ding to preterm delivery. 
Necessity of screening for ASB
Some national guidelines recommend ASB screening and treatment in pregnancy.1,6,7 
However, these guidelines are based on research conducted more than 30 year ago. 
Furthermore, our knowledge about methodology and the causing mechanisms of pye-
lonephritis has developed. Since the methods used in these early studies are inadequa-
tely described, interpretation of this evidence is difficult and the conclusions that can 
be drawn are limited. 
Although many articles have been published on ASB in pregnancy, the role of ASB in 
perinatal outcomes is not clear.8 Another problem is that most recent papers focus on 
the best treatment strategies instead of evaluating the actual need for a screen and 
treat program. 
The widespread use of antibiotics as a consequence of the screening programs is reason 
for concern. The ORACLE Children Study II showed increased functional impairment in 
children from mothers using antibiotics for the prevention of preterm labour in preg-
nancy.9 Other studies also showed an adverse effect of antibiotics on the offspring, 
such as increased antibiotic resistance in late-onset serious bacterial infections.10,11 Con-
sidering these results, one should carefully balance the consequences of bacteriuria 
in pregnancy against the possible effects of antibiotics, before routinely treating all 
women with ASB. 
Antibiotics choice and duration
There is no consensus in the literature on either the duration of therapy or the choice 
of antibiotic. As a result practice is guided by national or local practices and resistance 
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patterns.8 A recent Cochrane review on the treatment duration for ASB underlines this 
lack of clear evidence on the best treatment.12 
The latest guidelines of the Infectious Disease Society of America (IDSA), published in 
2005, recommend for the treatment of ASB a 3 to 7-day course for the treatment of 
ASB that includes sulphonamides, nitrofurantoin, nalidíxic acid, amoxicillin or trimetho-
prim.1 
E. coli is the most common pathogen found in ASB and treatment should be targeted 
to the most common pathogens.3 Nitrofurantoin has proven to be safe in pregnancy 
with very low resistance levels in the Netherlands.13-15 Nitrofurantoin is first choice in the 
treatment of cystitis in pregnancy in the Netherlands.16,17  
The Dutch guidelines of the Dutch Society of Obstetrics and Gynaecology (NVOG) and 
the Dutch General Practitioners Society (NHG) do not currently recommend routine 
screening and treatment of ASB in pregnancy because convincing evidence is lac-
king.16,17 The Netherlands is one of the few countries which can still properly investigate 
this important question because a non treating policy of woman with ASB does not 
violate the guideline. 
In view of the lack of good clinical evidence on the subject and the resulting practice 
variation, we think that an appropriately designed clinical trial evaluating the costs and 
effects of a screen and treat program is urgently needed. In a national cohort study 
women will be screened for ASB with the dipslide technique. Women with ASB will be 
randomised to either placebo or nitrofurantoin. 
Methods | design
Outline
The study will be a prospective cohort screening study with a randomised clinical trial 
embedded. We will screen a large cohort of women with low risk singleton pregnancies 
at 16–22 weeks gestation with the dipslide technique. Women with a positive dipslide 
without symptoms of a UTI will be randomly allocated to receive either nitrofurantoin 
or placebo for 5 days. To mask women for their bacteriuria status a small sample of 
women without ASB will also be offered the possibility to participate in the study. 
Women without ASB will always receive placebo. Both women and researchers will be 
unaware of the bacteriuria status and treatment allocation. Because of the blinding of 
bacteriuria status, women with GBS bacteriuria will not receive intrapartum antibiotics 
in the absence of other risk factors. 
The objective of the randomized trial is to evaluate whether nitrofurantoin treatment 
of women with ASB is effective in reducing the risk of preterm delivery and/or pyelo-
nephritis (primary outcome) and adverse neonatal outcome (secondary outcome). 
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Participants | eligibility criteria
The study is set in the Dutch Obstetric Consortium, a collaboration of obstetric practices 
in the Netherlands. A variety of clinics, including university hospitals, teaching hospitals, 
non-teaching hospitals, ultrasound centres and midwifery practices will participate in 
this trial. Women with a singleton pregnancy without symptoms of a urinary tract infec-
tion at 16–22 weeks of gestation can participate in the ASB screening study. 
Women with a history of spontaneous preterm delivery before 34 weeks, signs of thre-
atening preterm delivery, foetal congenital malformations, use of antibiotics at time of 
screening, known G6PD deficiency or allergy to nitrofurantoin or risk factors for com-
plicated UTI (diabetes mellitus, immunosuppressive medication, functional or structural 
abnormalities of the urinary tract) are excluded from the screening study. 
Procedures, recruitment, randomisation and collection of baseline data
ASB screening trial
In the ASB screening trial, we will offer low risk women with a singleton pregnancy 
the possibility to be screened for ASB with the dipslide technique. At the 16th week 
of gestation the timing of screening is considered optimal.4,18 For logistic reasons we 
decided to do the screening at the same time the structural ultrasound scan for foetal 
abnormalities is performed in the Netherlands. 
A single dipslide (Uricult®, Orion Diagnostica) consisting of two different media (green 
cysteine lactose electrolyte deficient medium and reddish MacConkey medium) will be 
used to diagnose ASB. Previous research showed that the dipslide is a promising alterna-
tive for the conventional culture, which is currently considered the gold standard.3,19,20 
The dipslide has 98.0% sensitivity and 99.6% specificity for detecting ASB in preg-
nancy.21 Urinary culture is not feasible in the Dutch antenatal care system since 70% of 
Dutch women attend antenatal care at a midwifery practice. Hence, there is no direct 
access to a microbiology laboratory to perform the cultures. 
The dipslide will be inoculated with midstream urine at a hospital, ultrasound centre or 
midwifery practice. Perineal cleansing prior to voiding is not necessary since it does not 
decrease bacterial contamination.22 The dipslides will be sent by mail to the laboratory 
for infectious diseases in Groningen, the Netherlands the same day. Laboratory techni-
cians will read the dipslide directly when incubated for 2 to 3 days at room temperature. 
If no colonies have been formed, the dipslide will be incubated for another 24 hours at 
35o Celsius. 
Dipslides are considered positive when the colony concentration is  ≥105 CFU/mL of a 
single microorganism or when two different colonies are present but one has a con-
centration of ≥105 CFU/mL. When Group B Streptococcus (GBS) is found also colony 
concentrations <105 CFU/mL are considered positive because treatment may still be be-
neficial.23 When more species are present the dipslide is considered contaminated. 
All women participating in the ASB screening study will receive two questionnaires. The 
first questionnaire contains questions about ethnicity, marital status, length, weight, 
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education, smoking, alcohol- and drug use, comorbidity, parity, inter-pregnancy in-
terval and exclusion criteria. This questionnaire will be filled out at the moment of 
screening. The second questionnaire will be sent to the participants 6 weeks after their 
due date. It contains questions about UTIs, use of antibiotics and hospital admissions 
during this pregnancy, pregnancy complications and pregnancy outcomes. Furthermore 
we will ask all women in the screening study for informed consent to collect data on 
their pregnancy outcomes. 
ASB treatment trial
Women eligible for the ASB treatment trial will be identified by the laboratory personnel 
participating in this study. A research midwife or -nurse will contact these women for 
participation in the treatment trial. 
Before entering the study, women will be informed about the aims, methods, reaso-
nably anticipated benefits and potential hazards of the study. Participation is voluntary 
and withdrawal of consent to participate is possible at any time during the study. After 
giving sufficient information, written informed consent will be asked for. Women eli-
gible for the ASB treatment trial who do not give informed consent, will be registered. 
Nitrofurantoin will not be offered to these women. 
After participant data have been entered in a web based database, computerized ran-
domisation will take place. The women with ASB will be randomised 1:1 for nitrofu-
rantoin and placebo. Women without ASB (used for blinding of bacteriuria status) will 
always receive placebo. 
Intervention
Each study participant will be given a jar labelled “ASB treat study” which contain either 
100 mg capsules of nitrofurantoin (Nitrofurantoin MC, TioFarma, the Netherlands) or 
identical-appearing capsules of placebo (TioFarma, the Netherlands). 
The oral study medication will be self-administered twice a day for 5 consecutive days. 
The label codes indicating nitrofurantoin or placebo are blinded for the participants and 
researchers. The deblinding list is present in the central pharmacy. For emergency cases, 
a closed envelope with the label codes is also available at the study centre. The data will 
be disclosed to the researchers in case of emergencies and otherwise after collection 
and analysis of the primary outcomes. Researchers involved in the follow up program 
of the offspring of women participating in this study will remain blinded for a longer 
period. For purpose of the interim analysis the label codes will become available to the 
epidemiologist involved in the study as A and B. 
All participants who receive study medication—i.e. the screen positives as well as the 
random subsample of screen negatives —, will have follow up dipslides done 1 week 
after the end of treatment. Participants with a persistent positive culture and a subsam-
ple of participants with a negative culture will receive again (blinded) study medication. 
The participants who received nitrofurantoin will again receive nitrofurantoin, placebo 
participants will again receive placebo. One week after this second intervention, once 
again a dipslide is performed. 
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Outcome measures
The primary outcomes for the screen and treat study are the development of pye-
lonephritis and delivery before 34 weeks. Pyelonephritis is defined as an episode of 
fever (≥38.0°C), symptoms (nausea, vomiting, chills, costo-vertebral tenderness) and a 
positive urine culture. The primary outcome measure will be recorded 6 weeks after the 
expected due date. 
Secondary outcome is an adverse neonatal outcome (death or severe morbidity). The 
composite morbidity rate contains the following variables: severe respiratory distress 
syndrome (RDS), bronchopulmonary dysplasia (BPD), periventricular leucomalacia > 
grade 1, intracerebral haemorrhage > grade II, necrotizing enterocolitis (NEC) > stage 
1, proven sepsis (including GBS sepsis) and death before discharge from the nursery. 
Other outcome parameters are: neonatal weight, time to delivery, preterm birth rate 
before 32 and 37 weeks, days of admission in neonatal intensive care unit, maternal 
morbidity (including UTI), chorioamnionitis, maternal admission days for (threatened) 
preterm labour and/or pyelonephritis and costs. 
Furthermore, we will look at growth, physical condition and neurodevelopmental out-
come of the child at 24 months (corrected) age. 
Apart from clinical outcome, the cost-effectiveness of screening for ASB (as done in ASB 
screening), and subsequent treatment in cases of ASB (as done in ASB treatment trial), 
will be assessed. 
Follow up of women and infants
We plan follow-up of infants at the corrected age of 24 months with the Ages & Stages 
Questionnaires (ASQ) and the Child Behavioural Checklist (CBCL). The checklists will be 
sent to the parents of the child. In case the parents do not return the questionnaire, a 
reminder will be sent. We will also ask them to report length, weight medical history 
and medical consumption of the child. 
Data analysis
The results of the screen cohort will allow us to describe the incidence of ASB in the 
Netherlands as well as to explore risk factors for developing ASB or pyelonephritis. 
The results of the randomised clinical trial will be analyzed according to the intention 
to treat principle. The effectiveness of nitrofurantoin versus placebo will be assessed by 
calculating relative risks and 95% confidence intervals. The number of primary and se-
condary outcomes will be compared between the ASB positive and ASB negative (ASB 
screen study) and treatment and control (ASB treat study) groups. 
Interim analysis
Interim analysis will be monitored by an independent Data Safety Monitoring Commit-
tee. We plan an interim analysis for futility and safety after 100 participants in the ASB 
treat study. 
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This analysis will be done by an independent person who will be unaware of the alloca-
tion of treatment when data are judged for effectiveness.
Statistical issues
Sample size calculation
Among women positive for ASB, we anticipate the occurrence of the primary outcome 
(delivery before 34 weeks and/or pyelonephritis) to be 10% in the treatment group and 
25% in the no treatment group. If ASB is not treated, 20% of pregnancies with ASB 
will be complicated by pyelonephritis compared to 2% of pregnancies without ASB.24 
Treatment of ASB results in a decrease of pyelonephritis compared to women who were 
not treated. Using a two-sided test with an alpha 0.05 and a beta of 0.8, 220 women 
with ASB (110 per arm) are needed in the study. Anticipating a 5% incidence of ASB, 
we need to screen 4.400 women. Obviously, final recruitment statistics will depend on 
the screen positive rate, which is one of the study questions. From our previous experi-
ence in the Triple P trial we learned that Dutch women are very reserved in taking study 
medication for asymptomatic conditions in pregnancy.25 If during this trial it becomes 
clear that very few women consent to participate in the ASB treat study we will not 
increase our screening cohort indefinitely to reach our planned randomisations. 
Economic evaluation
General considerations
The economic analysis will be performed from a societal perspective. Both costs and 
outcomes will be discounted with a discount rate of 5%. The economic analysis of 
the trial itself is not of interest. If nitrofurantoin is found to decrease the probability 
of pyelonephritis or preterm delivery, then the savings due to decreased maternal and 
neonatal admission will always outweigh the costs of nitrofurantoin, which are negli-
gible. The true economic question to be answered, when the treatment trial shows a 
beneficial effect, is whether the costs of screening (number needed to screen to detect 
one woman with ASB) outweigh the cost reduction and health benefits from treatment 
with nitrofurantoin. 
Cost analysis
The study design will enable us to compare the costs and effects of the following strate-
gies: (1) no screening for ASB; (2) screening for ASB and treatment of women with ASB
For each of these strategies, we will calculate the costs as well as the effects in terms 
of pyelonephritis or preterm delivery. In the cost-effectiveness analysis, we will then 
calculate the costs per prevented case of pyelonephritis or preterm delivery. Thus, the 
cost-effectiveness analysis will assess the balance between number needed to treat and 
number needed to screen. 
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Data safety monitoring committee
Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions 
(SUSARs) will be reported to a Data Safety Monitoring Committee (DSMC). The DSMC 
can order to perform an extra interim analysis and, if indicated, terminate the trial pre-
maturely. 
Ethical considerations
This study is approved by the National Central Committee on Research involving Human 
Subjects (CCMO - NL35375.018.11) and by the ethics committee of the Academic me-
dical centre Amsterdam (ref. no MEC 2011_073).
Discussion
To our knowledge there are no other ongoing trials in the Netherlands or other coun-
tries, evaluating a screen and treat strategy for ASB with the dipslide technique (http://
www.controlled-trials.com/mrCT/webcite). This trial will provide evidence for the use-
fulness and cost-effectiveness of screening for ASB at 16–22 weeks of pregnancy with a 
dipslide and subsequent nitrofurantoin treatment among low risk women.  
Abbreviations
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SEG, CJG and BWM were involved in conception and design of the study. BMK, CS and 
SEG, drafted the manuscript. All authors mentioned in the manuscript are members 
of the ASB study group. They participated in the design of the study during several 
meetings and are local investigators in the participating centres. All authors edited the 
manuscript and read and approved the final manuscript. 
Acknowledgements
This study is funded by the Dutch Organisation for Health Research and Development 
(ZonMw) grant 50-50110-96-530. 
ASB Asymptomatic bacteriuria
CFU Colony forming units
ML Millilitre
UTI Urinary tract infection
SAE Serious adverse Event
SUSAR Supspected Unexpected Serious Adverse Reaction
DSMC Data Safety Monitoring Committee
SEVENREFERENCES
References 
1. Nicolle LE, Bradley S, Colgan R, et al. Infectious 
Diseases Society of America guidelines for the 
diagnosis and treatment of asymptomatic bac-
teriuria in adults.  Clin Infect Dis 2005;40:643-
54. 
2. Patterson TF, Andriole VT. Detection, signifi-
cance, and therapy of bacteriuria in pregnancy. 
Update in the managed health care era.  Infect 
Dis Clin North Am 1997;11:593-608. 
3. Macejko AM, Schaeffer AJ. Asymptomatic 
bacteriuria and symptomatic urinary tract in-
fections during pregnancy. Urol Clin North Am 
2007;34:35-42. 
4. Millar LK, Cox SM. Urinary tract infections com-
plicating pregnancy. Infect Dis Clin North Am 
1997;11:13-26. 
5. Kass EH. Bacteriuria and pyelonephritis of preg-
nancy. Arch Intern Med 1960; 105:194-8. 
6. Lin K, Fajardo K. Screening for asymptoma-
tic bacteriuria in adults: evidence for the U.S. 
Preventive Services Task Force reaffirmation 
recommendation statement. Ann Intern Med 
2008;149:20-4. 
7. National Collaborating Centre for Women’s 
and Children’s Health. NICE clinical guideline 
62; Antenatal care: routine care for the healthy 
pregnant woman. 2008. 
8. Schnarr J, Smaill F. Asymptomatic bacteriuria 
and symptomatic urinary tract infections in 
pregnancy. Eur J Clin Invest 2008;38:50-7. 
9. Kenyon S, Pike K, Jones DR, et al. Childhood 
outcomes after prescription of antibiotics to 
pregnant women with spontaneous preterm 
labour: 7-year follow-up of the ORACLE II trial. 
Lancet 2008;372:1319-27. 
10. Bedford Russell AR, Murch SH. Could peripar-
tum antibiotics have delayed health conse-
quences for the infant?  BJOG 2006;113:758-
65. 
11. Ashkenazi-Hoffnung L, Melamed N, Ben-Ha-
roush A, et al. The association of intrapartum 
antibiotic exposure with the incidence and an-
tibiotic resistance of infantile late-onset serious 
bacterial infections.  Clin Pediatr 2011;50:827-
33. 
12. Widmer M, Gulmezoglu AM, Mignini L, Ro-
ganti A. Duration of treatment for asympto-
matic bacteriuria during pregnancy. Cochrane 
Database Syst Rev 2011:CD000491.
13. Dashe JS, Gilstrap LC. Antibiotic use in preg-
nancy.  Obstet Gynecol Clin North Am 
1997;24:617-29. 
14. Reeves DS. A perspective on the safety of anti-
bacterials used to treat urinary tract infections. 
J Antimicrob Chemother 1994;33:111-120. 
15. SWAB. NethMap 2010 - Consumption of an-
timicrobial agents and antimicrobial resistance 
among medically important bacteria in the Ne-
therlands. NethMap. 2010.
16. Nederlandse Vereniging voor Obstetrie en Gy-
naecologie. NVOG Guideline: urineweginfectie 
in de zwangerschap (version 2.0). 2011. 
17. Van Haaren KAM, Visser HS, Van Vliet S, et al. 
NHG-Standaard Urineweginfectie (Tweede her-
ziening). Huisarts Wet 2005;8:341-352. 
18. Stenqvist K, Dahlen-Nilsson I, Lidin-Janson G, et 
al. Bacteriuria in pregnancy. Frequency and risk 
of acquisition.  Am J Epidemiol 1989;129:372-
9. 
19. Smaill F, Vazquez JC. Antibiotics for asympto-
matic bacteriuria in pregnancy. Cochrane Da-
tabase Syst Rev. 2007:CD000490. 
20. Sheffield JS, Cunningham FG. Urinary 
tract infection in women. Obstet Gyne-
col.2005;106:1085-92. 
21. Mignini L, Carroli G, Abalos E, et al. Accuracy 
of diagnostic tests to detect asymptomatic 
bacteriuria during pregnancy.  Obstet Gynecol 
2009;113:346-52. 
22. Schlager TA, Smith DE, Donowitz LG. Perineal 
cleansing does not reduce contamination of 
urine samples from pregnant adolescents. Pe-
diatr Infect Dis J 1995;14:909-11. 
23. Anderson BL, Simhan HN, Simons KM, Wie-
senfeld HC. Untreated asymptomatic group 
B streptococcal bacteriuria early in pregnancy 
and chorioamnionitis at delivery.  Am J Obstet 
Gynecol 2007;196:524-5. 
24. Whalley P. Bacteriuria of pregnancy. Am J Ob-
stet Gynecol 1967;97:723-38.
25. van Os MA, van der Ven JA, Kleinrouweler CE, 
et al. Preventing preterm birth with progeste-
rone: costs and effects of screening low risk 
women with a singleton pregnancy for short 











and urinary tract infection 
in pregnant women with 
and without diabetes 
mellitus and gestational 
diabetes mellitus; 
a case-control study
C. Schneeberger1,2,3, S.E. Geerlings2, J.J.H.M. Erwich4, R.P. 
Stolk1, E. R. van den Heuvel1, P. Middleton3, C.A. Crowther3,5
1 Department of Epidemiology, University Medical Center Groningen 
(UMCG), University of Groningen, Groningen, the Netherlands. 2 De-
partment of Internal Medicine, division of Infectious Diseases, Academic 
Medical Center (AMC), Amsterdam, the Netherlands. 3 ARCH: Australian 
Research Centre for Health of Women and Babies, Robinson Institute, The 
University of Adelaide, Adelaide, Australia.  4 Department of Obstetrics and 
Gynaecology, University Medical Center Groningen (UMCG), University of 






Asymptomatic bacteriuria (ASB) and urinary tract infections (UTI) during pregnancy may 
contribute to adverse pregnancy outcomes for mother and infant. Diabetes mellitus 
(DM) and gestational diabetes mellitus (GDM) are considered to be important additional 
risk factor for ASB and UTI during pregnancy. 
AIMS
To investigate differences in prevalence of ASB and incidence of UTI, including causa-
tive organisms, in pregnant women with and without DM and GDM to inform ASB 
screening and treatment policies. 
METHODS
Data from 214 pregnant women who gave birth during 2010 at the Women’s and 
Children’s Hospital, Adelaide, Australia where cases were women with a clinical diag-
nosis of DM or GDM and controls were matched on date of birth. ASB was defined as 
the growth of at least 105 colony forming units/ml of one organism or any presence 
of group B Streptococcus (GBS) at the first urine culture collected during pregnancy 
without complaints of a UTI.  A clinical UTI was diagnosed by the treating physician, in 
combination with a positive urine culture it was defined as culture-confirmed UTI. 
RESULTS
No significant differences in prevalence of ASB (5.6% and 3.7%; relative risk (RR) 1.50; 
95% confidence intervals (CI) 0.44-5.17), incidence of clinical UTI (4.7% and 11.2%; 
RR 0.42; 95% CI 0.15-1.14) or culture-confirmed UTI (2.8% and 3.7% RR 0.75; 95% 
CI 0.17-3.27) between pregnant women with and without DM or GDM were present. 
No association was found between ASB and UTI. GBS was the most common causative 
organism of ASB in women with and without DM (66.7% and 50.0%).
CONCLUSIONS
In contrast with earlier research no significant differences in prevalence of ASB or in-
cidence of UTI was found between pregnant women with and without DM or GDM.
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Background
In the 1960s Kass and colleagues described the association of untreated asymptomatic 
bacteriuria (ASB), bacteriuria without symptoms of a urinary tract infection (UTI), with 
preterm birth and perinatal mortality.1,2 However, subsequent studies showed contra-
dictory results. The prevalence of ASB in pregnancy is 2-10%, although prevalence 
rates up to 40% have been reported.3,4 Earlier studies demonstrated that 30 to 40% 
of pregnant women with untreated ASB developed pyelonephritis.1,4,5 The hypothesis is 
that anatomic and physiological changes occurring during pregnancy facilitate bacterial 
growth and ascent of the bacteria to the kidneys.6 This led to further research and the 
introduction of ASB screening and treating policies in many countries. 
A systematic Cochrane review on the effect of antibiotic treatment for asymptomatic 
bacteriuria in pregnancy concluded that treatment of ASB reduces pyelonephritis and 
low birth weight.4 However the reduction in low birth weight found in this review has 
to be interpreted with care, given the poor quality of studies. Moreover, no decrease of 
preterm birth after antibiotic treatment was found.4
Recent studies have revealed possible adverse effects of maternal antibiotic use during 
pregnancy including malformations, cerebral palsy and the presence of antibiotic re-
sistant microorganisms in the newborn.7,8
In most countries, including Australia, screening and treatment of ASB during pregnan-
cy to prevent adverse pregnancy outcomes is recommended.9 This is even though the 
association between ASB and perinatal morbidity have not been clearly established and 
the whole range of possible side effects of maternal antibiotic use during pregnancy is 
not wholly identified yet and currently further investigated.4,8-12
Diabetes mellitus (DM) and gestational diabetes (GDM) are considered important ad-
ditional risk factor for both ASB and UTI in pregnant women.13,14 Furthermore the in-
cidence of GDM is increasing in high-income countries such as Australia.15 Previous 
studies with mainly small sample sizes have reported similar or increased prevalence of 
ASB up to 24% in pregnant women with DM compared to women without DM.16-18
The incidence of symptomatic UTI is higher in pregnant women with DM (3.3-8.8%) 
compared to women without DM (1.3-2.3%).11,16,18,19 Pregnant women with ASB more 
often develop a symptomatic UTI when they have DM compared to those without DM.16 
Many guidelines have been adapted in favour of a screen and treat strategy to prevent 
complications in pregnant women with ASB.9,20 It remains important to challenge this 
approach because the truly achieved reduction of complications in pregnancy following 
the screen and treat approach has to be balanced against the side effects of antibiotics 
for both mother and baby and the unnecessary costs.7,8, 21,22 
EIGHTMETHODS
This study aimed to describe current practice in a developed country, Australia, and 
to provide more background for ASB screening and treatment policies, especially for 
high-risk pregnant women with GDM or DM. The specific aims were to investigate dif-
ferences in prevalence of ASB and incidence of UTI, including causative organisms, in 
pregnant women with and without DM or GDM. 
Methods
Design and patients 
For this case-control study we used data from pregnant women with DM or GDM (ca-
ses) and without DM or GDM (controls) who received antenatal care in the Women’s 
and Children’s Hospital in Adelaide, Australia, during 2010. In Australian guidelines rou-
tine urine examination during antenatal assessment is advised and was part of standard 
care in the Women’s and Children’s Hospital in Adelaide.23,24 
Cases were randomly selected using systematic sampling with an interval length of two 
(alternating) on the basis of a list with names of all women who gave birth during 2010 
and who were diagnosed with DM or GDM (according to the hospital administration). 
Controls were randomly collected from a list of women in the same period. To make the 
two samples comparable, controls with the same birth dates as the cases were selected. 
Obstetric, demographic and laboratory data were extracted from medical records up to 
six weeks postpartum. Women were ineligible if they had no available urine culture re-
sult, a multiple pregnancy, anatomical abnormalities of the urinary tract or pre-existing 
medical conditions with a known association with UTI except for pregnancy and dia-
betes or if there was no access to the medical record. The Hospital Research and Ethics 
Committee provided ethical approval.
Definitions
ASB was defined as the growth of at least 105 colony forming units (cfu)/ml of one 
organism or any presence of group B Streptococcus (GBS) at the first urine culture 
(screening urine sample) collected during pregnancy without complaints of a UTI.  
A clinical UTI was defined as a clinical diagnosis made by the treating physician (UTI 
registered by the treating physician in the clinical record); a culture confirmed UTI was 
defined as a clinical UTI in combination with a positive urine culture. When women 
were admitted because of a UTI it was considered to be for pyelonephritis. Recurrent 
UTI (RUTI) was defined following treating physician. 
Urine cultures with growth less then 105 cfu/ml or with growth of more than two or-
ganisms were defined as mixed growth. Urine cultures without growth were defined 
as negative. 
Both DM (type 1 and type 2) and GDM were clinical diagnoses. Screening for GDM 
with a 50 gram oral glucose challenge test between 24 to 28 weeks gestation was part 
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Small for gestational age (SGA) was defined as birth weight in relation to gestational 
age smaller than the 10th percentile, appropriate for gestational age (AGA) between 
the 10th and 90th percentiles and large for gestational age (LGA) greater than 90th per-
centile.25 
Outcomes
The primary outcome was the prevalence of ASB diagnosed from the first available 
antenatal urine culture, as most guidelines recommend collecting urine during the first 
antenatal visit. Other outcomes were the incidence of both clinical and culture con-
firmed UTI including pyelonephritis, postpartum UTI (up to 6 weeks after birth), and 
causative uropathogens. Furthermore, the association between ASB and development 
of UTI was investigated.
The following maternal and neonatal characteristics were assessed: maternal age at 
birth, parity, race, type of DM (type 1, 2 or DMG), treatment of DM (insulin, oral hypo-
glycaemics and/or diet), history of recurrent urinary tract infections (RUTI), use of prop-
hylaxis or antibiotics two weeks before first urine culture, mode of birth (normal vaginal 
birth, operative vaginal birth, caesarean section), gestational age at birth (categorised 
as <32, 32-37, 37-40 and >40 weeks’ gestation), gender child, SGA, LGA, AGA, admis-
sion to neonatal intensive care unit independent of duration, five minute Apgar score 
less than seven, neonatal antibiotic use and positive neonatal blood cultures. 
Statistics
Data were analysed using SPSS software for windows, version 19. Fisher’s exact test 
and the Mann-Whitney test were used to calculate differences in characteristics of the 
women and infants born form women with and without DM. Relative risk (RR) and 
95% confidence intervals (95% CI) was calculated to estimate differences in binary 
outcomes. The Mann-Whitney test was used test differences for continuous outcomes.
Results
Maternal and neonatal characteristics
A total of 214 pregnant with DM and GDM (n=107) and without DM and GDM (n=107) 
were eligible for analysis. The 107 women with DM and GDM represent around 30% 
of the total number of pregnant women with DM who gave birth at the Women’s and 
Children’s Hospital during the year. Demographics of both groups were similar (Table 1a 
and Table 1b).  Of the 107 women, most were diagnosed with GDM (91.6%), of whom 
59 (60.2%) were treated with diet alone, 33 (33.7%) received oral hypoglycaemics and 
10 (10.2%) used insulin. Women without diabetes or GDM more frequently gave birth 
after 40 weeks of gestation. 
EIGHTRESULTS
ASB and UTI 
The mean gestational age at the time of first urine sample was between 11-12 weeks 
gestation for both diabetic and non-diabetic women (11.4, Standard deviation (SD)±4.2 
and 11.3, SD±4.5 weeks). The overall prevalence of ASB was 4.8% and no differences 
were found between women with and women without DM (5.6% and 3.7%; relative 
risk (RR) 1.50; 95% confidence intervals (CI) 0.44-5.17) (Table 2). Group B Streptococcus 
(GBS) was the most common causative organism of ASB (60%) followed by Escherichia 
coli (E. coli) (30%). No association was found between ASB and UTI during pregnancy. 
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Figure 1. Flow-diagram urinary tract infections in pregnant women with and without DM and GDM.
214 pregnant women
107 with diabetes mellitus 107 without diabetes mellitus















2 no culture 
available
Abbreviations: DM = diabetes mellitus; AB = antibiotics; GA = gestational age; ASB = asymptomatic 
bacteriuria; UTI = urinary tract infection; GBS = Group B Streptococcus
Definitions: ASB was defined as the growth of at least 10 5 cfu/ml of one or two organisms or any 
presence of group B Streptococcus at the first urine culture collected during pregnancy without 
complaints of a UTI; clinical UTI was defined as clinical diagnosis made by the treating physician; 
culture confirmed UTI was defined as clinical UTI in combination with a positive urine culture; positive 
culture was defined as growth of at least 105 cfu/ml of one or two organisms. 
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One woman with DM (0.9%) and four (3.7%) women without DM had symptoms of a 
UTI at the time of the first urine culture ‘the screening urine’ and were therefore diag-
nosed as UTI or pyelonephritis. Only one pregnant woman with ASB received antibiotic 
treatment. All women with GBS bacteriuria at the first urine culture received antibiotic 
prophylaxis during birth.  
No differences in clinical UTI during pregnancy were seen in pregnant women with and 
without DM (4.7% and 11.2%; RR 0.42; 95% CI 0.15-1.14). In seven of the 17 women 
with a clinical UTI, a positive culture was present (culture confirmed UTI), in eight wo-
men there was a mixed growth, and in two women no culture results were available. 
Sixteen of the 17 clinical UTIs were treated with antibiotics. Two women (one with and 
one without DM) were admitted because of a UTI during pregnancy. 
No differences in incidence of culture confirmed UTI, including pyelonephritis, during 
pregnancy (2.8% and 3.7%; RR 0.75; 95% CI 0.17-3.27) and postpartum (0.9% and 
0.9%; RR 1.00; 95% CI 0.06-15.78) were found between women with and without 
DM. In both pregnant women with and without DM, E. coli was the most common 
causative organism of UTI. GBS was not the causative organism for any of the UTIs. 






























History of RUTI 1 0.9% 4 3.7% 0.369













Insulin 18 16.8% NA NA NA
Oral hypoglycemics 40 37.4% NA NA NA
Diet 105 98.1% NA NA NA
Abbreviations: DM = diabetes mellitus; GDM= gestational diabetes mellitus RUTI = recurrent urinary tract in-
fection; NA = not applicable. a P-value calculated either with Fisher’s exact test or Mann-Whitney test. Figures 
are numbers and percentages; or mean and standard deviation.
EIGHTDISCUSSION
In both women with and women without diabetes or GDM no association was found 
between ASB or clinical UTI during pregnancy and adverse pregnancy or neonatal out-
comes, including preterm birth and SGA.
Discussion
In our study, based on clinical practice ASB screening data, we found that the overall 
prevalence of ASB was rather low (4.8%). Moreover no differences in prevalence of ASB 
or incidence of culture confirmed UTI and clinical UTI was present between pregnant 
women with and without DM or GDM. Group B Streptococcus was the most common 
causative organism of ASB in both women with and without DM.  
No association was seen between ASB or UTI and adverse pregnancy outcomes inclu-
ding preterm birth (<37 weeks) or SGA babies. Although it should be pointed out that 
the study groups were small and therefore this dataset was only able to detect large 
differences in pregnancy outcomes. 
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•	 < 32 weeks
•	 32-37 weeks
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Apgar at 5 minutes <7 2 1.9% 5 4.7% 0.445
Admission to NICU 4 3.7% 1 0.9% 0.369
Antibiotic use <6 weeks 18 16.8% 18 16.8% 1.000
Positive blood culture <6 weeks 0 - 1 0.9% 1.000
Abbreviations: DM = diabetes mellitus; SGA = small for gestational age; AGA= appropriate for gestational 
age; LGA= large for gestational age; NICU = neonatal intensive care unit. 
a P-value calculated using the Fisher’s exact test. 
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Little is known about the practical implementation and the efficiency of screening and 
treating policies for ASB to prevent adverse pregnancy outcomes in pregnant women 
generally and especially in pregnant women with DM or GDM. The strength of this 
study is that it gives insight to the practical implementation and the efficiency of the ac-
tual screening and treating policy for ASB, including low colony count GBS bacteriuria, 
in a developed country (Australia) for both women with and without DM.  





RR (95% CI) or 
P-value †
Antenatal ASB
GA at first urine result (weeks)
 
11.4±4.2 11.3±4.5 0.609
AB use < 2 weeks for “ASB screening”
Results first urine culture “ASB screening”
•	 ASB without GBS
•	 GBS ASB
•	 Culture-confirmed UTI (symptoms present)
•	 No significant growth 
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Abbreviations: DM = diabetes mellitus; AB = antibiotics; GA = gestational age; ASB = asymptomatic bacteriu-
ria; UTI = urinary tract infection; GBS = Group B Streptococcus; RR = relative risk; 95% CI = 95% confidence 
intervals. Definitions: ASB was defined as the growth of at least 105 cfu/ml of one or two organisms or any 
presence of group B Streptococcus at the first urine culture collected during pregnancy without complaints of 
a UTI; clinical UTI was defined as clinical diagnosis made by the treating physician; culture confirmed UTI was 
defined as clinical UTI in combination with a positive urine culture; positive culture was defined as growth of 
at least 105 cfu/ml of one or two organisms. † RR and 95% CI for binary variables, P-values calculated with 
Mann-Whitney test for continuous variables.
EIGHTDISCUSSION
According to national and international guideline recommendations, there seems to be 
an under-treatment of ASB in pregnant women in this dataset, in contrast with UTIs. In 
this study only for one in ten pregnant women with ASB was antibiotic treatment recor-
ded. A possible explanation for this low treatment rate could be the high percentage of 
GBS ASB. There are no formal recommendations for management of low colony count 
GBS bacteriuria during pregnancy; even though GBS bacteriuria may indicate heavy 
vaginal GBS colonization.17 In this study we did not find an association between GBS 
ASB and UTI. 
One of the limitations of the study was that only hospital-records and laboratory data-
base were available, while general practitioners could also have diagnosed and treated 
UTIs contemporaneously, which may not have been recorded in the hospital files. This 
may partly explain the reduced incidence of UTI in pregnant women with DM and GDM 
found in this study compared with earlier studies.16 In addition, all women with GBS 
bacteriuria at the time of first urine culture received antibiotic prophylaxis during birth. 
Therefore, it is not possible to make conclusions about the effect of GBS ASB in the 
postpartum period. 
Three earlier studies found either similar or increased percentages of ASB (including 
GBS ASB) in both pregnant women with DM (4.0%-24%) and pregnant women wit-
hout DM (4.6%-10.9%).16-18 Only Golan et al. showed an association between ASB and 
UTI in their prospective cohort study with monthly follow-up including repeating cultu-
res. Among the pregnant women with DM and ASB the incidence of UTI was 41.1% 
compared to 4.2% in those without ASB.16
Nevertheless, in general accurate up-to-date numbers of ASB and UTI in pregnant wo-
men including causing organisms are not available due to a variety of reasons. Practice 
treatment is often started immediately when typical dysuria complaints are present wit-
hout performing or awaiting for urine culture results. It may be difficult to distinguish 
between ‘real’ UTI and pregnancy related symptoms, especially in pregnant women. 
Pregnancy symptoms, such as frequency and abdominal pain, impede the differentia-
tion between ASB and UTI.2 In order to make a contribution to accurate numbers we 
separated culture confirmed UTI and clinical UTI. It must be noted that detailed infor-
mation on symptoms of UTI was often missing in the medical records. 
This study reveals that for more than 50% of the time when antibiotics for UTI were 
prescribed during pregnancy there was no documented information about a positive 
urine culture available within the health records. The Australian guidelines state that a 
urine culture is the golden standard for all suspected UTIs.23,24 Performing a culture be-
fore commencing treatment should prevent over-treatment by discriminating between 
‘real’ UTI and pregnancy symptoms. Recent studies have shown that maternal antibiotic 
use during pregnancy can be associated with adverse effects for the newborn.7,8 
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Our study demonstrated that pregnant women with DM or GDM do not have an incre-
ased risk for ASB or UTI, that the overall prevalence of ASB in pregnant with and wit-
hout DM or GDM was low and finally that GBS bacteriuria is common in both pregnant 
women with and without DM or GDM. This is essential background information for the 
discussion regarding ASB screening and treating policies for pregnant women currently 
in place in developed countries.
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To compare the prevalence of asymptomatic bacteriuria (ASB) and the incidence of 
urinary tract infection (UTI) in pregnant women with and without (gestational) diabetes 
mellitus ((G)DM). 
METHODS
We performed a cohort study in five hospitals and two midwifery clinics in the Nether-
lands. Pregnant women with and without (G)DM were screened for the presence of 
ASB around 12 and 32 weeks’ gestation. Characteristics of participants as well as out-
come data were collected from questionnaires and medical records. ASB was defined as 
the growth of at least 105 colony forming units/ml isolated from the urine of a woman 
without UTI complaints. UTI was considered to be present when a treating physician 
had diagnosed UTI and prescribed antibiotics. 
RESULTS
We studied 202 women with and 272 women without (G)DM. Of all women 31.7% 
with and 94.9% without and (G)DM provided a week 12 sample. The prevalence of 
ASB was comparable in women with and without (G)DM (12 weeks’ n=322; 4.7% and 
2.3%; relative risk (RR) 2.02; 95% confidence interval (CI) 0.52-7.84; 32 weeks’ n=422; 
3.2% and 3.0%; RR 1.06; 95% CI 0.36-3.09), as was the incidence of UTI (16.8% and 
12.9%; RR 1.31; 95% CI 0.85-2.02). Neither ASB nor UTI were associated with preterm 
birth or babies being small for gestational age.   
CONCLUSIONS
In pregnant women with and women without (G)DM, the overall prevalence of ASB 
was low. Neither ASB nor UTI did differ significantly between the groups. Our data dis-
courage a routine ASB screen and treat policy in pregnant women with (G)DM.
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Background
A significant number of bacteriuria cultured from the urine of a woman without 
symptoms of a urinary tract infection (UTI) is called asymptomatic bacteriuria (ASB).1,2 
In women with a normal pregnancy, the reported prevalence of ASB varies between 
2-10% with peaks up to 40%.2,3 
Associations between ASB and pregnancy complications, including symptomatic UTI 
and preterm birth, have been found in studies dating back to the sixties and seventies.4 
These studies led to the introduction of ASB screening, and subsequent treating (antibi-
otics) policies for pregnant women all over the world.5
A more recent meta-analysis of these studies showed a reduced incidence of pyelo-
nephritis (relative risk (RR) 0.23, 95% confidence interval (CI) 0.13 to 0.41) and low 
birthweight babies (RR 0.66, 95% CI 0.49 to 0.89) in pregnant women with ASB who 
were treated with antibiotics compared to those who were not treated with antibiotics. 
No differences were found in the incidence of preterm delivery.4 
Causal mechanisms explaining the relation between ASB or UTI and adverse pregnancy 
outcomes remain unresolved while more recent studies revealed adverse effects on the 
infant of maternal antibiotic use during pregnancy.6-9 The expanding knowledge on 
antenatal care and the changing epidemiology of pregnancy related conditions under-
score in our opinion the need for re-evaluation of existing screening policies for ASB in 
pregnant women. 
The prevalence of diabetes mellitus (DM) and gestational diabetes mellitus (GDM), 
thought to be risk indicators for both ASB and UTI, are increasing.10,11 In spite of this 
recent data on the prevalence of ASB, the incidence of UTI and the association of ASB 
with adverse pregnancy outcomes in pregnant women with and without DM or GDM 
not distorted by the presence of an ASB screening and treating policy in Western coun-
tries are limited.12-14 
Both limited evidence of the effectiveness of a screen and treat regimen as well as the 
Dutch restraint use of antibiotics, underlie the lack of a standard screen-and-treat policy 
for ASB during pregnancy in Dutch perinatal care.15 This situation provides a unique 
environment to test the principles behind these policies in Western countries.
The aim of this study was to investigate the prevalence of ASB and incidence of UTI, 
including causative organisms, in pregnant women with and without DM or GDM. 
Secondly, we intended to study the associations of ASB and UTI with maternal and 
neonatal outcomes in the Netherlands.
Material and methods
Study design and participants
We enrolled pregnant women with and without DM or GDM, receiving regular ante-
natal care in a prospective cohort study. The study was performed from June 2009 to 




Women were asked to submit a midstream urine sample during routine prenatal visits 
around 12 weeks’ gestation (range 9 to 20 weeks) and 32 week’s gestation (range 27 
to 38 weeks). At the same visit participating women were asked to fill out a question-
naire containing questions about their UTI history, current UTI complaints (e.g. burning 
sensation while urinating), ethnicity, sexual behaviour and antibiotic use.  Women were 
also asked to send urine samples using a dipslide and additional questionnaires by mail 
when experiencing UTI symptoms. Neither the women nor to the treating physicians 
were informed on the results of the urine culture. 
Demographic and clinical information with respect to diagnosis and treatment of UTI 
were obtained from questionnaires, hospital records and/or general practitioner (GP) re-
cords. Obstetric data were extracted from medical records up to six weeks after delivery. 
Exclusion criteria and ethics
Women who did not submit at least one urine for culture, had a positive urine culture 
in combination with UTI complaints at the time of inclusion, those who had a multiple 
pregnancy, pre-existing medical conditions with a known association with UTI except 
for pregnancy and DM or anatomical abnormalities of the urinary tract were excluded. 
Informed consent was attained. The Ethics committee of the UMCG approved the study 
and the boards of the other participating hospitals subsequently agreed with execution 
of the study. 
Laboratory
Urine samples were refrigerated between 4-7oC and transported to one of the three 
participating laboratories for medical microbiology.
Culture plates were examined daily for growth and interpreted as follow:
1. Negative was defined as no growth, growth less than 105 colony forming units per 
millilitre (cfu/mL), growth of non-uropathogens including skin flora or growth of 
mixed bacterial flora (more than 2 organisms); 
2. Positive was defined as the presence of one or two different uropathogens with a 
growth of at least 105 cfu/mL. 
Common uropathogens are Escherichia coli (E. coli), Proteus mirabilis, Klebsiella pneu-
moniae, Enterococcus species and Pseudomonas aeruginosa. Organisms that are nor-
mally found in and around external genitalia and are only rarely associated with infec-
tions (including lactobacilli, corynebacteria en coagulase negative staphylococci) were 
considered non-uropathogens and contaminants. 
Definitions
ASB was defined as a positive urine culture (the growth of at least 105 cfu/ml of one or 
two uropathogens) from a woman without complaints of a UTI. UTI was considered to 
be present when a treating physician had diagnosed urinary tract infection (UTI) and 
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prescribed antibiotics, as recorded in either a questionnaire or medical record (hospital, 
midwifery clinic or GP). Both DM (type 1 or type 2) and gestational DM (GDM) were 
clinical diagnosis made by the treating physicians. Women with DM or GDM during 
pregnancy were assigned to the diabetes group (from here: (G)DM). Preterm birth was 
defined as delivery before a gestational age of 37 weeks. Being small for gestational 
age (SGA) was defined as birth weight below the 10th percentile, appropriate for ge-
stational age (AGA) between the 10th and 90th percentiles and large for gestational age 
(LGA) above the 90th percentile.15 
Outcomes
The primary outcome was ASB at 12 and/or 32 weeks’ gestation. Secondary outcomes 
were the incidence of UTI, causative uropathogens, and the association between ASB, 
UTI and (G)DM. The following maternal and neonatal characteristics were assessed: 
use of prophylaxis or antibiotics two to four weeks before collection of the study urine 
samples, gestational age at delivery (categorised as <32, 32-36, 37-39 and ≥40 weeks’ 
gestation), preterm birth (<37 weeks), gender child, SGA, LGA, AGA, admission to 
neonatal intensive care unit independent of duration, five minute Apgar score less than 
seven and neonatal antibiotic use within the first six weeks of life. 
Statistics
Fisher’s exact test and the Mann-Whitney test were used to calculate differences in 
characteristics of the women and infants born from women with and without (G)DM. 
Relative risk (RR) and 95% confidence intervals (95% CI) were calculated to estimate 
differences in binary outcomes. The Mann-Whitney test was used to test differences for 
continuous outcomes. Regarding missing data for the primary and secondary endpoints 
complete case analyses per exposure were performed. Data were analysed using SPSS 
software for Windows, version 21.
Power analysis
The prevalence of ASB in non-pregnant women with DM has been reported around 
26%, versus 6% in women without DM.17 The prevalence of ASB in pregnant women 
is estimated around 5%, which is similar to that of non-pregnant women. However 
pregnant women will develop more often a UTI.3,5,11 To get reliable prevalence figures, 
we aimed to include 50 pregnant women with (G)DM and ASB therefore we needed to 
screen at least 200 pregnant women. With two groups of 200 women a difference of 
at least 12% in the incidence of UTI can be detected between women with and without 
(G)DM when the proportion pregnant women with a UTI is 10% to 20% (1-ß=0.80, 
2-sided =0.05, Fisher’s exact test). 
NINERESULTS
Results
Study population & general characteristics
From June 2010 until August 2012 a total of 528 pregnant women participated in the 
study, of whom 54 women were excluded for final analysis for several reasons including 
twin pregnancy, structural abnormality of the maternal urinary tract or loss to follow-up 
(see Figure 1). Leaving 474 pregnant women eligible for analysis; 202 women with and 
272 without (G)DM. 
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Figure 1. Flow-diagram Flowchart inclusion and exclusion women with and without (G)DM
528 pregnant women enrolled
232 pregnant women with (G)DM 296 pregnant women without (G)DM
30 pregnant women with (G)DM excluded
•	 8 No study urine culture available
•	 1 Positive urine culture plus complaints (UTI)  
•	 7 Twin pregnancy
•	 5 Urogenital disorder
•	 2 Lost to follow-up
•	 2 Immunocompromised
•	 2 Withdrawn 
•	 1 Termination of pregnancy
•	 2 Spontaneous abortion (<22 weeks)
24 pregnant women with (G)DM excluded
•	 6 No study urine culture available
•	 4 Urogenital disorder
•	 3 Lost to follow-up
•	 2 Immunocompromised
•	 5 Withdrawn 
•	 1 Aged <18 years at inclusion
•	 3 Spontaneous abortion (< 22 weeks)
202 pregnant women with (G)DM 272 pregnant women without (G)DM
Abbreviations: (G)DM =(gestational) diabetes mellitus; UTI = urinary tract infection
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Characteristics of both women with and without (G)DM and infants are presented in 
Table 1a and 1b. Caucasian women accounted for nearly two third of all women. All 
women without (G)DM were included through one of the two midwifery clinics and 
almost all women with (G)DM through both non-university and university hospitals. 
In more than 50% of both women with and without (G)DM at least one UTI was ever 
diagnosed during their lifetime. 
Women with (G)DM were on average two year older compared to women without 
(33.4 and 31.2 years, p=<0.001). Of all pregnant women with diabetes, two-third was 
diagnosed with GDM. The majority of women with (G)DM used insulin. Infants born 
from women with (G)DM were more often born before 40 weeks’ gestation and were 
more often LGA compared to those born from women without (G)DM. 
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For both women with and without DM the maximum number of missing values for any characteristic was 
7 except for ethnicity with a maximum number of missing values of 26. Abbreviations: UTI= urinary tract 
infection; (G)DM= (gestational) diabetes mellitus; NA = not applicable. a P-value calculated either with Fisher’s 
exact test or Mann-Whitney test. Figures are numbers and percentages; or mean and standard deviation.
NINERESULTS
ASB and UTI 
Since most women with GDM were diagnosed after 20 weeks’ gestation only 64 
(31.7%) women with DM collected a week 12 urine sample compared to 258 (94.9%) 
women without DM. Sixteen percent of all women who collected a week 12 urine sam-
ple  (n=322) did not collect a second urine sample around week 32. 
The overall prevalence of ASB was 2.8% (9/322) at week 12 and 3.1% (13/422) at 
week 32. No differences were found between women with and women without 
(G)DM at week 12 (n=322; 3 (4.7%) and 6 (2.3%); RR 2.02; 95% CI 0.52-7.84) and 
week 32 (n=422; 6 (3.2%) and 7 (3.0%); RR 1.06; 95% CI 0.36-3.09). E. coli was 
the most common causative organism of ASB at 12 (66.7%) and 32 weeks’ gestation 
(38.5%). Of all women who collected a week 12 urine sample 4.0% (13/322) and of 
all women who collected a week 32 sample 2.1% (9/422) were known to have used 
antibiotics in the four weeks prior to the day of urine collection. 
The overall incidence of UTI was 14.6% (69/474). No differences were found between 
women with and women without (G)DM (34 (16.8%) and 35 (12.9%); RR 1.31; 95% 
CI 0.85-2.02).
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•	 < 32 weeks
•	 32-37 weeks
•	 37-40 weeks


















Apgar at 5 minutes <7 10 5.0% 10 3.7% 0.499
Admission to NICU 6 3.1% 10 3.8% 0.799
Antibiotic use <6 weeks 20 10.6% 23 8.5% 0.521
For both women with and without DM the maximum number of missing values for any characteristic was 14. 
Abbreviations: (G)DM = (gestational) diabetes mellitus; SGA = small for gestational age; AGA= appropriate 
for gestational age; LGA= large for gestational age; NICU = neonatal intensive care unit. a P-value calcula-
ted using the Fisher’s exact test or Mann-Whitney test. Figures are numbers and percentages; or mean and 
standard deviation.
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Similar results were found when repeating the analysis only including women with 
GDM compared with women without DM (data not shown). 
In two women ASB was diagnosed in both the week 12 and week 32 urine sample. In 
four (20.0%) out of the 20 women with ASB at 12 and/or 32 weeks’ gestation a UTI 
was diagnosed by the treating physician during pregnancy. In three women the UTI was 
already diagnosed and treated with antibiotics before ASB was diagnosed in the urine 
sample collected for this study.  
We received 16 urine samples (urine dipslides) by post of 15 women suffering from UTI 
symptoms. Four of these 16 (25%) were positive, confirming the diagnosis.  
In women with a history of one or more UTIs during her life (n=285) compared to those 
without a history of UTI (n=177) a lower prevalence of ASB (6 (2.1%) and 13 (7.3%); 
RR 0.29; 95% CI 0.11-0.74) and higher incidence of UTI (56 (19.6%) and 12 (6.8%); 
RR 2.90; 95% CI 1.60-5.25) was found. Detailed information concerning ASB and UTI 
is provided in Table 2. 
Table 2. Prevalence of ASB and incidence of UTI in women with and women without (G)DMa
Week 12 With (G)DM Without (G)DM RR (95% CI) or 
P-value †Number of samples N=64 N=258
























Week 32 With (G)DM Without (G)DM RR (95% CI) or 
P-value †Number of samples N=64 N=258

























Number of women with a 






≥1 UTI diagnosed 34 16.8% 35 12.9% 1.31 (0.85-2.02)
Abbreviations: (G)DM =(gestational) diabetes mellitus; ASB = asymptomatic bacteriuria; UTI = urinary tract 
infection; GBS = Group B Streptococcus; RR = relative risk; 95% CI = 95% confidence intervals. a Figures are 
numbers and percentages; or mean and standard deviation. b RR and 95% CI for binary variables, p-values 
calculated with Mann-Whitney test for continuous variables.
NINEDISCUSSION
Pregnancy outcomes in women with ASB or UTI 
No differences were found in adverse pregnancy or neonatal outcomes between preg-
nant women with (20) and without ASB (454) including preterm birth (10.0% and 
7.7% RR 1.30 95% CI 0.34 to 5.02) and SGA (5.0% and 5.3%; RR 0.91 95%; CI 0.13 
to 6.36). Neither were there differences between women with (n=69) and women wit-
hout at least one UTI during pregnancy (n=405) with respect to preterm birth (8.7% 
and 7.7% RR 1.14 95% CI 0.49 to 2.62) and SGA (7.2% and 4.9%; RR 1.49; 95% CI 
0.58 to 3.83). 
Discussion
The overall prevalence of ASB found in Dutch women was low in both the first (around 
12 weeks’ gestation) and third trimester of pregnancy (around 32 weeks’ gestation). 
The results of our study support the recommendation of the current Dutch guidelines 
not to screen and treat for ASB in pregnant women.15 Since the found prevalence of 
ASB and incidence of UTI was not increased in pregnant women with (G)DM, we dis-
courage a targeted ASB screen and treat policy in those women. Also, no associations 
were found between women with ASB or UTI and adverse pregnancy outcomes inclu-
ding preterm birth and SGA. 
The strengths of this study are the prospective design and the completeness of follow-
up till six weeks after delivery. Therefore this study provides essential up-to-date back-
ground information for ASB screening and treatment policies in pregnant women with 
and without DM or GDM. A limitation is that only a limited number of women with (G)
DM collected a week 12 urine sample, thus generating a lack of precision in the esti-
mate of prevalences. The largest part of women with diabetes (nearly 2/3) had GDM 
and GDM is often diagnosed in the second trimester. However, including only women 
with GDM and not women with DM in the analyses did not change the results.
The prevalence of ASB in both women with (4.7% week 12 and 3.2% week 32) and 
without (G)DM (2.3% week 12 and 3.0% week 32) found in our study was lower than 
expected, especially in pregnant women with DM. Other studies reported ASB prevalen-
ces between 4.0%-18% in pregnant women with and 4.6%-8.2% without DM and/or 
GDM.12-14 Rizk et al. found comparable prevalences in pregnant with and without GDM 
using a similar definition of ASB as we did.14 Golan et al. provided a limited definition of 
ASB and did not describe how mixed growth was handled.12 The retrospective design, 
which is often accompanied by reporting bias and exclusion of women with mixed cul-
tures, may explain the higher ASB prevalence found by Alvarez and colleague.13
145
146
NINE PRABUTI NETHERLANDS: ASB & UTI IN PREGNANT WOMEN WITH & WITHOUT DM
As our study, these previous studies did not find significant associations between ASB 
or symptomatic UTI and preterm birth or SGA, albeit all women with ASB in these previ-
ous studies received antibiotic treatment.12-14 ASB screening and treatment programmes 
were introduced in order to prevent adverse pregnancy outcomes.5 Recent studies have 
shown that maternal antibiotic use during pregnancy can be associated with adverse 
effects for the infant.7-9 These data warn caution for a low threshold to use antibiotics 
in pregnancy. 
UTI is known to be one of the most common diagnoses during pregnancy.18,19 The inci-
dence of UTI during pregnancy in our study (14.6%) is comparable or higher than the 
incidence in pregnant women reported in earlier studies and increased in comparison 
to the incidence reported in non-pregnant women.18,20,21 A weakness of our study is 
that UTI diagnoses were made by treating physicians and were mostly not confirmed 
by objective laboratory measurements. Treating physicians may be biased in diagnosing 
UTIs by common knowledge of increased incidence during pregnancy. This may lead to 
over-diagnosing UTI and an overestimated incidence in our study. This may also explain 
why a history of UTI was associated was increased incidence of UTI during pregnancy 
but a decreased prevalence of ASB. UTI history may decrease the threshold to report 
symptoms or diagnose and treat a new infection. Still, a history of UTI might be a more 
important risk factor for UTI during pregnancy than ASB. This is in line with a recent 
study by Cai et al. in young women, which even suggested that ASB may have a pro-
tective role and prevent (recurrent) UTI.22 
Analyses of data obtained by our questionnaires showed that UTI like symptoms such 
as frequency and lower abdominal pain are common in pregnant women. These preg-
nancy-associated complaints can be mistaken for UTI symptoms. Currently most preg-
nant women receive antibiotic treatment for symptoms mimicking UTI without a confir-
mative urine culture thus generating overtreatment possibly leading to overtreatment. 
Symptoms alone may therefore not be sensitive enough to diagnose UTI in pregnant 
women. This is illustrated by our finding that only 25% of the women with symptoms 
of a UTI who sent a dipslide had a positive urine culture result.
The common used criterion of growth of at least 105 cfu/mL of one or two microorga-
nisms implies that the diagnosis of ASB is straightforward. However for symptomatic 
UTI, lower colony counts (≥103 cfu/mL) sufficient proof of infection. The clinical rele-
vance of asymptomatic lower colony count group B Streptococcus (GBS) bacteriuria 
is investigated.23 In an earlier study we showed that urine samples of pregnant wo-
men are often contaminated with skin flora (>80%) possibly resulting in mixed growth 
(>2 microorganisms).24 Interpretation of mixed growth or low colony count is difficult 
for both clinical practice and research purposes and is possibly resulting in under- or 
over-diagnoses (and treatment) of ASB. To properly investigate the need for an ASB 
screening and treatment programme a clear definition of ASB and reproducible diag-
nostic method is insurmountable. 
NINEDISCUSSION
Before a screen policy is implemented several criteria must be met. The problem (pre-
valence of ASB) and consequences (poor pregnancy and neonatal outcomes) need to 
be substantial, the disease requires to be well defined, a specific and sensitive test to 
identify those at risk and an adequate strategy to prevent this risk should be present.25 
Most importantly, our study showed that the prevalence of ASB is low in both women 
with and without (G)DM and that ASB is not associated with poor pregnancy and neo-
natal outcomes. Moreover our questionnaire data and urine culture results revealed 
once again that diagnosing and defining ASB is complicated. Finally recent literature 
described that antibiotic treatment, the proposed strategy to prevent possible adverse 
effects of ASB, may have consequences for both the mother and the infant itself.  
In summary, in pregnant women with and women without (G)DM, the overall preva-
lence of ASB was low. Neither ASB nor UTI did differ significantly between the groups. 
Our data discourage a routine screen and treat policy in pregnant women with (G)DM.
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Background of screening policies: Wilson and Jungner criteria
Screening is a valuable tool and may lead to early detection and treatment of disease, 
preventing subsequent disease and disease related sequelae. Unfortunately screening, 
like any other treatment, has the potential to do harm. Therefore, the evaluation of a 
screening programme is a delicate process weighing desirable and undesirable conse-
quences.1,2 
The Wilson and Jungner criteria were published almost 50 years ago in a report en-
titled ‘Principles and practice of screening for disease’.1 To date these criteria are still 
valuable landmarks for the decision making process to select and introduce an effective 
screening programme. 
Preventing disease and subsequent complications in a newborn with a future life is 
possibly one of the highest attainable goals in public health. Preterm birth (< 37 weeks’ 
gestation) is the pre-eminent cause of perinatal mortality and morbidity in developed 
countries.3 During the past decades several attempts have been made to reduce pre-
term birth with the use of screening (& treatment) programmes such as screening of 
cervical length and infectious diseases.4,5
Colonization and related infections of the urinary tract have explicitly been identified 
as one of the risk factors for preterm birth with potential lifelong sequelae.3,6  Asymp-
tomatic bacteriuria (presence of bacteria in urine without symptoms of a urinary tract 
infection) was considered the pre-clinical and possibly also pre-pathological stage of 
symptomatic urinary tract infections including pyelonephritis.3,6 However this assump-
tion is now being questioned. 
Around the same time as the landmark publication describing the Wilson and Jungner 
criteria ASB screening programmes were considered and introduced in developed coun-
tries to prevent pyelonephritis and/or preterm birth.
In this thesis a number of aspects related to ASB and UTI have been investigated in three 
patient groups; women with diabetes mellitus (DM), pregnant women and pregnant 
women with DM. The experiences gained while performing the studies in combination 
with the results found formed the foundation for the main question of this discussion: 
is screening for ASB during pregnancy to prevent pyelonephritis and preterm birth desi-






Figure 1. The Wilson and Jungner criteria discussed1,2
The condition
For the purpose of this discussion the two following criteria are combined: 
The condition sought should be an important health problem (1) and the na-
tural history of the condition, including development from latent to declared 
disease, should be adequately understood (2)
The condition we seek to prevent is preterm birth, which potentially caused by coloni-
zation and/or infections of the urinary tract during pregnancy.3 ASB was considered the 
latent stage, UTI the early symptomatic stage and pyelonephritis the late complicated 
stage of disease.6-10 This assumption is reconsidered as described above. The hypothesis 
is that by screening and treating for ASB during pregnancy primarily the risk for develo-
ping pyelonephritis is reduced and subsequently the risk for preterm birth.7,9-11 However, 
both the importance and the natural history of colonization and subsequent infections 
of the urinary tract and/or preterm birth are ambiguous. 
Preterm birth
The exact etiology of preterm birth is poorly understood and thought to be the result 
of a combination of physiopathological, genetic and environmental factors.3 To the 
best of our knowledge, there is no experimental evidence supporting the direct relation 
between colonization of the urinary tract and preterm birth. It has been hypothesized 
that certain bacterial products including endotoxins and/or phospholipases influence 
the synthesis of prostaglandins, important mediators of uterine activity.12
DISCUSSION
The condition
1. The condition sought should be an important health problem
2. The natural history of the condition should be adequately understood
3. There should be recognisable latent or early symptomatic stage
The treatment and test
4.  There should be an accepted treatment for patients with recognized disease
5. There should be an agreed policy on whom to treat as patients
6. There should be a suitable test
7. The test should be acceptable to the population
8. Facilities for diagnosis and treatment should be available
The costs
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed) should 
be economically balanced in relation to possible expenditure on medical care as a whole
The screening programme
10. Case-finding should be a continuing process and not a “once and for all” project
11. There should be a defined target population (revised)
12. There should be scientific evidence of screening programme effectiveness (revised)
13. The overall benefits of screening should outweigh the harm (revised) 
TENTHE CONDITION
Asymptomatic bacteriuria, pyelonephritis & preterm birth
In pregnant women ASB prevalence between 2% and 10% have been reported.13,14 
Pregnant women are more prone to develop ascending UTI because up to 90% of 
pregnant women develop dilatation of the renal system in combination with decreased 
peristalsis of the ureters and bladder facilitating bacterial colonisation and ascending 
infection in pregnancy.15 Studies from the 60s, 70s and 80s show that around 30% to 
40% of pregnant women with untreated ASB developed pyelonephritis compared to 
less than 2% of those without ASB.8,14,16-18 The consequences of not treating ASB on 
preterm birth are less well established.7 
A meta-analysis of 11 randomized or quasi-randomised control trials showed that the 
incidence of pyelonephritis was reduced in pregnant women with ASB who were trea-
ted with antibiotics compared to those who were not treated with antibiotics (relative 
risk (RR) 0.23, 95% confidence intervals (CI) 0.13 to 0.41) and that treatment of ASB 
with antibiotics was associated with reduced incidence of low birthweight babies (RR 
0.66, 95%-CI 0.49 to 0.89).7 However, no differences were found in preterm birth. 
The authors concluded that the overall quality of the studies were poor.7 Moreover 
most trials were performed more than 25 years ago, before the widespread use of the 
ultrasound to measure the duration of pregnancy.19 Therefore, more timely studies are 
urgently needed. 
Two of our studies (‘Pregnancy, ASB & UTI’ (PRABUTI) study Netherlands and PRABUTI 
Australia) described in chapter 8 and 9 provide up-to-date numbers on the prevalence 
ASB in pregnant women in two developed countries. The found that prevalence of 
ASB in pregnant women with and without diabetes mellitus varied between 4.7% and 
2.3% in the Netherlands (no ASB screening programme in place) and 5.6% and 3.7% 
in Australia (ASB screening programme in place). In the PRABUTI study performed in the 
Netherlands no association was found between ASB and UTI including pyelonephritis 
or adverse pregnancy outcomes even though women with ASB were not treated. Study 
urine culture results were kept anonymised since currently screening for ASB is not part 
of standard care in the Netherlands. It has been noted that the number of ASB cases 
was limited and the study sample small, therefore, only able to detect large differences. 
The results of the ‘ASB screen and treat’ study described in chapter 7will be available 
in the near future. For this prospective cohort study more than 5,000 pregnant women 
were screened for ASB in the Netherlands. For the ASB treat study ASB positive women 
were randomised for treatment with nitrofurantoin or placebo. This study will provide 
important up-to-date data on the prevalence of ASB, association with pyelonephritis 
and/or preterm birth and the effectiveness of an ASB screening and treatment pro-
gramme in pregnant women to prevent pyelonephritis and/or preterm birth. 
Urinary tract infection & preterm birth
Accurate data to estimate the incidence of UTI in pregnant women are missing. Studies 
report an UTI incidence varying around 2% (culture confirmed UTI) to 15% (ICD episo-
des collected by a health maintenance organization).9,20,21 The lack of information on 
incidence of UTI during pregnancy was one of the reasons to perform both PRABUTI 
studies (described in chapter 8 and 9) showing an incidence of UTI between 4.7% in 
pregnant women with and 11.2% in women without DM in Australia (definition based 




without DM in Netherlands (definition based on antibiotic prescription).
Our studies revealed possible reasons why accurate data on UTI incidence are missing. 
Some symptoms of UTI such as urgency and frequency are also common pregnancy 
complaints, which can make it more difficult to recognize a UTI and to distinguish 
between ASB and a symptomatic UTI. Additionally, treatment of a UTI is often com-
menced based on symptoms before proper diagnostics are performed, distorting the 
‘true’ incidence of UTI. In the PRABUTI study performed in Australia a lower incidence 
of culture confirmed UTI was found compared to the incidence of clinical UTI; 2.8% in 
women with and 3.7% in women without DM. 
In both PRABUTI studies no association was found between UTI and preterm birth. 
Another larger retrospective population based study from Israel showed that a UTI (po-
sitive urine culture in a woman with symptoms of dysuria, urgency and frequency) 
during pregnancy is independently associated with preterm birth (15.1% vs. 7.8%).9
Pyleonephritis & preterm birth
Pyelonephritis was estimated to occur in 2% of pregnancies with a recurrence rate up 
to 23% within the same pregnancy or soon after birth.22,23 Recent studies showed that 
the incidence of antepartum pyelonephritis, often defined as a hospital admission for a 
UTI, has decreased in developed countries, now estimating an incidence of antepartum 
pyelonephritis between 0.07% and 0.5%.10,24 
The reduction may have various reasons including the introduction of ASB screening 
programmes and/or improved antenatal care. These recent studies concluded once 
more that antenatal pyelonephritis is associated with preterm birth (10.3%-20% ver-
sus. 7.8%-7.9%).10,24 
However, the percentage of preterm births directly attributable to pyelonephritis (the 
number, which can be prevented when the incidence of antenatal pyelonephritis is 
reduced to zero) is uncertain since both conditions (pyelonephritis and preterm birth) 
have overlapping risk factors and possibly even a common cause.25
In conclusion, we can discuss whether the presence of ASB and the development of 
UTI in pregnant women is an important health problem; nonetheless, many questions 
concerning the natural history of the condition, including development from latent to 
declared disease (pyelonephritis and/or preterm birth), remain and are not adequately 
understood.
There should be a recognizable latent or early symptomatic stage (3)
ASB when considered as latent stage and UTI as an early symptomatic stage, are both 
recognizable conditions that may be associated with an increased risk of adverse preg-
nancy outcomes. However, ASB is an asymptomatic stage and not necessarily a latent 
stage since only a small percentage of pregnant women with ASB develop one of the 
associated diseases; symptomatic lower UTI, pyelonephritis and/or preterm birth.7,26,27 
Moreover, most of the pregnant women who developed a symptomatic UTI did not 
suffer from bacteriuria at the moment of screening (often performed in the first half of 
pregnancy).26,27 In an old study by Lawson and Miller they reported that only 19.1% of 
pregnant women who developed symptomatic urinary tract infection had bacteriuria 
DISCUSSION
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on initial screening.26 In our retrospective PRABUTI study performed in Australia none 
of the pregnant women who developed UTI had bacteriuria on initial screening. In our 
prospective study performed in the Netherlands only one of the 20 women who had 
either positive week 12 or week 32 samples developed a UTI during pregnancy.
Another key issue while discussing the value of this criterion is that ASB is not a per-
manent stage since ASB can dissolve spontaneously. Long-term follow-up studies of 
untreated ASB are mainly performed in non-pregnant patients with DM. A study with 
an 18 months follow-up period showed an increased incidence of UTI in women with 
type 2 DM and ASB compared to those without ASB at baseline (34% vs. 19%) and 
comparable incidence of UTI in women with type 1 DM and ASB compared to those 
without DM (12% vs.15%).28 Even though an increased incidence of symptomatic UTI 
in women with ASB was found, still only one third of the women with ASB developed a 
symptomatic UTI. Moreover, a study by Nicolle and colleagues demonstrated that many 
women have intermittent ASB, either spontaneously or due to antibiotic treatment.29
Most of these (long) term ASB follow-up studies were performed in non-pregnant wo-
men, and thereby the duration of a pregnancy is limited. In our prospective study (PRA-
BUTI Netherlands) pregnant women with and without DM provided a urine sample at 
12 and 32 weeks’ gestation. Only two out of 12 women (who collected two samples) 
had a positive urine culture result at 12 and 32 weeks’ gestation. An old study from Go-
wer et al. reported that of the 164 women who had bacteriuria during pregnancy, six to 
twelve months after pregnancy a quarter of these women still suffered from bacteriuria 
independently of antibiotic treatment.30 
The changeable nature of the presence of bacteriuria makes it difficult to determine 
when pregnant women should be screened for ASB. In most countries screening takes 
place early in pregnancy.13 For a study by Stenqvist et al. they screened 3,254 pregnant 
women at each prenatal visit (minimal three visits) showing that the risk of bacteriuria 
increased from 0.8% at 12 weeks’ gestation to 1.93% at the end of pregnancy. They 
recommend screening for ASB around the 16th week of pregnancy.31 McIsaac et al.  sho-
wed that a urine culture before 20 weeks’ gestation only detected half of the ASB cases 
of all cases identified with three urine cultures: at fewer than 20 weeks’, at 28 weeks 
and 36 weeks’ gestation.32 This study did not assess the association between one, two 
or three urine cultures and pyelonephritis or preterm birth. 
The varying course of ASB in combination with the limited evidence for associations 
with negative long-term effects support the hypothesis that ASB is more likely a com-
mensalism state than a disease. It is not clear whether a recognizable latent or early 
symptomatic stage for pyelonephritis or preterm birth is present.
The treatment
There should be an accepted treatment for patients with recognized disease (4)
Currently the most common way to treat both asymptomatic colonization (ASB) and 
symptomatic infections (UTI and pyelonephritis) of the urinary tract are antibiotics. The 
ability of antibiotics to restrain the growth or kill microorganisms causing infections 




urine together with the sensitivity of the organisms to that antibiotic.33,34 
Although a Cochrane meta-analysis showed that antibiotic treatment of ASB compared 
to no treatment (placebo) reduced the incidence of pyelonephritis with a reduction va-
rying between 1%-4% to 20-35%.7,13 Treatment of ASB with antibiotics did not led to 
reduction in preterm birth. Moreover treatment of ASB with antibiotics does not always 
lead to a disease free interval, in this case pregnancy due to relapse or recurrence of 
ASB.29,30 
A present issue that may have an effect on antibiotic treatment of ASB and prevention 
of other infectious diseases including clinical UTIs is the increasing prevalence of antimi-
crobial resistance.35 Antibiotics can only reduce the presence of microorganisms when 
the present microorganism is sensitive to the given antibiotic.33,34 Screening for ASB and 
subsequent treatment with antibiotics may cause an increase of the use of antibiotics, 
especially if the number needing treatment is high. This again may subsequently under-
mine the effectiveness of the screening programme because one of the main causes of 
antimicrobial resistance is the overuse of antibiotics.
But what should a clinician prescribe when ASB is present? A Cochrane review ad-
dressing antibiotic regimens for treatment of ASB in pregnancy could not draw any 
definite conclusion based on the five included studies.36 Another Cochrane review on 
the duration of treatment of ASB during pregnancy analysing 13 studies could only con-
clude that a single-dose treatment of antibiotics may be less effective than a seven-day 
treatement. However, a single-dose regimen was associated with less side-effects. The 
authors note that the overall quality of included trials was low.37 
So far we are only talking about antibiotics and not about an optimal and acceptable 
treatment of ASB in pregnant women. Many other interventions have been proposed 
to treat bacteriuria including cranberry products, probiotics and behavioural interventi-
ons.38 Firstly, not all antibiotics may be safe to use during (certain stages of) pregnancy. 
Secondly, antibiotics may cause several side-effects such as gastro-intestinal symptoms 
and vaginal candidiasis.38,39
Another important factor to consider that may possibly influence the adherence and 
therewith the acceptability to either pharmacological or non-pharmacological interven-
tions is the presence of nausea and vomiting, common in pregnancy due to physiologic 
changes in pregnancy.40 Only a limited number studies investigating the effectiveness 
of alternative interventions have been performed. 
We performed a Cochrane review entitled interventions for preventing recurrent urinary 
tract infections during pregnancy. Only one trial was identified comparing a daily dose 
of nitrofurantoin and close surveillance with close surveillance alone not showing an 
effect of the additional nitrofurantoin (see chapter 6). This review reveals that close 
surveillance may be a way to prevent recurrent UTI.  
One of the possible non-pharmacological interventions is cranberry products.41 So far 
little evidence of the effect and side-effects of cranberry products during pregnancy are 
known. A meta-analysis of studies in non-pregnant women showed that cranberries 
are effective in reducing urinary tract infection recurrence (2 trials, sample size 250, 
RR 0.53, 95% CI 0.33-0.83).41 And currently a Cochrane review is being performed 
to determine the role of cranberries in the treatment of ASB in pregnant women.42 A 
recent study investigated the safety of cranberry product use during pregnancy using 
the Norwegian Mother and Child cohort including more than 100,000 pregnancies. No 
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increased risk for malformations and other adverse pregnancy outcomes were found.43 
Randomised control trials comparing different pharmacological and non-pharmacologi-
cal interventions are necessary to investigate potentially affective interventions to treat 
ASB in pregnant women. Moreover, the acceptability of different interventions, inclu-
ding willingness of pregnant women to use the intervention during pregnancy should 
be investigated. 
In conclusion, at this moment it is uncertain if we can consider antibiotics as the ac-
cepted treatment for ASB in pregnant women seeing the recent studies on adverse 
events related to antibiotic use during pregnancy and the limited data on alternative 
treatments. 
There should be an agreed policy on whom to treat as patients (5)
The distinction between significant (disease) and insignificant colonisation (not related 
with symptoms or adverse events) of the urinary tract often is not clear-cut. Physiologi-
cal variables tend to distribute around the mean and result in a normal curve.1 People 
with the disease represent the extreme end of the curve. The border-line group, presen-
ted by the area under the curve in between the pregnant women without the disease 
and with the disease (right tail of the curve) may be larger due to the bell-curved shape. 
The variety of definitions and diagnostic criteria used for ASB underscore that it is not 
clear whom to treat as patients and whom not to. A urine culture is the gold standard 
used to diagnose bacteriuria. Growth of 105 colony forming units (cfu)/ml of one (or 
maximum two) uropathogens is a commonly used definition.6,13 Some argue that two 
consecutive urine cultures are desirable, but the interval between the two urine cultu-
res is not clearly defined. In (pregnant) women with complaints of symptomatic UTI, a 
growth of 103 cfu/mL is considered clinically relevant and considered ‘disease’. A similar 
cut-off point for asymptomatic Group B Streptococcus (GBS) bacteriuria is often used 
since treatment may be beneficial.44 
Furthermore, it is not clear which microorganisms are considered as uropathogens and 
which as contaminants in ASB. This probably explains why studies report a wide range 
of ASB prevalence up to 40%. The most common organism associated with bacteriuria 
is Escherichia coli. Examples of microorganisms alternately defined as uropathogen are 
coagulase negative staphylococci (CNS) and Acinobacter spp.45 
Summarizing, currently it is not certain whom to treat as a patient and whom not to, 
meaning this criteria is not met. Before introducing a screening and treatment pro-
gramme a clear definition with clinical relevance should be identified. An internationally 
used definition of ASB would be a possible way to make data on ASB more comparable 
which may facilitate a more evidence based decision as to if an ASB screening pro-
gramme is needed in pregnant women. 
To be able to draft a clinically relevant definition of ASB, we mean that investigating the 
risk for adverse pregnancy outcomes related to different cut-off points for the definition 
of a positive urine culture, including lower cut-off points (e.g ≥ 103 cfu/mL) is desirable. 
Since at present in most developed countries an ASB screening and treatment policy 




between untreated ASB and adverse pregnancy outcomes. However, the association 
between low-colony count bacteria and adverse pregnancy outcomes can be investiga-
ted since in most countries only a growth of ≥105 cfu/mL is considered clinically relevant 
and therefore treated.
The test used in screening 
Two criteria combined; there should be a suitable test or examination (6) and 
the test should be acceptable to the population (7)
A urine culture is considered the gold standard for diagnosing bacteriuria.33 The big-
gest challenge related to the diagnosis of ASB (and UTI) is differentiating between true 
bacteriuria and contamination.14 Schnarr et al. wrote the following: ‘The original crite-
rion for diagnosing ASB was ≥105 cfu/mL of a single uropathogen in two consecutive 
samples with a 95% probability that the woman has true bacteriuria. The detection 
of ≥105 cfu/mL in a single voided midstream urine is accepted as a more practical and 
adequate alternative although there is only an 80% probability the woman has true 
bacteriuria’.14 
But does ‘true’ bacteriuria exist and is it possible to distinguish ‘true’ bacteriuria from 
contamination? Urine itself is considered to be sterile (when bacteriuria is not present) 
conversely; the urethra (the tube that drains urine from the bladder) and the vaginal 
and perineal skin surrounding the urethra are known to be colonized with a motley 
crew of commensal bacteria.45 These bacteria are often considered as non-pathogens, 
bacteria that do not cause infection or disease, however when these bacteria are in-
troduced in a different environment like the bladder (via the urethra) they can become 
pathogens (uropathogens). Especially in women, who have a short urethra compared 
to men, bacteria present on the vaginal and perineal skin can easily enter and colonize 
the urinary tract.45
The term bacteriuria implies that it includes all bacteria found in urine (sample). Ideally 
the term bacteriuria should be used to refer to bacteria cultured in a urine sample that 
originate from the urinary tract including bladder and kidneys. A possible way to im-
prove the validity (the ability to separate those with disease from those without disease) 
of a urine culture is a proper urine sample. It was hypothesized that more elaborate 
sampling methods such as midstream clean-catch urine sample and collection of the 
first concentrated urine sample in the morning help minimizing contamination compa-
red to midstream sample. However, in our study we found comparable contamination 
rates after using all three sample collection methods (chapter 5).
Moreover, a high prevalence of clinically irrelevant quantities of contamination (>80% 
contained skin flora) was found by analysing urine samples using both Gram stain or 
urine culture to analyse samples. When the bacteria (skin flora) normally defined as 
contaminants may overgrowth a possible present uropathogen it might become more 
difficult to distinguish between ‘true’ bacteriuria and contamination. This may happen 
when the urine for example was not examined in a timely fashion or refrigerated.
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Other urine sample techniques that could possibly reduce contamination, which in ge-
neral are not considered acceptable, are urine collection after catheterization or blad-
der puncture.45,46 With these methods the vaginal and genital skin full of skin flora are 
by-passed minimizing contamination with skin flora, though both methods are less 
comfortable for women and may introduce bacteria in the bladder. In general when, a 
test used for a screening programme is less accepted by the population, the uptake of 
the screening programme is lower.1 
Finally, performing a urine culture is more expensive and demands more manpower 
than rapid dipstick tests, which are often used in more resource-poor settings. A dip-
stick test contains several pads of reagents for detecting the presence of leucocytes 
and/or nitrite, which react (change colour) when brought into contact with urine.45 The 
downside of dipsticks for diagnosing ASB is the poor positive and especially negative 
predictive value possibly leading to over-treatment and under-treatment.1,36,47 Magnini 
and colleagues found a positive likelihood ratio for detecting ASB in pregnant women 
with a dipstick (positive result defined as nitrites or leukocyte esterase or both) of only 
6.95 (95% CI 5.80 – 8.33) and a negative likelihood ratio of 0.50 (95% CI 0.54-0.57).47 
The issues around the collection of ‘suitable’ urine sample (read no contamination) 
required for unambiguous urine culture results make it especially uncertain whether a 
suitable test which is acceptable to the population is available.
Facilities for diagnosis and treatment should be available (8)
General prerequisites for a diagnostic programme are the presence of a convenient 
moment to perform the test. The test must be easy to perform, cheap and providing an 
easy to read and clear answer with unequivocal consequences for follow-up. 
Numerous screening programmes are in place for pregnant women including infectious 
diseases such as human immunodeficiency virus (HIV), hepatitis B virus and Treponema 
pallidum.5 Most screening tests are performed around 12 weeks gestation, a suitable 
environmental opportunity for introducing an additional screening.5 
As partly described in the preceding paragraph here are several methods to diagnose 
bacteriuria. The most common tests used in screening programmes are a urine culture 
and in more poor resource settings a rapid dipstick test.  A urine culture is a basic diag-
nostic test most likely available at all microbiology laboratories in the Netherlands. As 
an initial screening test a dipstick test is easier to perform and can be performed by the 
treating gynaecologists, midwife or even assistant during an antenatal care visit. 
A possible obstacle to overcome is that it takes time to inform women about the be-
nefits and possible consequences of ASB screening and this time needs to be reserved 
during one of the already planned antenatal visits. 
Moreover performing a urine culture is elaborate. Based on the experiences gained 
while performing the PRABUTI and the CUP study (described in chapter 5, 8 and 9) the 
collection of a proper urine sample needed for a urine culture is possibly going to be 
the biggest challenge. Even though pregnant women more often have to pee, peeing 
on demand is not always possible for every woman, especially since a midstream urine 
sample is desirable.  An alternative option is allowing women bring a urine sample from 
home, risking improper (not in the fridge, unsterile cup) storage of the sample between 




urine test (overgrowth of contaminants). 
The development of new technologies to make the process including urine collection 
more user-friendly would be worthwhile when considering the introduction of a ASB 
screening programme. Currently the UriSwab sponge impregnated with boric acid 
being is investigated.48 The boric acid preserves the urine which makes it possible to use 
normal mail to transport the urine sample to the intended laboratory.  
Follow-up and treatment of pregnant women with positive urine tests can be perfor-
med by the GP or the gynaecologist. Midwifes are not certified to prescribe antibiotics 
in the Netherlands. In the Netherlands, UTI is the most frequent reason for a GP visit 
during pregnancy.49 Therefore, training and guiding GPs in the treatment of ASB in 
pregnant women will be fairly straightforward. Altogether, it seems that facilities for 
diagnosis and treatment for this disease are available.
The costs
The cost of case-finding (including diagnosis and treatment of patients diag-
nosed) should be economically balanced in relation to possible expenditure on 
medical care as a whole (9)
Preterm birth is extremely costly due to increased maternal and neonatal admissions 
and will almost always outweigh the costs of a screening programme like ASB screening 
even with a high number of patients to treat as long as effectiveness of the programme 
has been shown.50 Studies showed that the cumulative costs for children born preterm 
during the first 10 years of life doubled compared those who are born term.51 
Not only preterm birth but also pyelonephritis in pregnant women is costly since a hos-
pital admission is often needed. Rouse and colleagues concluded based on an analytic 
decision model that screening for ASB to (only) prevent pyelonephritis with either a 
urine culture or a leukocyte esterase-nitrite dipstick is cost-effective when the preva-
lence of ASB is 6% of higher.52 
An economic evaluation using the ASB-study (chapter 7) screen and treat data will be 
performed in the near future to evaluate if the costs of screening outweigh the reduc-
tion in costs and health benefits.
However mainly due to lacking evidence on the effectiveness of ASB screening and tre-
ating policies we conclude that it is currently not clear whether the cost of case-finding 
is economically balanced in relation to possible expenditure on medical care as a whole.
The screening programme
Case-finding should be a continuing process and not a “once and for all” project 
(10)
This criterion is less applicable since a good antenatal care system, with comprehensive 
coverage is already present in the Netherlands.  In the past screening programmes 
were often linked to events such as fairs. One of the problems with the single occasion 
DISCUSSION
TENTHE SCREENING PROGRAMME
screening programmes is that often those at least risk, are attending the screening.  
Emerging screening criteria 
Over the years emerging criteria were developed and in 2008 the WHO proposed eight 
additional screening criteria.2 We will address three of the additional criteria since most 
of the suggested additional criteria concern genetic screening and those are not appli-
cable to the present research question whether screening for ASB in pregnant women 
is desirable.  
There should be a defined target population (11)
When introducing a screening programme it is worthwhile to consider if all or only 
a subgroup of pregnant women needs to be screened and whether it is possible to 
identify pregnant women with certain risk factors for the presence of ASB. This reason 
precisely was the impetus for both PRABUTI studies (chapter 8 and 9). One of the risk 
factors for both ASB and symptomatic UTI is diabetes mellitus (DM).27,53-54 Diabetes 
mellitus including gestational DM is an increasingly prevalent endocrine disease.53 Even 
though earlier studies showed that ASB is more prevalent in non-pregnant women with 
DM compared to those without DM, both PRABUTI studies did not find a difference in 
prevalence of ASB and incidence of UTI between pregnant women with DM and preg-
nant women without DM.54 These results do not support the introduction of a more 
‘selective’ screening programme for only pregnant women with DM. 
More insight into the natural course of ASB and possibly related consequences may 
help in identifying other risk factors in order to narrow the target population.  One 
may think of certain types of micro-organisms that predict the progression from ASB 
into symptomatic UTI and/or preterm birth or underlying abnormalities of the urinary 
tract.26,30 Choosing a proper target population with substantial risks for the disease 
often improves the effectiveness of the screening programme, but this group is not 
identified in pregnant women. 
There should be scientific evidence of screening programme effectiveness (12) 
Studies addressing the effectiveness of ASB screening programmes that are nowadays 
in place in several Western countries are lacking.11 A screening programme can fulfil 
all criteria described above but the effectiveness can be limited when “the uptake”, 
namely the number of women eligible for screening for whom a urine culture result is 
reported, is low. Barriers for women to attend the screening programme may be stress 
related to awaiting the result and/or possibly having the ‘disease’, an unwillingness to 
use antibiotics during pregnancy, or lack of knowledge.1 
Our retrospective study performed in Australia, where screening for ASB is recom-
mended, provides some insight in the practical implementation and the efficiency of 
screening and treating policies in pregnant women generally and especially in preg-
nant women with DM. We found that in most records of pregnant women randomly 
selected a urine culture was available, however, only in a limited number of women 




surveillance system should be in place to monitor its quality. To identify barriers to parti-
cipation, qualitative research such as interviews or focus-groups are preferred. 
In conclusion, the scientific evidence of this screening programme effectiveness is not 
clear.
The overall benefits of screening should outweigh the harm (13) 
Maybe the most important criterion of the whole list is: ‘Primum non nocere’ or ‘first, 
do no harm’. Nowadays often referred to as non-maleficence, one of the principles of 
bioethics is making healthcare workers aware that doing nothing may be better than 
doing something (treating) when this causes more harm than benefits.1,2 
Emerging evidence showing possible long-term consequences of antibiotic use in preg-
nant women are reason for concern.55-57 Recent studies showed several associations 
between antibiotics used during pregnancy and adverse neonatal outcomes including 
increased risk for cerebral palsy, early onset sepsis with antibiotic-resistant micro-orga-
nisms, malformations and epilepsy. These side-effects may be worse than the disease, 
especially since it is not clear that the treatment causing the side-effects is preventing 
preterm birth. 
Not only may the antibiotic treatment cause more harm than good. Since existing diag-
nostic tests for ASB have less than 100% specificity pregnant women will be diagnosed 
with ASB while they are not suffering from ASB (false-positive).45,47 This will provoke 
a ‘‘diagnostic odyssey’’ rather than prevent one and this harm could potentially cause 
more anxiety than detecting [ASB] could relieve’ as Harris and colleagues state.58 
Conclusion
Drastic improvements in health care including antenatal care due to the increasing 
knowledge and ground-breaking developments have taken place in the last 50 years.19,59
Examples are the introduction of different new antibiotics and the ultrasound to monitor 
the fetus. But also several associations between, for example, certain foods, smoking 
and infectious diseases (besides infections of the urinary tract) and adverse pregnancy 
outcomes were demonstrated. Subsequently measures such as screening (GBS colo-
nization) and counselling programmes (stop smoking-programmes) were introduced.5 
New insights challenge the preconception that ASB in pregnant women is a disease of 
great importance associated with preterm birth. Recent studies suggest that ASB might 
be more an expression of commensalism than a disease.60 If this is the case, an ASB 
screening programme may not be effective to reduce the burden of preterm birth.
An association does not always represent a causal relationship; the association between 
ASB during pregnancy and preterm birth, established a long time ago, may have been 
confounded by other (yet) unidentified risk factors for preterm birth.  
How can we explain the results of studies that have shown that treatment of ASB with 
antibiotics reduces the incidence of preterm birth compared to treatment with pla-
cebo?16,61 This finding seems to support the hypothesis that there is a direct association 
between colonization of the urinary tract and preterm birth. However preterm birth is 
thought to be the result of a combination of factors including several infectious diseases 
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and antibiotics may achieve this reduction in preterm birth rate, by indiscriminate reduc-
tion of bacterial colonization and/or infectious loads elsewhere in the body.3
For example, both maternal genital Chlamydia infection and vaginal GBS colonization 
are associated with preterm birth. Some of the antibiotics used for the treatment of 
ASB will also cure smouldering asymptomatic genital infection or heavy vaginal GBS 
colonization, thereby conceivably reducing the risk for preterm birth.62,63 Finally infec-
tions outside of the urogenital tract such as periodontal infections, which have been 
associated with preterm birth, may also be unintentionally treated with an antibiotic 
treatment initiated for ASB.64
Preterm birth is evidently an important health care problem, but in our opinion an ASB 
screening programme is not one of the magic bullets to prevent it. Several studies found 
associations between ASB and preterm birth, whether or not via symptomatic UTI, but 
so far the natural history remains unknown.55-57 In more than 50% of preterm birth no 
obvious risk factors were identified.65 Regarding associations and causal relations sur-
rounding preterm birth and UTI we are possibly only aware of the tip of the iceberg. 
More experimental or laboratory research to identify causal pathways leading to pre-
term birth or cascades possibly activated via ASB is desirable.
Maybe our current tests are not sensitive enough to detect ‘signals’ or ‘substances’ 
produced by certain bacteria in certain circumstances that lead to preterm delivery or 
other adverse events similar to the hypothesis that endotoxins and/or phospholipases 
influence the synthesis of prostaglandins.12
Table 1. Summarizing Wilson and Jungner criteria for ASB screening in pregnant women to prevent 
pyelonephritis or/and preterm birth
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The condition
The condition sought should be an important health problem
The natural history of the condition should be adequately understood




The treatment and test
 There should be an accepted treatment for patients with recognized disease
There should be an agreed policy on whom to treat as patients
There should be a suitable test
The test should be acceptable to the population







The cost of case-finding (including diagnosis and treatment of patients diagnosed) 




Case-finding should be a continuing process and not a “once and for all” project
There should be a defined target population (revised)
There should be scientific evidence of screening programme effectiveness (revised)







According to the available evidence presented in relation to the Wilson and Jungner cri-
teria, summarized in table 1, there is still too much uncertainty.1 Insight into the natural 
course of ASB during pregnancy is lacking, the borderline-group is large, test results 
ambiguous, the effectiveness of ASB treatment with antibiotics or any other treatment 
to prevent preterm birth not established and the possible harms of antibiotic use during 
pregnancy may be worse than the disease.
Firstly, we conclude that the evidence for the introduction of an ASB screening pro-
gramme in the Netherlands is too limited. Secondly, the revealed uncertainties push 
for a rigorous audit of ASB screening and treatment policies currently in place in other 
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Bacteriuria, the presence of bacteria in urine, is common and can be divided into asymp-
tomatic bacteriuria (ASB) and bacteriuria with symptoms, which is called urinary tract 
infection (UTI). Typical UTI symptoms are dysuria, urgency and frequency. ASB is defined 
as significant bacteriuria (≥105 colony forming units (cfu)/mL) without the presence UTI 
related complaints. 
Both ASB and UTI are frequently diagnosed in clinical practice and may have conse-
quences particularly in women with diabetes mellitus (DM) and pregnant women, as 
for example the development of pyelonephritis and preterm birth. In spite of this, es-
sential evidence for pivotal decisions in (Dutch) clinical guidelines on diagnosis and ma-
nagement of ASB and UTI in these two groups is missing.  In this thesis several studies 
are presented to fill some of these existing knowledge gaps focused on three patient 
groups: women with DM, pregnant women and pregnant women with DM. 
Chapter 2 provides an overview of studies published in 2012 and 2013 on epidemio-
logy, risk factors, complications and treatment of UTI and ASB in two special patient 
groups: women with DM and pregnant women. Most published papers confirmed exis-
ting knowledge on ASB and UTI in these special patient groups. Emerging topics were 
adverse effects of treatment of DM and bacteriuria itself and the association between 
ASB including group B Streptococcus (GBS) bacteriuria in pregnant women and adverse 
pregnancy outcomes. 
To start with women with DM: the newly developed type 2 DM agents, sodium-glucose 
cotransporter-2 (SGLT2) inhibitors, were found to be associated with a small increased 
risk for UTI due to increased glycosuria. Moreover, this review highlighted that evidence 
regarding optimal treatment of UTI in diabetic patients is still lacking. 
Concerning pregnant women: antibiotic treatment of ASB or UTI during pregnancy was 
related to short-term and possibly even long-term consequences in the neonate such as 
epilepsy and antibiotic resistance. In light of the possible adverse effects of antibiotics, 
more studies exploring the possibilities for non-antibiotic interventions to prevent or 
treat ASB and UTI are needed. 
Another topic was GBS bacteriuria, which can be considered a sign of heavy vaginal 
colonization and is more often associated with adverse pregnancy complications such 
as chorioamnionitis. However, the treatment implications of GBS bacteriuria for clinical 
practice are not clear. 
Finally this review emphasizes that up-to-date studies investigating whether screening 
and treatment of ASB  (including GBS bacteriuria during pregnancy) are still necessary 





Women with diabetes mellitus
Diabetes, a highly prevalent endocrine disease, is considered a risk factor for UTI. Cur-
rently, there are no controlled clinical trials investigating the optimal antimicrobial tre-
atment strategy for UTI in women with DM and recommendations are based mainly on 
the opinion of experts. 
Chapter 3 and 4 present the results of analysis of a large Dutch registration database 
containing pharmacy-dispensing data of 10,366 women with and 200,258 women 
without DM. This database was used to compare current treatment strategies for UTIs 
with respect to recurrence rates in women with compared to those without DM. A UTI 
was defined as a first course of trimethoprim, nitrofurantoin, fosfomycin, or norfloxacin 
and a recurrence was defined as a second prescription for one of the above-mentioned 
agents or a first prescription with amoxicillin (clavulanic acid), fluoroquinolones, or tri-
methoprim/sulfamethoxazole between 6 and 30 days after initial treatment.   
These two studies showed that both premenopausal (aged ≤55 years) and postmenon-
pausal women with DM compared with those without DM more often receive treat-
ment for a longer duration (5 days or more) (premenopausal 26.5% vs. 19.2%; post-
menopausal 32.8% vs. 28.8%) but still had a higher recurrence rate (Premenopausal 
16.1% vs. 12.2%; postmenopausal 19.1% vs. 16.4%).
Furthermore postmenopausal women with DM had more UTI recurrences (second pres-
cription) when they were treated with nitrofurantoin (22.7%) compared to trimetho-
prim (17.7%) or norfloxacin (14.2%) irrespective of the treatment duration. Finally there 
was a trend that longer treatment duration was associated with higher recurrence rates. 
In conclusion, despite the fact that patients with DM more often received longer initial 
treatment than patients without DM, both pre- and postmenopausal women with DM 
more often had recurrences of their UTIs. Moreover postmenopausal women with DM 
had more UTI recurrences when they were treated with nitrofurantoin, agent of first 
choice, compared to trimethoprim or norfloxacin. Even though these data provide more 
insight in current treatment strategies prescribed for UTI in women with DM, rando-
mised controlled trials comparing different strategies are warranted to elucidate the 
optimal treatment strategy for UTI in pre- and postmenopausal women with DM. 
Pregnant women
It is essential to adequately diagnose ASB in pregnant women, because of the possible 
complications for both the mother and her newborn.  The main study objective of 
the cross-sectional study described in Chapter 5 was to estimate and compare con-
tamination rates of three different urine-sampling methods in pregnant women to as-
sess bacteriuria. Urine is supposed to be sterile but may become contaminated during 
micturition with flora and epithelial cells from both the vagina and urethra. Contami-
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nation of a urine sample can contribute to under- or overdiagnosis of bacteriuria. Col-
lection of uncontaminated voided urine samples is difficult and sometimes not feasible 
in pregnant women because of practical factors like weight gain and increased vaginal 
discharge. 
The question remained whether the more laborious urine-sampling including morning 
(first void) and clean-catch sample (voiding after cleaning) outweigh the extra effort 
compared to a midstream (voiding without further instructions) sample. 
The following end points were considered contaminants: epithelial cells, Gram-positive 
rods or mixed bacteria in the Gram stain, and mixed growth or skin flora in the urine 
culture. The three different samples collected by 113 pregnant women within 24 hours 
revealed that low numbers of Gram-positive rods were more likely present in Gram 
stains of midstream samples compared with clean-catch samples (77.7% vs. 66.7%) 
and that morning samples showed more mixed growth compared with midstream sam-
ples (6.2% vs. 0.9%). All other endpoints were the same after the different collection 
methods.  Only a slight agreement or consistency between samples of the same preg-
nant woman was found. 
The presence of skin flora was high (>80%) in all three samples, meaning that most 
samples could be considered contaminated. However when distinguishing between 
relevant and irrelevant contamination we argued that only in 4% a second sample was 
warranted because the first sample was not interpretable due to contamination. 
The findings that in pregnant women the contamination rate of midstream samples 
is comparable with the contamination rates of morning and clean-catch samples and 
that the quantity of contaminants varied among the three samples collected by one 
woman emphasize that more complex, unpractical, and time-consuming morning and 
clean-catch samples are not superior. Therefore, we recommend a midstream sample to 
assess bacteriuria in pregnant women.
In Chapter 6, the literature was systematically reviewed for trials of any intervention 
for preventing recurrent UTI (RUTI) in pregnant women. Interventions to prevent RUTI 
can be pharmacological such as antibiotics or non pharmacological such as cranberry 
products, acupuncture, probiotics or behavioural modifications. 
Only one trial was identified involving 200 pregnant women who received nitrofuran-
toin (antibiotics) and close surveillance (regular clinic visit, urine cultures and antibiotics 
when a positive culture was found) or close surveillance alone. Suppressive therapy with 
daily dose of nitrofurantoin and close surveillance was not shown to prevent more RUTI 
compared with close surveillance alone. 
A significant reduction of ASB was found in women (only reported in women with high 
clinic attendance rate) who received nitrofurantoin and close surveillance (relative risk 




tic recurrences were seen in women with more than 90% clinic attendance rate. Due 
to lack of evidence no conclusions can be drawn. Future randomised controlled trials 
comparing different pharmacological and non-pharmacological interventions are ne-
cessary to assess the optimal intervention to prevent RUTI in women who are pregnant. 
Given the significant differences found in the group with a high clinical attendance, 
future trials should further assess the effect of close surveillance on preventing RUTI in 
pregnant women. 
Older studies dating back to the 60’s, 70’s and 80’s described associations between 
untreated ASB, symptomatic UTI including pyelonephritis and adverse pregnancy out-
comes such as preterm birth. As a result ASB screening and treatment (with antibiotics) 
programs were implemented as routine care. However the exact etiology of preterm 
birth including a causal relation with ASB is still poorly understood. 
Moreover, the knowledge on antenatal care has been further developed including in-
sight in long-term consequences of antibiotic use during pregnancy. Lacking good cli-
nical evidence for an ASB screen and treat program in pregnant women underscores 
the need for an appropriately designed clinical trial evaluating the costs and effects of 
a screen and treat program. 
Since Dutch national guidelines do not recommend screening and treatment of ASB 
in pregnant women, the Netherlands is one of the few countries in which this can be 
properly investigated.
Chapter 7 describes the protocol for the ASB screen and treat study.  For this national 
cohort study over 4.000 women will be screened for ASB with the dipslide technique 
between 16-22 weeks’ gestation and women with ASB will be randomised to either 
placebo or nitrofurantoin. Primary outcomes of this trial are pyelonephritis and/or pre-
term birth before 34 weeks. The trial will provide evidence for the benefit and cost-
effectiveness of screening for ASB in the second trimester in low risk women and the 
effectiveness of nitrofurantoin to prevent pyelonephritis and/or preterm birth.
Pregnant women with diabetes mellitus
DM and gestational diabetes mellitus (GDM) are considered to be important additional 
risk indicators for ASB and UTI during pregnancy. A remaining question for clinical 
guidelines is: do we have to screen all pregnant women for ASB during pregnancy or 
can we identify certain risk factors for ASB in pregnant women such as DM? Chapter 
8 and 9 describe two studies both investigating differences in prevalence of ASB and 
incidence of UTI, including causative organisms in pregnant women with and without 
DM or GDM to provide recommendations for ASB screening and treatment policies. 
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The first “PRegnancy, ASB and UTI” (PRABUTI) study is a retrospective study performed 
in Australia where an ASB screening and treatment policy is in place. For this study 
data of 214 pregnant women with and without DM were analysed. No differences in 
prevalence of ASB (5.6% and 3.7%; RR 1.50; 95% CI 0.44-5.17), incidence of clinical 
UTI (4.7% and 11.2%; RR 0.42; 95% CI 0.15-1.14) or culture-confirmed UTI (2.8% 
and 3.7% RR 0.75; 95% CI 0.17-3.27) between pregnant women with and without 
DM or GDM were demonstrated. No association was found between ASB and UTI and 
GBS was the most common causative organism of ASB in women with and without DM 
(66.7% and 50.0%). 
The second PRABUTI-study is a prospective study performed in the Netherlands. For 
this study 474 pregnant women with and without DM and GDM were screened for the 
presence of ASB around 12 and 32 weeks’ gestation. Also in this study the prevalence 
of ASB was comparable in women with and without DM or GDM around both week 12 
(n=322; 4.7% and 2.3%; RR 2.02; 95% CI 0.52-7.84) and 32 week (n=422; 3.2% and 
3.0%; RR 1.06; 95% CI 0.36-3.09), as was the incidence of UTI (16.8% and 12.9%; 
RR 1.31; 95% CI 0.85-2.02). Neither ASB nor UTI were associated with preterm birth or 
small for gestational age-babies. 
In both studies the overall prevalence of ASB was low in pregnant women with and 
without DM or GDM. Moreover, ASB and UTI did not differ significantly between the 
two groups.  These results provide essential background information for the discussion 
regarding ASB screening and treating policies for pregnant women currently in place 
in developed countries. The data presented do not support a routine screen and treat 
policy in pregnant women with DM or GDM.
Finally in Chapter 10 the results of all studies described in this thesis are interpreted to 
address the question “is screening for ASB during pregnancy to prevent pyelonephritis 
and/or preterm birth desirable?” using the Wilson and Jungner criteria. These criteria 
published in 1968 by the World Health Organisation are still often applied for decision-
making in screening programs. This discussion underscores that evidence for the ef-
fectiveness of ASB screening and treatment policy is limited and that still too many 
uncertainties exist to implement such a strategy. Key issues are that the natural course 
of ASB during pregnancy is unknown and diagnosing ASB is often disturbed by conta-
minated urine samples. This can possibly result in under- and over diagnosis, which can 
have important consequences since recent studies revealed that maternal antibiotics 








Bacteriurie, de aanwezigheid van bacteriën in de urine, is een veel voorkomende be-
vinding bij vrouwen. Bacteriurie wordt onderverdeeld in asymptomatische bacteriurie 
(bacteriurie zonder klachten) en blaasontsteking of urineweginfectie (bacteriurie met 
klachten). Typische klachten van een urineweginfectie zijn pijn bij het plassen en vaak 
kleine beetjes plassen.
Zowel  asymptomatische bacteriurie (ASB) als urineweginfecties (UWI’s) komen relatief 
veel voor bij vrouwen met suikerziekte (diabetes mellitus (DM)) en bij zwangere vrou-
wen. Daarnaast kunnen ASB en UWI’s bij vrouwen met DM en bij zwangere vrouwen 
ernstige gevolgen hebben, zoals het ontwikkelen van een nierbekkenontsteking (pye-
lonefritis) of vroeggeboorte. Mogelijk mede omdat bij patiënten met DM en zwangere 
vrouwen het immuunsysteem onderdrukt is, hebben zij een verhoogde kans op infec-
ties in vergelijking met de algemene populatie. Het is echter onbekend hoe de diagnose 
van ASB en UWI’s bij vrouwen met DM en zwangere vrouwen moet worden gesteld en 
hoe dit moet worden behandeld. Meer kennis is nodig is om richtlijnen over de diag-
nose en behandeling van ASB en UWI’s bij zwangere vrouwen en vrouwen met DM te 
onderbouwen. In dit proefschrift komen verscheidene studies aan de orde, die opgezet 
zijn om enkele hiaten op dit gebied op te vullen.
In Hoofdstuk 2 worden artikelen, gepubliceerd in 2012 en 2013, samengevat, die de 
epidemiologie, risicofactoren, complicaties en behandeling van UWI’s en ASB in vrouwen 
met DM en zwangere vrouwen evalueren. De meeste artikelen bevestigden hetgeen al 
bekend was over ASB en UWI’s in deze twee risicogroepen. Nieuwe belangrijke aspec-
ten die naar voren kwamen waren de bijwerkingen gerelateerd aan de behandeling van 
DM en de behandeling van ASB zelf en de associatie tussen ASB in zwangere vrouwen, 
inclusief groep B streptokokken (GBS) bacteriurie, met ongunstige zwangerschapsuit-
komsten. In vrouwen met DM werd beschreven dat een nieuw medicijn voor DM type 
2, een natrium-glucose-cotransporter 2-remmer (SGLT-2-remmer), geassocieerd is met 
een licht verhoogd risico op UWI’s vanwege de toegenomen glucosurie (aanwezigheid 
van suiker in de urine). Daarnaast werd wederom vastgesteld, dat we nog steeds niet 
weten hoe we het beste UWI’s kunnen behandelen in patiënten met DM. 
Uit studies bij zwangere vrouwen bleek dat antibioticabehandeling van ASB en/of UWI’s 
tijdens de zwangerschap gerelateerd is aan korte en mogelijk zelfs lange termijn gevol-
gen voor de pasgeborene zoals epilepsie en antibioticaresistentie. Dit resultaat bena-
drukt het belang van onderzoek naar alternatieve behandelingen, zoals cranberry’s, om 
ASB en UWI te voorkomen en/of te behandelen. Een ander belangrijk onderwerp was 
bacteriurie met een groep B streptokok (GBS) tijdens de zwangerschap. GBS bacteriurie 
wordt beschouwd als een uiting van hevige vaginale kolonisatie, wat is geassocieerd 
met nadelige zwangerschapsuitkomsten zoals infectie van de placenta en vruchtwater-
membranen (chorioamnionitis). Voor de klinische praktijk is het echter niet duidelijk of 




Tot slot wordt benadrukt dat up-to-date studies, die onderzoeken of screening en be-
handeling van ASB tijdens de zwangerschap wenselijk is, nodig zijn. Mede gezien het 
feit dat antibiotica gebruik gedurende de zwangerschap (de behandeling van ASB) mo-
gelijk geassocieerd is met lange termijn gevolgen voor de pasgeborene. 
Vrouwen met diabetes mellitus
DM is een veel voorkomende endocriene ziekte en wordt beschouwd als een belang-
rijke risicofactor voor het ontwikkelen van UWI’s. Ondanks het feit dat vrouwen met 
DM vaker UWI’s hebben, weten we op dit moment niet hoe we deze het beste kunnen 
behandelen. Gerandomiseerde trials naar de optimale duur van antibiotica therapie 
voor een UWI in vrouwen met DM ontbreken. De huidige aanbevelingen zijn gebaseerd 
op expert opinion.
In Hoofdstuk 3 en 4 worden de resultaten beschreven van de analyse van een grote 
Nederlandse apothekersdatabase met voorschrijfgegevens van 10,366 vrouwen mét 
en 200,258 vrouwen zonder DM tussen 1999 en 2005. Het doel van deze studie was, 
om meer inzicht te krijgen in het huidige antibiotische behandelbeleid voor UWI’s bij 
vrouwen met DM. 
Een UWI werd gedefinieerd als een eerste recept voor trimethoprim, nitrofurantoïne, 
fosfomycine of norfloxacine (tevens inclusie criteria); een terugkerende of recidief UWI 
als een tweede recept voor één van de bovenstaande antibiotica of een recept voor 
amoxicilline (clavulaanzuur), fluorchinolonen of co-trimoxazol tussen 6 en 30 dagen na 
inclusie. 
Uit deze twee studies blijkt dat zowel pre- als postmenopauzale vrouwen met DM vaker 
een langere antibiotische behandeling (5 dagen of meer) (premenopauzaal 26.5% vs. 
19.2%; postmenopauzaal 32.8% vs. 28.8%) voorgeschreven kregen voor een UWI, 
vergeleken met vrouwen zonder DM. Desondanks hadden vrouwen met DM vaker een 
recidief UWI (premenopauzaal 16.1% en postmenopauzaal 15.2%) vergeleken met 
vrouwen zonder DM (12.2% en 12.7% respectievelijk ).
Daarnaast hadden vrouwen met DM vaker een recidief UWI (tweede recept) als ze wer-
den behandeld met nitrofurantoïne (22.7%) in vergelijking met trimethoprim (17.7%) 
en norfloxacine (14.2%), onafhankelijk van de duur van de initiële antibiotische behan-
deling. Verder was er sprake van een trend waarbij een langere antibiotische behande-
ling was geassocieerd met een hoger UWI recidief percentage. 
Concluderend hadden zowel pre- als postmenopauzale vrouwen met DM vaker een 
recidief UWI dan vrouwen zonder DM, ondanks het feit dat vrouwen met DM langer 
werden behandeld met antibiotica voor een UWI. Daarnaast hadden vrouwen met DM 
vaker een recidief als ze in eerste instantie behandeld waren met nitrofurantoïne, ver-
geleken met trimethoprim en norfloxacine. 
TWELVERISICOGROEPEN
Ondanks het feit dat deze twee studies meer inzicht geven in het huidige voorschrijf-
gedrag van antibiotica voor UWI’s in vrouwen met DM, is een gerandomiseerde studie 
waarbij verschillende antibiotische behandelingen met elkaar worden vergeleken nood-
zakelijk, om de optimale therapie voor UWI’s in vrouwen met DM te kunnen bepalen. 
Zwangere vrouwen
Het is belangrijk om de eventuele aanwezigheid van bacteriën in de urine van een zwan-
gere vrouw goed te kunnen aantonen, om de diagnose ASB of UWI te kunnen stellen. 
Dit is met name belangrijk, omdat bacteriurie bij zwangere vrouwen mogelijk nadelige 
gevolgen heeft voor de moeder en de pasgeborene. Het hoofddoel van de studie be-
schreven in Hoofdstuk 5, de ‘the most reliable to Collect Urine in Pregnant women’, 
oftewel CUP- studie, was het vaststellen van bacteriurie bij zwangere vrouwen door het 
kwantificeren en vergelijken van hoeveelheden contaminanten in urinemonsters, ver-
zameld via drie verschillende verzamelmethoden. Urine is in principe steriel, maar kan 
gecontamineerd raken tijdens het plassen door flora- en epitheelcellen, die afkomstig 
zijn van de vagina en urethra. Gecontamineerde urinemonsters kunnen resulteren in 
onder en over diagnose van ASB en UWI’s. Het opvangen van een niet-gecontamineerd 
urinemonster is moeilijk en soms zelfs onmogelijk in zwangere vrouwen door praktische 
factoren zoals toegenomen vaginale afscheiding en gewichtstoename. 
Een belangrijke vraag, die nog onbeantwoord was, is of meer complexe, onpraktische- 
en tijdrovende verzamelmethoden zoals midstream ochtendurine (eerste urineportie ’s 
ochtends) en midstream clean-catch urine (urine opvangen na het schoonmaken van de 
externe genitaliën) minder gecontamineerde urinemonsters oplevert in vergelijking met 
een midstream urinemonster (zonder verdere instructies). 
De volgende uitkomsten werden gezien als contaminanten: epitheelcellen, gramposi-
tieve staven of de aanwezigheid van meerdere soorten bacteriën in het grampreparaat 
en groei van meerdere soorten micro-organismen en/of huidflora in de kweek.
In totaal hebben 113 zwangere vrouwen drie verschillende urinemonsters verzameld. 
Bij het vergelijken van de 3 verschillende typen urinemonsters bleek dat een laag aantal 
grampositieve staven in het grampreparaat vaker werd gezien in midstream urinemon-
sters vergeleken met midstream clean-catch urinemonsters (77.7% vs. 66.7%). Verder 
werden in de midstream ochtend urinemonsters vaker meerdere soorten bacteriën ge-
kweekt in vergelijking met midstream urinemonsters (6.2% vs. 0.9%). Er werd geen 
verschil gevonden tussen de andere uitkomsten, en dus contaminatie, van de drie ver-
schillende urinemonsters. Over het algemeen was er maar een kleine overeenkomst in 





In veel urinemonsters werd huidflora gevonden (>80%), wat betekent dat strikt gezien 
een groot deel van de samples gecontamineerd is. Op het moment dat er onderscheid 
gemaakt werd tussen relevante en irrelevante contaminatie, bleek dat maar in 4% de 
gevallen een tweede urinemonster nodig was omdat het eerste monster niet te beoor-
delen was door de aanwezigheid van contaminatie. 
Het feit dat er in zwangere vrouwen geen verschil in contaminatie percentages wordt 
gevonden tussen midstream urinemonsters en midstream ochtend of midstream clean-
catch urinemonsters, in combinatie met het feit dat de hoeveelheid contaminatie niet 
overeen kwam tussen de drie monsters verzameld door één vrouw, laat zien dat de 
meer complexe, onpraktische- en tijdrovende collectie methoden, namelijk ochtend en 
clean-catch urinemonsters, geen toegevoegde waarde hebben. Daarom raden wij een 
midstream urinemonster aan om bacteriurie aan te tonen in zwangere vrouwen.
In Hoofdstuk 6 worden de resultaten van een systematische review van studies, waar-
bij onderzoek is gedaan naar interventies om recidiverende UWI’s bij zwangere vrouwen 
te voorkomen, beschreven. Interventies kunnen farmacologisch zijn, zoals antibiotica, 
maar ook niet-farmacologisch, zoals cranberry’s, acupunctuur, probiotica, of gedrags-
veranderingen. 
Er werd maar één studie gevonden. Voor deze studie werden 200 zwangere geran-
domiseerd voor nitrofurantoïne (antibiotica) en ‘close surveillance’  (bestaande uit re-
gelmatig controle met urinekweken en antibiotica bij een positieve kweek), of ‘close 
surveillance’ alleen. De resultaten lieten zien dat gedurende de zwangerschap nitro-
furantoïne samen met ‘close-surveillance’ niet resulteerde in minder UWI recidieven 
dan ‘close-surveillance’ alleen. Daarentegen werd bij zwangere vrouwen met een hoog 
percentage controle-onderzoeken wel een significante vermindering van ASB gevonden 
in vrouwen die werden behandeld met nitrofurantoïne en ‘close surveillance’ (relatief 
risico (RR) 0.55, 95% betrouwbaarheidsinterval (BI) 0.34 tot 0.89; n=102). Geen van 
de vrouwen met een hoog aantal controle-onderzoeken (follow-uppercentage >90%) 
heeft een symptomatische recidief UWI gehad. Vanwege het geringe aantal studies 
naar interventies om recidiverende UWI’s te voorkomen in zwangere vrouwen, konden 
geen conclusies worden getrokken. Gerandomiseerde studies die verschillende inter-
venties, farmacologisch en niet-farmacologisch, met elkaar vergelijken zijn noodzakelijk 
om te weten te komen wat  de beste manier is om recidiverende UWI’s bij zwangere 
vrouwen te voorkomen. Met name onderzoek naar het effect van ‘close surveillance’ op 
het voorkomen van recidiverende UWI’s lijkt wenselijk gezien de gevonden significante 
verschillen in de groep met vrouwen met een hoog aantal controle-onderzoeken.  
De associatie tussen onbehandelde ASB en UWI’s (inclusief pyelonefritis) en nadelige 
zwangerschapsuitkomsten zoals vroeggeboorte, is beschreven in gedateerde onderzoe-
ken uit de jaren 60, 70 en 80. Op basis van bevindingen in die studies is ASB screening 
en behandeling (ASB screen & treat) tijdens de zwangerschap in veel landen  standaard 
zorg geworden om de eventuele nadelige gevolgen te voorkomen. 
TWELVERISICOGROEPEN
Tot dusver is het causale verband tussen ASB en vroeggeboorte nog niet opgehelderd 
en is de effectiviteit van een ASB screen & treat programma niet onderzocht. 
In de tussentijd heeft de verloskundezorg zich verder ontwikkeld. Ook is er meer inzicht 
ontstaan in de nadelige gevolgen van antibiotica gebruik tijdens de zwangerschap voor 
zowel moeder als kind. Het ontbrekende bewijs voor het nut van een ASB screen & treat 
programma benadrukt de noodzaak voor een gerandomiseerde trial om het effect, 
evenals de kosten, hiervan te onderzoeken.
In de Nederlandse richtlijnen wordt een ASB screen & treat programma niet geadviseerd, 
in tegenstelling tot de internationale richtlijnen. Het is daarom ook geen onderdeel van 
het prenatale zorgpakket. Mede hierdoor is Nederland één van de weinige landen waar 
de gevolgen van niet screenen voor ASB nog gedegen kan worden onderzocht. 
In Hoofdstuk 7 wordt het protocol beschreven van deze gewenste trial. Het gaat om 
een landelijke cohort studie waarvoor ruim 4.000 zwangere vrouwen zullen worden 
gescreend voor ASB tussen de 16 en 22 weken zwangerschap. Vrouwen met ASB ? 
worden gerandomiseerd voor een behandeling met nitrofurantoïne of voor placebo. De 
primaire uitkomsten van de studie zijn pyelonefritis en/of vroeggeboorte (<34 weken). 
Deze studie zal meer inzicht geven in de effectiviteit en kosteneffectiviteit van een ASB 
screen & treat programma in het tweede trimester van de zwangerschap in laag-risico 
zwangere vrouwen. Daarnaast zal deze studie inzicht geven in de effectiviteit van nitro-
furantoïne in het  voorkomen van vroeggeboorte in vrouwen met ASB.
DM inclusief diabetes mellitus gravidarium (DMG) wordt gezien als een belangrijke ex-
tra risicofactor voor ASB en UWI’s in zwangere vrouwen. Een belangrijke vraag blijft; als 
er een ASB screen & treat programma wordt opgezet, moeten alle zwangere vrouwen 
dan worden gescreend voor ASB of alleen vrouwen met een verhoogd risico, zoals 
zwangere vrouwen met DM of DMG? Om hier een uitspraak over te kunnen doen is 
het van belang om te weten of ASB daadwerkelijk vaker voorkomt in zwangere vouwen 
met DM of DMG en of onbehandelde ASB in vrouwen met DM of DMG geassocieerd is 
met nadelige zwangerschapsuitkomsten zoals vroeggeboorte. 
In Hoofdstuk 8 en 9 worden twee studies beschreven naar verschillen in prevalentie 
van ASB en incidentie van UWI’s tussen zwangere vrouwen met en zonder DM of DMG 
en de aanwezigheid van een eventuele associatie tussen ASB en UWI’s met nadelige 
zwangerschapsuitkomsten zoals vroeggeboorte. 
De eerste ‘PRegnancy, ASb & UTI’ studie of PRABUTI studie, beschreven in Hoofdstuk 
8, is een retrospectieve studie uitgevoerd onder 214 zwangere vrouwen bevallen in 
Women’s and Children’s Hospital in Adelaide, Australië. In Australië is een ASB screen 
& treat programma onderdeel van standaard zorg tijdens de zwangerschap. Er werden 
geen verschillen gevonden in ASB prevalentie (5.6% vs. 3.7%; RR 1.50; 95% BI 0.44-
5.17), incidentie van klinische UWI’s (4.7% vs. 11.2%; RR 0.42; 95% BI 0.15-1.14) en/




3.27) respectievelijk tussen zwangere vrouwen met en zonder DM of DMG. Er werd 
ook geen associatie gevonden tussen ASB en/of UWI’s gedurende de zwangerschap en 
vroeggeboorte of laag geboortegewicht.
De tweede PRABUTI studie beschreven in Hoofdstuk 9 is een prospectieve studie die 
uitgevoerd is in Nederland. Voor deze studie zijn 474 vrouwen met en zonder DM of 
DMG gescreend op ASB door middel van een urinekweek rond 12 en 32 weken zwan-
gerschap. Wederom werd er geen verschil gevonden tussen zwangere vrouwen met 
en zonder DM of DMG in zowel de prevalentie van ASB rond 12 weken (n=322; 4.7% 
versus 2.3%; RR 2.02; 95% BI 0.52-7.84) als rond 32 weken zwangerschap (n=422; 
3.2% versus 3.0%; RR 1.06; 95% BI 0.36-3.09). Ook was er geen verschil in incidentie 
van UWI’s, gedefinieerd als een antibioticarecept voor een UWI  tussen zwangere vrou-
wen met en zonder DM of DMG (16.8% versus 12.9%; RR 1.31; 95% BI 0.85-2.02). 
Ook bij deze studie werd geen verband gevonden tussen ASB en/of UWI en nadelige 
zwangerschapsgevolgen zoals vroeggeboorte. 
In beide studies werd een lage ASB prevalentie gevonden in zowel zwangere vrouwen 
met als zonder DM of DMG. Kortom deze uitkomsten ondersteunen (de invoer van) 
ASB screen & treat programma voor zwangere vrouwen met DM of DMG niet. Beide 
studies bieden belangrijke achtergrondinformatie voor beslissing beschreven in richtlij-
nen. 
Tot slot worden in Hoofdstuk 10 alle studies die beschreven zijn in dit proefschrift ge-
bruikt om de overkoepelende vraag te beantwoorden of screening voor ASB gedurende 
de zwangerschap wenselijk is om pyelonefritis en/of vroeggeboorte te voorkomen. Dit 
wordt gedaan aan de hand van de Wilson en Jungner criteria. Deze criteria zijn in 1968 
gepubliceerd door de Wereldgezondheidsorganisatie en worden nog steeds gebruikt 
om te beoordelen of de invoer van een screeningsprogramma wenselijk is. Samengevat 
is er een gebrek aan bewijs voor de effectiviteit van een ASB screen & treat programma 
voor zwangere vrouwen. Op dit moment bestaan er nog te veel onderzekerheden. 
Voorbeelden van belangrijke hiaten en/of problemen zijn dat het natuurlijke beloop van 
onbehandelde ASB  en de associatie hiervan met vroeggeboorte niet bekend is en dat 
ASB moeilijk te diagnosticeren is en deze diagnose wordt verstoord door contaminatie. 
Dit laatste leidt mogelijk tot onder- en over-diagnose. Dit kan belangrijke consequenties 
hebben, omdat recente studies hebben aangetoond dat antibiotica gebruik gedurende 












Urinemonsters, heel veel urinemonsters, een artikel indienen vanuit de jungle in Ecua-
dor, krokodillentranen, huzarensalade bakjes gevuld met urine, een concert van Angus 
& Julia Stone, roze multomappen, veel huidflora, het skypen op bizarre tijden, mijn 
liefde die het woord promotie niet meer kan horen, het dromen over SPSS syntax, 
een E. coli uitbeelden op de dansvloer, de stapels statussen, “oh ja”-momenten on-
der de douche, een huisgenoot waarschuwen voor urinemonsters in de ijskast, to-do-
lijstjes zonder einde, ATC-codes, een fout ontdekken tijdens het ophangen van mijn 
eerste poster, het vrijdagmiddag-ik-heb-deze-week-niet-genoeg-gedaan-schuldgevoel, 
het vele nadenken over onbelangrijke dingen, de volledig onnodige uitstapjes naar de 
boekwinkel in het AMC, helden zoals Archie Cochrane en Atul Gawande,  het hebben 
van veel vrije tijd maar nooit echt vrij zijn, het uren invoeren van onbruikbare data, mijn 
congresmiddag in Chicago verruilen voor een Frank Lloyd Wright Tour, de vreugde-
sprongetjes bij de acceptatie van een artikel, de keukenvloer van ons huis bezaaid met 
artikelen, rijden door de outback (in de regen), verslaafd aan de e-mail ververs knop, de 
UTI-angels, en tot slot het niet kunnen geloven dat het toch echt AF IS! Het is slechts 
een kleine greep uit de gedachten en herinneringen die door mijn hoofd dwarrelen bij 
het schrijven van dit dankwoord.
Introduction
Zonder goede promotoren en co-promotoren komt er geen boekje. 
Geachte professor Stolk, beste Ronald, jij wist op het juiste moment, meestal als ik even 
echt verdwaald was, in te grijpen en me een duwtje in de goede richting te geven. Te-
gelijkertijd heb jij mij de ruimte gegeven om mijn eigen draai aan dit promotietraject te 
geven en om het onderzoek uit te voeren op locaties naar keuze: “Caroline, waar zit je 
nu weer...... Sint Maarten, Adelaide, Londen, Genève?”    
Geachte professor Erwich, beste Jan Jaap, jouw praktijk- en onderzoekservaring binnen 
het obstetrische veld zijn onmisbaar geweest voor vele hoofdstukken in dit proefschrift. 
Waar ik je erg dankbaar voor ben is dat door jouw inbreng dit proefschrift een Austra-
lisch tintje heeft gekregen. 
Geachte dr. Geerlings, lieve Suzanne, jij bent mijn held, mijn voorbeeld. Betrokken, en-
thousiast, energiek en pragmatisch. Het zijn stuk voor stuk eigenschappen die jou een 
copromotor maken om trots op te zijn en om over op te scheppen tegen andere pro-
movendi. Ik hoop in de toekomst nog vaak met je te mogen samenwerken. Onderzoek 




De leden van de leescommissie, prof. A.I.M. Hoepelman, prof. S.A. Scherjon en prof. 
C.M.J.E. Vandenbroucke-Grauls ben ik zeer erkentelijk voor hun bereidwilligheid om 
zitting te nemen in de promotiecommissie en voor het kritisch beoordelen van mijn 
proefschrift. 
Methods
Meer dan 1000 urinemonsters.......! Zonder hulp, geen urinemonsters. 
De deelname van patiënten in wetenschappelijke studies is essentieel om de gezond-
heidszorg te kunnen verbeteren. Ik wil daarom in de eerste plaats alle (zwangere) vrou-
wen bedanken die hebben mee gedaan aan één van de studies. Zonder de door hen 
zorgvuldig (en soms creatief) verzamelde urinemonsters was het onmogelijk geweest 
om deze studies uit te voeren. 
Verder wil ik graag de medewerkers van alle deelnemende verloskundepraktijken (Ver-
loskundigen Vida en Verloskundige Stadspraktijk), de poliklinieken verloskunde van 
verschillende ziekenhuizen (het Universitair Medisch Centrum Groningen, het Martini 
Ziekenhuis, het Academisch Medisch Centrum, het Onze Lieve Vrouwen Gasthuis en 
het Jeroen Bosch Ziekenhuis), en natuurlijk ook de medische laboratoria die de vele uri-
nemonsters hebben verwerkt (CERTE, Academisch Medisch Centrum en Jeroen Bosch 
Ziekenhuis), hartelijk bedanken voor hun inzet. 
Wie vooral niet vergeten mogen worden zijn de mensen die veel werk achter de scher-
men hebben verricht; alle betrokken secretaresses, polikliniekassistentes, koeriers en 
analisten. Aukje, jij was er van het begin tot het einde bij, altijd gezellig!
Results
Zonder mede-auteurs was ik nooit  auteur geworden.
Beste Ben Willem of nu Ben (prof. B.W.J. Mol), geen simpele praatjes maar diepgaande 
gesprekken. Jij laat mensen nadenken over het waarom van de dingen die we doen en 
laten in de gezondheidszorg.  
Beste Edwin (prof. E.R. van den Heuvel), het gebruik van potlood & gum om de chaos 
van de vele uitkomsten van de verscheidene urinetesten te ordenen, blijkt erg praktisch. 
Ik heb veel plezier beleefd aan de samenwerking met jou. 
Beste Alewijn (dr. A. Ott), samen met Dineke hebben we eindeloos gefilosofeerd over 
hoe de diagnostiek van bacteriurie anders en beter kan. Deze discussies waren een be-
langrijke inspiratiebron voor mij. 
Beste Caroline (dr. C.E. Visser), jij hebt mij gehopen bij de logistiek en het definiëren 
(lees: het omzetten in eentjes en nulletjes) van contaminanten. Dat was zeer verhelde-
rend.
RESULTS
Beste Hans (dr. J.H. de Vries), onder jouw prettige begeleiding heb ik mijn eerste stap-
pen in de wereld van de wetenschap gezet. 
Beste Ron (dr. R.M. Herings), dank dat ik gebruik mocht maken van de waardevolle 
PHARMO database.
Lieve Brenda (bijna dr. B.M. Kazemier) en mede ASB-fan, het was een feestje om met 
jou samen te werken, zoveel vrolijkheid.
Down Under: Dear Caroline (prof. C.A. Crowther) and Philippa (ms. P. Middleton), 
thank you very much for welcoming me in Adelaide. I always enjoyed our meetings 
together: discussing all the wonderful Australian things (kookaburras, Flinders ranges, 
wine) while at the same time you were helping me to improve my English and to or-
ganize my thoughts. I am very grateful to all the people working with ARCH and the 
Patient Record Department of the Women’s and Children’s Hospital in Adelaide, who 
helped me collect the necessary data. I would like to extend my sincerest gratitude to 
Andrea, Pat, Mary, Jacki and the LIMIT-girls. Dear Emer/Emu, I am happy we are still in 
touch. Adelaide will always feel a bit like home. 
Discussion
Ook zonder wetenschapsstudenten geen boekje; Berthe, Linda, Gineke en Heleen, ik 
heb veel waardering voor jullie inzet, met name bij het uitvoeren van de wat saaiere 
klusjes zoals het verzamelen van urinemonsters en het invoeren van statussen. Het was 
ontzettend leuk om jullie te mogen begeleiden.  
Ook wil ik mijn gezellige F4-buddies niet vergeten; Niekie, Caroline, Mariëlle, Thomas, 
Marlous, Hanneke, Karien, Emelie, Frederike en Thijs. Met sommigen heb ik nog de eer 
gehad om onze hersenen te laten kraken tussen de multomappen in de bruin-groene 
variant van het doorloophok. De huidige F4-ers hebben het borrelpercentage gelukkig 
significant weten te verhogen, maar de gemiddelde overlevingsduur van winegums 
helaas weer verlaagd. 
Lieve UTI-angels Caatje2 en Niekie, we hebben veel lief en leed gedeeld waarvan het 
leed gelukkig in alle gevallen een happy end kent (promotieboekjes, mannen, kinderen, 
opleidingen). Jullie zijn en blijven speciaal voor mij. 
Ik grijp meteen even deze kans om mijn excuses aan te bieden voor de ruimte (lees: de 
hele vloer en andere beschikbare oppervlaktes) die ik met mijn urinepotjes, papieren en 
andere frutsels heb ingenomen. 
Beste Len, ik weet niet of ik zo ver zou zijn gekomen zonder jouw hulp in tijden dat het 





Mijn promotietraject was geen rechte, ononderbroken, lijn. Ik heb het geluk gehad 
dat ik het traject heb kunnen combineren met gave andere projecten, waaronder mijn 
coschappen (MD/PhD-traject Junior Scientific Masterclass), een master Public Health 
aan de London School of Hygiene and Tropical Medicine (LSHTM), het werk als arts-
assistent kindergeneeskunde in het Wilhelmina Kinderziekenhuis (WKZ), betrokken zijn 
bij de follow-up van de Triple P studie,  het organiseren van het 80-jarige lustrum van 
de Vereniging van Nederlandse Vrouwelijke Artsen (VNVA), en onlangs mijn stage bij de 
World Health Organization (WHO). Tijdens deze omzwervingen heb ik veel bijzondere 
mensen leren kennen die mij op de één of andere manier gesteund hebben tijdens dit 
promotietraject. 
Beste Carsten (dr. C.R. Lincke), ik ben heel erg blij dat ik door toeval in het Maasstad 
terecht ben gekomen voor mijn laatste coschap. Ik ben je eeuwig dankbaar voor je 
adviezen. Jouw eerlijkheid en openheid naar collega’s toe is iets wat ik graag nastreef. 
Dear Lucilla (prof. L. Poston), Paul (mr. P.T. Seed), Hazel (prof. H.M. Inskip), Suzanne (ms. 
S. Barr) and Angela (ms. A. Flynn), working on the UPBEAT-project was challenging but 
with your guidance instructive and fun. Thank you for this opportunity. 
Beste oud collega’s van het WKZ en in het bijzonder Joost (dr. J.J. Frenkel), Edward (prof. 
E.E.S. Nieuwenhuis) en Michiel (dr. M.L. Houben), ik heb warme herinneringen aan mijn 
(eerste) tijd als arts-asssistent bij jullie. Menno, ik ben heel blij dat jij de editing hebt 
gedaan, just like I pictured it. 
I would like to thank both the department of Essential Medicines and Health Products 
and the department of Maternal, Newborn, Child and Adolescent Health for offering 
me the chance to spend the summer at the WHO. Dear Nicolla (dr. N. Magrini), you 
are philosopher and inspirer. ‘And indeed there will be time’.  Dear Matthews (prof. M. 
Mathai), I enjoyed writing a paper with you on something that is (was) way out of my 
comfort zone: task-shifting in emergency obstetric care.
Beste Aleid (dr. A.G. Van Wassenaer) en Janneke (drs. J. van ’t Hooft), follow-up studies 
zijn weer een heel andere tak van sport. Ik heb veel van jullie geleerd en ik kijk uit naar 
het resultaat van de Triple P follow-up.
Beste VNVA bestuursgenoten en lustrumcommissie, ik kom altijd weer opgeladen thuis 
na een event. 
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Het voelt alsof ik ben opgegroeid in een heel groot warm nest tussen lieve familie, oud-
Weerd-bewoners, Kenia-kennissen, de club uit Rosmalen en alle bijbehorende aanhang. 
Lieve Beekvliet-gang (Pink Ladies J), ik had me geen betere manier kunnen bedenken 
om het inleveren van mijn manuscript bij de leescommissie te vieren, dan met onze 
roadtrip in RV Dolly door California. Het voelt goed en vertrouwd. 
Lieve Pepers, Butten, RSDers, geneeskunde-buddies, corneateam-vrienden en Jaxxia-
nen, al ligt onze fantastische studententijd in Groningen achter ons, het vormt een 
mooie basis voor een levenslange vriendschap. Hopelijk kom ik ooit nog van mijn roze-
scriptie-monster af (lees: altijd druk druk druk voor één of andere deadline).  
Dear LSHTM friends, we had a great time in London. I am happy I finally found some 
friends who never get bored of talking about inequalities in health & health care, publi-
cation bias and the story of John Snow. Sashi, Ann & Angelina; lovely ladies!! Tossing 
our graduation caps last year was a special moment.
Lieve Jus en Juul, fijn dat we vaak samen in hetzelfde (gezellige) schuitje zitten. Lieve 
Josje, wat een geluk dat jij mijn huisgenoot was op de Butjesstraat. Lieve Marjo, door 
jou wordt de verdediging een feestje. Lieve Lot, Hidde, Sop, Jeroen en guppen, dat er 
nog maar veel berggeiten-weekenden mogen volgen. Lieve Alberd, Kris, Hessel, An-
netje (& Florine), benzine is het beste medicijn!
Funding
Lieve paranimfen, maar vooral lieve vriendinnetjes, wat fantastisch dat jullie 3 december 
naast mij staan. 
Lieve Pautje (bijna dr. P.G. de Jong), je hebt het vermogen om tegelijk enthousiasme en 
rust uit te stralen en daarmee weet jij mij, dat af en toe ongeleide projectiel, weer op 
het juiste pad te helpen. Ik hoop je nog lang dichtbij me te hebben. Ik kan niet wachten 
tot het moment dat we de champagne voor jou kunnen open trekken.  
Lieve Sophie, lieve Botsie, als er iemand me altijd (vol trots) heeft gesteund tijdens dit 
promotietraject ben jij het wel! Ik ben trots op jou en trots dat jij mijn vriendinnetje bent 
en ook al zo lang (1e klas middelbare school). Eindeloos praten, waarbij discussies over 
de status van de Ebola epidemie of de immer uitbreidende schending van privacyrech-






En dan terug naar de roots: lieve familie bedankt!
Dear Grossvati and Vreni, thank you very much for your interest and support. 
Lieve tante Meie, dankzij  jou konden een aantal dromen werkelijkheid worden.
Lieve oma Pauline, samen naar een congres in Sydney, heel bijzonder.
Lieve oma Vught, jouw deur staat altijd open. 
Lieve opa Vught, ik had je hier heel graag bij gehad. 
Lieve Yolaine en Marcel, zo lang ik jullie ken (nu 14 jaar) hebben jullie mijn plannen en 
keuzes gesteund. Merci beaucoup! Ik kijk er naar uit om eindelijk echt familie te wor-
den. Lieve Laury, wat was het gezellig toen we tegelijkertijd in Londen zaten en ik ben 
blij dat jij onze getuige wil zijn. 
Lieve zusjes, nu weten jullie het zeker. Ik ben inderdaad de ‘nerd’ van de drie. Maar 
wat ben ik happy en trots dat jullie mijn zusjes zijn. Jullie hebben aan een half woord 
genoeg. Bovendien hebben we veel gewoontes (glazen laten slingeren, in een trein-
tje slapen, door elkaar praten) en interesses (Koning Arthur, Guus Meeuwis, Gubbels) 
gemeen die vaak voor buitenstaanders (zoals vriendjes) niet te begrijpen zijn,  lekker 
vertrouwd! Stein, ik ben blij dat Brigitte jou gevonden heeft. 
Lieve mama, midden in de nacht kan ik je bellen over grote maar ook kleine problemen. 
En je hebt het (soms tot mijn grote frustratie) altijd door als er iets mis is. Ik heb fijne en 
leuke herinneringen aan onze open gesprekken aan de keukentafel (na het uitgaan), 
aan de telefoon of tijdens één van de stedentrips of vakanties. Jij motiveert mensen om 
het beste uit zichzelf te halen. 
Lieve papa, het is de goede lezer misschien al opgevallen maar mijn eerste gepubli-
ceerde artikel hebben we samen geschreven, en stiekem nog wel meer. Tijdens het 
uitlaten van Guusje of het bereiden van rendang samen filosoferen over hoe ik van de 
vele losse eindjes  een boeiend stuk kon maken.  Je hebt me ‘besmet’ met je passie voor 
infectieziekten en onderzoek. Jouw aanstekelijke en bovenal onuitputtelijke positivisme 
is bewonderenswaardig. Zonder jou was dit proefschrift er niet geweest!
Lieve papa en mama, samen vormen jullie een mooi setje (ouders), mijn voorbeeld. 
ADDENDUM
Addendum
Lieve Bruno (ik laat een koosnaam uit de dierentuin collectie maar even achterwege), 
HET IS AF... De enige voorwaarde die je hebt gesteld voordat we gaan trouwen. Er 
blijft alleen een klein probleem over en dat is dat je hoopt dat mijn ietwat hectische 
weekindeling er totaal anders uit gaat zien na het afronden van deze promotie. Ik ben 
bang dat ik je moet teleurstellen, sommige dingen zitten nu eenmaal in de aard van het 








1. Schneeberger C, Kazemier BM, Geerlings SE. Asymptomatic bacteriuria and urinary 
tract infections in special patient groups: women with diabetes mellitus and preg-
nant women. Curr Opin Infect Dis 2014;27:108-14. 
2. Schneeberger C, Geerlings SE. Asymptomatische bacteriurie en urineweginfecties 
bij patiënten met diabetes mellitus. Ned Tijdschr Med Microbiol 2012;4:167-171
3. Schneeberger C, van den Heuvel ER, Erwich JJ, Stolk RP, Visser CE, Geerlings SE. 
Contamination rates of three urine-sampling methods to assess bacteriuria in preg-
nant women. Obstet Gynecol 2013;121:299-305.
4. Schneeberger C, Geerlings SE, Middleton P, Crowther CA. Interventions for pre-
venting recurrent urinary tract infection during pregnancy. Cochrane Database Syst 
Rev 2012;11:CD009279.
5. Kazemier BM, Schneeberger C, de Miranda E, van Wassenaer A, Bossuyt PM, Vo-
gelvang TE, Reijnders FJL, Delemarre FMC, Verhoeven CJM, Oudijk MA, van der Ven 
JA, Kuiper PN, Feiertag N, Ott A, de Groot CJM, Mol BWJ, Geerlings SE. Costs and 
effects of screening and treating low risk women with a singleton pregnancy for 
asymptomatic bacteriuria, the ASB study. BMC Pregnancy Childbirth 2012;12:52.
6. Schneeberger C, Stolk RP, Devries JH, Herings RM, Geerlings SE. Recurrence of uri-
nary tract infections in postmenopausal diabetic women using different antibiotics. 
Journal of diabetes mellitus 2012;2:261-263.
7. Schneeberger C, Geerlings SE, Middleton P, Crowther CA. Protocol: Interventions 
for preventing recurrent urinary tract infection during pregnancy. Cochrane Data-
base Syst Rev 2011;8.
8. Schneeberger C, Stolk RP, Devries JH, Schneeberger PM, Herings RM, Geerlings 
SE. Differences in the pattern of antibiotic prescription profile and recurrence rate 





1. Poster presentation, the 2014 Molecular International UTI conference, Au-
gust 2014, Malmö, Sweden. C. Schneeberger, J.J.H.M. Erwich, R.P. Stolk, E.R. 
van den Heuvel,  B.W.J. Mol, A. Ott, S.E. Geerlings. Asymptomatic bacteriuria and 
urinary tract infections in pregnant women with and without diabetes mellitus
2. Poster presentation, Society for Gynecologic Investigation (SGI), 61st 
Annual Meeting, March 2014, Florence, Italy. Kazemier BM, Koningstein FN, 
Schneeberger C, Ott A, Bossuyt PM, de Miranda E, Vogelvang TE, Verhoeven CJ, 
Langenveld J, Woisky M, Oudijk MA, Reijnders FJ, van der Ven AJEM, Vlegels MTW, 
Kuiper PN, Feiertag N, Mol BWJ, de Groot CJ, Geerlings SE. Maternal and neonatal 
consequences of (un)treated asymptomatic bacteriuria in pregnancy, the ASB trial. 
3. Poster presentation, Society for Maternal-Fetal Medicine’s (SMFM) 34th 
Annual Meeting, February 2014, New Orleans, USA. Kazemier BM, Koningstein 
FN, Schneeberger C, Ott A, Bossuyt PM, de Miranda E, Vogelvang TE, Verhoeven 
CJ, Langenveld J, Woisky M, Oudijk MA, Reijnders FJ, van der Ven AJEM,  Kuiper 
PN, Feiertag N, Vlegels MT, Mol BWJ, de Groot CJ, Geerlings SE. Prevalence and 
risk factors for asymptomatic bacteriuria in low risk pregnant women, the ASB 
screening study.
4. Poster presentation, 22nd ECCMID, April 2012, London, United Kingdom. 
Schneeberger C, Geerlings SE, Erwich JJHM, Stolk RP, Middleton P, Crowther CA. 
Asymptomatic bacteriuria and urinary tract infections in pregnant women with and 
without diabetes mellitus.
5. Poster presentation, 17th Congress of the Federation of Asian and Oceania 
Perinatal Societies (FAOPS) and the 16th Annual Congress of the Perinatal 
Society of Australia and New Zealand (PSANZ), March 2012 Sydney, Austra-
lia. Schneeberger C, Geerlings SE, Erwich JJHM, Stolk RP, Middleton P, Crowther 
CA. Asymptomatic bacteriuria and urinary tract infections in pregnant women with 
and without diabetes mellitus.
6. Poster presentation, 17th Congress of the Federation of Asian and Oceania 
Perinatal Societies (FAOPS) and the 16th Annual Congress of the Perinatal 
Society of Australia and New Zealand (PSANZ), March 2012 Sydney, Aus-
tralia. Schneeberger C, Geerlings SE, Middleton P, Crowther CA. Interventions for 
preventing recurrent urinary tract infection during pregnancy: a Cochrane review.
7. Oral, masterclass Nick white, Academisch Medisch Centrum (AMC), Novem-
ber 2008, Amsterdam, the Netherlands. Treatment differences of urinary tract 
infections between women with and without diabetes.
8. Poster presentation, 48th the Interscience Conference on Antimicrobial 
Agents and Chemotherapy (ICAAC), October 2008, Washington, USA. 
Schneeberger C, Stolk RP, Devries JH, Herings RM, Geerlings SE. Treatment of Uri-
nary Tract Infections in Women with Diabetes Mellitus; Lower Recurrence Rate with 
Norfloxacin Compared to Nitrofurantoin or Trimethoprim. 
9. Poster presentation, the annual conference of the Netherlands Epidemio-
logy Society (WEON), June 2008, Groningen, the Netherlands. Schneeberger 
C, Stolk RP, Devries JH, Schneeberger PM, Herings RM, Geerlings SE. Significant 
Differences in Treatment Strategies and Recurrence Rates of Urinary Tract Infections 
in Women with and without Diabetes Mellitus. 
10. Oral, Annual Dutch Diabetes Research Meeting (NVDO), January 2008, 
Amersfoort, the Netherlands. Treatment of urinary tract infections in women 
with diabetes mellitus; norfloxacin compared with nitrofurantoin or trimethoprim.
11. Poster presentation, 47th the Interscience Conference on Antimicrobial 
Agents and Chemotherapy (ICAAC), September 2007, Chicago, USA. Schnee-
berger C, Stolk RP, Devries JH, Schneeberger PM, Herings RM, Geerlings SE. Sig-
nificant Differences in Treatment Strategies and Recurrence Rates of Urinary Tract 







Intern, World Health Organization (WHO), Geneva, Switzerland
 The department of Essential Medicines and Health Products
 The department of Maternal, Newborn, Child and Adolescent Health
Since January 2014
(Aspirant) committee member Vereniging van Nederlandse Vrouwelijke Artsen (VNVA)
2009—2014
PhD fellow, Junior Scientific Masterclass (JSM) MD/PhD programme
University of Groningen (RUG), Groningen, the Netherlands 
2013—2014
Paediatric Resident, Wilhelmina Children’s Hospital, Utrecht, the Netherlands
2012—2013
Master in Public Health, London School of Hygiene & Tropical Medicine (LSHTM), 
London, United Kingdom 
 Public Health stream including the following courses: Organisational Management,  
 Applied Communicable Disease Control and Health Services
 Thesis title: ‘Maternal diet patterns and glycaemic load in obese pregnant women 
 and determinants thereof. An exploratory study of data from the UPBEAT pilot trial’
2011—2013
Researcher, Dutch Consortium for Healthcare Evaluation and Research in Obstetrics 
and Gynecology, Academic Medical Center (AMC), the Netherlands
 Involved in the coordination of the ‘ASB-study: Cost-effectiveness of screening and treatment of 
 asymptomatic bacteriuria to prevent preterm delivery and pyelonephritis’ 
 Coordinated the 2-years follow-up of the ‘Preventing preterm birth with progesterone: costs and effects 
 of screening low risk women with a singleton pregnancy for short cervical length (the Triple P study)’ 
2003 —2011
Medical school, University of Groningen (RUG), Groningen, the Netherlands 
 General practice rotation, Amsterdam, the Netherlands
 Paediatrics rotation, Maasstad Hospital, Rotterdam, the Netherlands
 Paediatrics rotation, Sint Maarten Medical Center, Saint Martin, Dutch Antilles
 Urology rotation  Klinikum, Oldenburg, Germany
 Senior rotations, Martini Hospital, Groningen, the Netherlands
 Junior rotations, University Medical Center Groningen, Groningen, the Netherlands
2005—2007
Explantation employee, Bio Implant Services and Eurotransplant, the Netherlands
Before 2003
Pre-university education: Gymnasium Beekviet, Sint-Michielsgestel, the Netherlands
211

